aspirin has been researched along with Myocardial Ischemia in 447 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
Myocardial Ischemia: A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (CORONARY ARTERY DISEASE), to obstruction by a thrombus (CORONARY THROMBOSIS), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (MYOCARDIAL INFARCTION).
| Excerpt | Relevance | Reference |
|---|---|---|
| "In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin." | 9.24 | [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. ( Kochubiei, O; Ovrakh, T; Serik, S, 2017) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 9.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 9.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 9.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| "We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease." | 9.12 | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006) |
| " It was the aim of the present study to assess whether the response to aspirin and clopidogrel may be influenced by the 807 C/T polymorphism of the glycoprotein Ia (GpIa) gene in patients with non-ST elevation acute coronary syndrome (NSTE ACS)." | 9.12 | Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Romero-Barra, M; Saut, N, 2007) |
| " We investigated if adding clopidogrel to aspirin treatment could attenutate stress-induced platelet activation and myocardial ischemia in patients with coronary artery disease (CAD)." | 9.12 | Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. ( Hjemdahl, P; Hofman-Bang, C; Ivert, T; Li, N; Perneby, C; Tornvall, P; Wallén, NH, 2007) |
| " We aimed to assess the effectiveness of ximelagatran and acetylsalicylic acid for prevention of death, non-fatal myocardial infarction, and severe recurrent ischaemia after a recent myocardial infarction." | 9.10 | Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. ( Bylock, A; Emanuelsson, H; Goodvin, A; Nyström, P; Wallentin, L; Weaver, WD; Wilcox, RG, 2003) |
| " We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction." | 9.08 | Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. ( , 1998) |
| "This study compared the effects of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina." | 9.07 | Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. ( Cunningham, D; Fox, K; Hendry, G; Holdright, D; Hubbard, W; Patel, D; Sutton, G; Thomas, R, 1994) |
| "The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications." | 9.05 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. ( Angiolillo, DJ; Calderone, D; Capodanno, D, 2020) |
| "A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome." | 8.98 | Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. ( Bennaghmouch, N; Bode, K; Brueckmann, M; de Veer, AJWM; Dewilde, WJM; Kleine, E; Lip, GYH; Mahmoodi, BK; Ten Berg, JM, 2018) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 8.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "Based on the downregulation of CAIX level, both in vitro and in vivo, AcAs can overcome the acquired resistance and more effectively attenuate myocardial ischemia and hypoxia injury than that of aspirin." | 8.12 | An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection. ( Fan, K; Gou, S; Liu, J; Yin, X; Zhang, B; Zhou, W, 2022) |
| "Beside its therapeutic role in the thrombotic vascular events, Clopidogrel confers significant protection against ischemic myocardial injury by counteracting the platelet-mediated inflammation and oxidative stress associated with HFD-C consumption in animals." | 7.96 | Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice. ( Korish, AA, 2020) |
| "Aspirin is recommended in stable coronary artery disease based on myocardial infarction and stroke studies." | 7.81 | Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. ( Bavry, AA; Cooper-DeHoff, RM; Gong, Y; Handberg, EM; Pepine, CJ, 2015) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 7.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| "To quantify the relative risk of epistaxis for patients taking low-dose aspirin or clopidogrel compared to patients taking neither drug." | 7.75 | Clopidogrel versus low-dose aspirin as risk factors for epistaxis. ( Molony, NC; Rainsbury, JW, 2009) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 7.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "To identify the risk factors for myocardial ischemia in patients undergoing aspirin therapy for coronary artery disease (CAD) presenting with upper gastrointestinal hemorrhage and to ascertain the impacts on mortality and length of hospital stay." | 7.74 | Silent myocardial ischemia in coronary artery disease patients under aspirin therapy presenting with upper gastrointestinal hemorrhage. ( Chen, CC; Chong, CF; Kuo, CD; Wang, TL, 2007) |
| " Aspirin non-responsiveness is more frequent in severe infections, such as pneumonia." | 7.74 | Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. ( Karlsson, F; Modica, A; Mooe, T, 2007) |
| "Silent myocardial ischemia (SMI) is a relatively common complication in patients with coronary artery disease (CAD) under aspirin therapy presenting with upper gastrointestinal hemorrhage (UGIH)." | 7.74 | A risk score to predict silent myocardial ischemia in patients with coronary artery disease under aspirin therapy presenting with upper gastrointestinal hemorrhage. ( Chen, CC; Chong, CF; Kuo, CD; Wang, TL, 2007) |
| " All of them concomitantly received 100 mg/day aspirin because of previous ischaemic heart disease and presented similar clinical features: sudden onset of abdominal pain during a severe cough episode due to bronchial infection." | 7.73 | Prophylaxis with enoxaparin can produce a giant abdominal wall haematoma when associated with low doses of aspirin among elderly patients suffering cough attacks. ( Gonzalez-Ordonez, AJ; Macías-Robles, MD; Peliz, MG, 2005) |
| "Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available." | 7.73 | Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006) |
| "Aspirin has been shown to be beneficial after a myocardial infarction and for other acute coronary syndromes." | 7.71 | Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics? ( Elwood, P; Smith, A; Woollard, M, 2001) |
| " The effect of the nitro-derivative of aspirin, NCX4016, was assessed on ischaemic ventricular arrhythmias and myocardial infarct size in anaesthetized pigs in comparison to native aspirin." | 7.71 | NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. ( Del Soldato, P; Miller, AM; Wainwright, CL; Work, LM, 2002) |
| "Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats." | 7.70 | Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis. ( Jayakumar, R; Jayasundar, S; Malarvannan, P; Puvanakrishnan, R; Ramesh, CV, 1998) |
| "The effects of aspirin and indomethacin on the ventricular arrhythmias produced by ligation (ischaemia) and unligation (reperfusion) of the circumflex branch of the left coronary vessel were evaluated in fifty male rabbits weighing 1." | 7.69 | Effects of aspirin and indomethacin on ventricular arrhythmias--comparative study. ( Bhatti, AS; Khan, HH, 1994) |
| "We conducted a retrospective case-control study to compare the frequency of myocardial infarction (MI) or unstable angina (UA) precipitated by aspirin-induced upper gastrointestinal (GI) bleeding among patients with and without ischemic heart disease(IHD), and to determine whether the risk of MI or UA is related to the hemoglobin level on admission." | 7.69 | Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. ( Amital, H; Bar Dayan, Y; Levy, Y; Shoenfeld, Y, 1996) |
| "Our results show that myocardial ischemia/reperfusion stimulates production of NO by circulating neutrophils, an effect that was enhanced in the presence of aspirin." | 7.69 | Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits. ( Alonso, J; Caramelo, C; Casado, S; Cernadas, MR; de Frutos, T; de Miguel, LS; Digiuni, E; López-Farré, A; Millás, I; Montón, M; Mosquera, JR; Riesco, A, 1996) |
| "Aspirin treated patients have lower Vascular Endothelial Growth Factor titer levels in the perioperative course." | 6.71 | Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. ( Fogel, M; Gerrah, R; Gilon, D, 2004) |
| "We examined the prevalence and medical treatment of hypertension among 15,904 ACS patients randomized in the SYMPHONY and 2nd SYMPHONY trials." | 6.71 | Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical ( Armstrong, PW; Aylward, PE; Bhapkar, MV; Frazier, CG; Klein, WW; Kristinsson, A; McGuire, DK; Newby, LK; Sadowski, Z; Shah, SH; Weaver, WD, 2005) |
| "Treatment with aspirin emerged as an independent predictor of reduced cardiovascular (RR = 0." | 6.68 | Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Israeli BIP Study Group. ( Behar, S; Benderly, M; Goldbourt, U; Harpaz, D; Kishon, Y, 1996) |
| "Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making." | 6.58 | Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. ( Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018) |
| "Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal." | 6.42 | Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. ( Michiels, JJ, 2003) |
| "Aspirin was better than placebo, safer than oral anticoagulants, and no different from clopidogrel." | 6.40 | Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? ( Patrono, C, 1998) |
| " This study intends to carry out an evaluation of whether combining rivaroxaben with aspirin will be effective and safe in treating patients experiencing chronic CAD." | 5.72 | Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis. ( Li, X; Wang, H; Wu, H; Wu, X; Xie, G, 2022) |
| "In aspirin-treated ACS patients, MRP-8/14 and 11-dehydro-TXB2 were lower versus those not receiving aspirin (P<0." | 5.40 | Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. ( Davì, G; Di Marco, M; Di Nicola, M; La Barba, S; Lattanzio, S; Liani, R; Mascellanti, M; Paloscia, L; Pascale, S; Santilli, F, 2014) |
| "Aspirin was more effective than L-arginine in prolonging prothrombin time." | 5.37 | Protective effect of L-arginine in experimentally induced myocardial ischemia: comparison with aspirin. ( Abdel Maksoud, SM; El-Maraghy, SA; Gad, MZ; Saleh, AI, 2011) |
| "A patient with Kawasaki disease is reported who had a medium-sized CAA prematurely occluded with thrombi during regression, resulting in myocardial ischemia." | 5.35 | Accelerated thrombotic occlusion of a medium-sized coronary aneurysm in Kawasaki disease by the inhibitory effect of ibuprofen on aspirin. ( Kwon, K; Sohn, S, 2008) |
| "Concomitant ischemic heart disease (IHD) is common in older individuals with heart failure (HF)." | 5.31 | Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure? ( Barbour, MM; Hume, AL; Lapane, KL; Lipsitz, LA, 2002) |
| "Coronary thrombosis was produced by insertion of a thrombogenic copper coil into the LAD of 40 anesthetized pigs." | 5.30 | Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran. ( Hatori, N; Mattsson, C; Nordlander, R; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD, 1998) |
| "Aspirin 0." | 5.28 | Combined effect of captopril and aspirin in renal hemodynamics in elderly patients with congestive heart failure. ( Averbuch, M; Finkelstein, A; Greenland, M; Kornowski, R; Lehrman, H; Levo, Y; Pines, A; Schwartz, D, 1992) |
| "Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces thrombotic events in patients undergoing percutaneous coronary intervention (PCI), but these benefits come at the expense of increased risk of bleeding when compared with aspirin monotherapy." | 5.27 | Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial. ( Cho, BR; Cho, DK; Choi, JH; Choi, SH; Gwon, HC; Hahn, JY; Im, ES; Lee, JM; Lee, JY; Lee, SH; Oh, JH; Oh, SK; Park, TK; Song, YB; Yang, JH, 2018) |
| "In patients with ischemic heart disease and type 2 diabetes mellitus in 4-6 weeks after acute coronary syndrome (ACS) on stable dual antiplatelet therapy (DAPT) with aspirin and clopidogrel co-adminstrated with rosuvastatin residual platelet reactivity on adenosine diphosphate was higher than in patients receiving atorvastatin." | 5.24 | [IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME]. ( Kochubiei, O; Ovrakh, T; Serik, S, 2017) |
| "Dual antiplatelet therapy beyond 1 year after placement of a drug-eluting stent, as compared with aspirin therapy alone, significantly reduced the risks of stent thrombosis and major adverse cardiovascular and cerebrovascular events but was associated with an increased risk of bleeding." | 5.19 | Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. ( Braunwald, E; Cohen, DJ; Cutlip, DE; Dauerman, HL; Driscoll-Shempp, P; Garratt, KN; Hermiller, J; Holmes, DR; Kandzari, DE; Kereiakes, DJ; Krucoff, MW; Lee, DP; Massaro, JM; Mauri, L; Normand, SL; Pow, TK; Rinaldi, MJ; Simon, DI; Steg, PG; Ver Lee, P; Wiviott, SD; Yeh, RW, 2014) |
| "Patients with medically managed unstable angina or non-ST-segment elevation myocardial infarction were enrolled in the TRILOGY ACS trial (2008 to 2011) comparing clopidogrel vs prasugrel." | 5.16 | Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. ( Armstrong, PW; Brown, E; Chan, MY; Cornel, JH; Erlinge, D; Fox, KA; Goodman, SG; Gurbel, PA; Huber, K; Jakubowski, JA; Neely, B; Neely, M; Ohman, EM; Prabhakaran, D; Roe, MT; Tantry, US; White, HD; Zhou, C, 2012) |
| "The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of atherosclerotic diseases." | 5.15 | Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. ( Akai, Y; Doi, N; Jinnouchi, H; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2011) |
| "In this large observational analysis of patients undergoing PCI, low-dose aspirin appeared to be as effective as higher doses in preventing ischaemic events but was also associated with a lower rate of major bleeding and an improved net efficacy to safety balance." | 5.14 | Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. ( Avezum, A; Fox, KA; Gersh, BJ; Haladyn, K; Jolly, SS; Mehta, SR; Peters, RJ; Pogue, J; Rupprecht, HJ; Yusuf, S, 2009) |
| " Apixaban, an oral direct factor Xa inhibitor, is a novel anticoagulant that may reduce these events but also poses a risk of bleeding." | 5.14 | Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. ( Alexander, JH; Becker, RC; Bhatt, DL; Cools, F; Crea, F; Dellborg, M; Fox, KA; Goodman, SG; Harrington, RA; Huber, K; Husted, S; Lewis, BS; Lopez-Sendon, J; Mohan, P; Montalescot, G; Ruda, M; Ruzyllo, W; Verheugt, F; Wallentin, L, 2009) |
| "We measured the urinary excretion of ATL in 24 patients with both ischaemic heart disease and osteoarthritis, chronically treated with aspirin and co-administered celecoxib 200 mg b." | 5.14 | Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors. ( De Caterina, R; Renda, G; Romano, M; Zurro, M, 2010) |
| "In CHARISMA, there was an increased risk of bleeding with long-term clopidogrel." | 5.14 | Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR ( Berger, PB; Bhatt, DL; Brennan, DM; Fox, KA; Fuster, V; Hacke, W; Montalescot, G; Shao, M; Steg, PG; Steinhubl, SR; Topol, EJ, 2010) |
| "Prasugrel is superior to clopidogrel in preventing ischemic events in patients with an acute coronary syndrome who are undergoing percutaneous coronary intervention, but it is associated with an increased risk of major bleeding." | 5.13 | Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys ( Antman, EM; Braunwald, E; Chandna, H; Hasin, Y; Macias, W; McCabe, CH; Murphy, SA; Voitk, J; Widimsky, P; Wiviott, SD, 2008) |
| "We performed a placebo-controlled, randomized study to address whether celecoxib or ibuprofen undermines the functional range of inhibition of platelet cyclooxygenase (COX)-1 activity by aspirin in patients with osteoarthritis and stable ischemic heart disease." | 5.12 | Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. ( Capone, ML; D'Amelio, E; De Caterina, R; Grana, M; Patrignani, P; Patrono, C; Price, TS; Renda, G; Sacchetta, D; Santarelli, F; Sciulli, MG; Tacconelli, S; Zimarino, M; Zurro, M, 2006) |
| " It was the aim of the present study to assess whether the response to aspirin and clopidogrel may be influenced by the 807 C/T polymorphism of the glycoprotein Ia (GpIa) gene in patients with non-ST elevation acute coronary syndrome (NSTE ACS)." | 5.12 | Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome. ( Alessi, MC; Bonnet, JL; Camoin, L; Cuisset, T; Frere, C; Juhan-Vague, I; Lambert, M; Morange, PE; Quilici, J; Romero-Barra, M; Saut, N, 2007) |
| " We investigated if adding clopidogrel to aspirin treatment could attenutate stress-induced platelet activation and myocardial ischemia in patients with coronary artery disease (CAD)." | 5.12 | Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease. ( Hjemdahl, P; Hofman-Bang, C; Ivert, T; Li, N; Perneby, C; Tornvall, P; Wallén, NH, 2007) |
| " Platelet-leukocyte conjugate formation (induced by thrombin receptor activating peptide (TRAP)) and platelet aggregation (induced by ADP and arachidonic acid) were assessed in 30 patients with unstable angina or non-ST elevation myocardial infarction." | 5.11 | Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes. ( Bolton, ED; Braunstein, JB; Chiles, KA; Faraday, N; Gerstenblith, G; Heldman, AW; Schulman, SP, 2004) |
| "To evaluate whether aspirin reduces the incidence and frequency of daily life myocardial ischaemia in a cohort of patients with chronic stable coronary artery disease." | 5.11 | Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor. ( Andreotti, F; Ikonomidis, I; Nihoyannopoulos, P, 2004) |
| "In the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) trial, 12 562 patients were randomized to clopidogrel or placebo in addition to aspirin, and the primary outcome was cardiovascular (CV) death, myocardial infarction (MI), or stroke." | 5.11 | Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. ( Fox, KA; Gersh, BJ; Lakkis, N; Mehta, SR; Peters, R; Yusuf, S; Zhao, F, 2004) |
| "Effectiveness of a prolonged form of diltiazem was studied in 20 patients with stable effort angina and chronic cardiac failure (NYHA functional class II)." | 5.10 | [Dilzem-retard efficiency in patients with ischemic heart disease and heart failure]. ( Gadzhiev, AN, 2002) |
| "We studied stent thrombosis in 4,607 patients with acute coronary syndromes who received a coronary stent as part of routine care during 2 trials of aspirin versus sibrafiban for secondary prevention." | 5.10 | Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials). ( Berger, PB; Bhapkar, MV; Califf, RM; Harrington, RA; Moliterno, DJ; Newby, LK; Ohman, EM; Tolleson, TR; Topol, EJ; Van de Werf, F; Verheugt, FW; White, HD, 2003) |
| " We aimed to assess the effectiveness of ximelagatran and acetylsalicylic acid for prevention of death, non-fatal myocardial infarction, and severe recurrent ischaemia after a recent myocardial infarction." | 5.10 | Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial. ( Bylock, A; Emanuelsson, H; Goodvin, A; Nyström, P; Wallentin, L; Weaver, WD; Wilcox, RG, 2003) |
| "Combining aspirin with LDS did not improve outcomes after acute coronary syndromes and caused more bleeding compared with aspirin alone." | 5.09 | Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes. ( , 2001) |
| "The combination of aspirin and warfarin is likely to be more effective than either agent alone in the prevention of ischemic heart disease (IHD), but its practical value also crucially depends on a low incidence of serious bleeding." | 5.08 | Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk. ( Meade, TW; Miller, GJ, 1995) |
| " We evaluated tirofiban, a specific inhibitor of the platelet glycoprotein IIb/IIIa receptor, in the treatment of unstable angina and non-Q-wave myocardial infarction." | 5.08 | Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. ( , 1998) |
| "In a multicenter trial of antithrombotic therapy in unstable angina or non-Q wave myocardial infarction, 358 patients admitted within 48 h of chest pain were randomized to antithrombotic therapy with either 1) aspirin alone, or 2) aspirin plus heparin followed by aspirin plus warfarin, and were prospectively followed up for 12 weeks." | 5.07 | Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. ( Adams, PC; Chamberlain, D; Chesebro, JH; Cohen, M; Fox, KA; Fuster, V; McBride, R; Parry, G; Wieczorek, I; Xiong, J, 1993) |
| "This study compared the effects of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina." | 5.07 | Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina. ( Cunningham, D; Fox, K; Hendry, G; Holdright, D; Hubbard, W; Patel, D; Sutton, G; Thomas, R, 1994) |
| "The results of the THEMIS trial, conducted in DM patients with stable coronary artery disease and no prior stroke or myocardial infarction, showed that although ticagrelor in addition to aspirin reduced the risk of ischemic events, this was associated with a parallel increase in bleeding complications." | 5.05 | An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus. ( Angiolillo, DJ; Calderone, D; Capodanno, D, 2020) |
| " Similarly, in patients with stable coronary artery disease, two-thirds of whom had a history of myocardial infarction, dual antithrombotic therapy with very-low-dose rivaroxaban and aspirin also resulted in improved ischaemic outcomes." | 5.01 | Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease? ( Geisler, T; Kristensen, SD; Storey, RF; Sumaya, W, 2019) |
| "A systematic electronic literature search was done in MEDLINE, EMBASE, and Cochrane CENTRAL Register of Controlled Trials for studies including published data of patients ≥18 years of age with nonvalvular atrial fibrillation, randomized to either VKAs or NOACs, or receiving aspirin therapy at any time during the study that report all-cause stroke or systemic embolism, vascular death, myocardial infarction, major bleeding, or intracranial hemorrhage as an outcome." | 4.98 | Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials. ( Bennaghmouch, N; Bode, K; Brueckmann, M; de Veer, AJWM; Dewilde, WJM; Kleine, E; Lip, GYH; Mahmoodi, BK; Ten Berg, JM, 2018) |
| "After acute coronary syndromes (ACS), the so-called dual antiplatelet therapy (DAPT), which usually consists of low-dose of aspirin in combination with a thienopyridine (clopidogrel, prasugrel) or with a cyclopentyltriazolopyrimidine (ticagrelor), reduces the risk of ischemic events." | 4.93 | Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia. ( Bianco, D; Brunelli, C; Chiarella, F; Massobrio, L; Rosa, GM; Valbusa, A, 2016) |
| "Vorapaxar is a novel antiplatelet agent that has demonstrated efficacy in reducing atherosclerotic events in patients with a history of MI or PAD without a history of stroke, transient ischemic attack, or ICH when taken in combination with aspirin and clopidogrel." | 4.91 | Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease. ( Arif, SA; D'Souza, J; Gil, M; Gim, S, 2015) |
| "The safety of fixed-dose combination aspirin-extended-release (ER) dipyridamole for stroke prevention in patients with ischemic heart disease is reviewed." | 4.86 | Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease. ( Crown, N; Mysak, T, 2010) |
| "Theoretical models suggest that a polypill containing low-dose aspirin, three blood pressure-lowering drugs at half dose and a potent statin, administered to a large proportion of the population at risk for cardiovascular events, could reduce ischemic heart disease and strokes by over 80%." | 4.85 | Polypill: the evidence and the promise. ( Lonn, E; Yusuf, S, 2009) |
| " This review documents recent advances in the use of clopidogrel for the management of myocardial ischemia." | 4.84 | The role of clopidogrel in the management of ischemic heart disease. ( Galla, JM; Lincoff, AM, 2007) |
| "Clopidogrel has demonstrated improved outcomes for patients with acute coronary syndromes in several large randomized controlled trials." | 4.84 | Clopidogrel: who, when, and how? ( Cannon, CP, 2007) |
| "Aspirin is a relatively inexpensive and effective agent for secondary stroke prevention, and lower doses of aspirin appear as effective as higher doses." | 4.81 | Antiplatelet agents for secondary prevention of ischemic stroke. ( Delanty, N; Kantor, J; Majid, A, 2001) |
| "In the medical literature reports are accumulating a number of case reports suggesting the potential efficacy and safety of the combination of low-dose aspirin and warfarin to improve the efficacy of antithrombotic therapy in several clinical conditions, ranging from unstable angina to myocardial infarction." | 4.79 | [The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?]. ( Casazza, F; Cimminiello, C; Soncini, M, 1995) |
| " The recent clinical reports suggest that there is a narrower window of safety with recombinant hirudin than initially thought particularly when it is used in conjunction with thrombolytic agents and aspirin in acute myocardial infarction." | 4.79 | Advances in antithrombotic therapy: novel agents. ( Hirsh, J; Turpie, AG; Weitz, JI, 1995) |
| "Based on the downregulation of CAIX level, both in vitro and in vivo, AcAs can overcome the acquired resistance and more effectively attenuate myocardial ischemia and hypoxia injury than that of aspirin." | 4.12 | An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection. ( Fan, K; Gou, S; Liu, J; Yin, X; Zhang, B; Zhou, W, 2022) |
| "Beside its therapeutic role in the thrombotic vascular events, Clopidogrel confers significant protection against ischemic myocardial injury by counteracting the platelet-mediated inflammation and oxidative stress associated with HFD-C consumption in animals." | 3.96 | Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice. ( Korish, AA, 2020) |
| " For patients with MINS who are not at high risk of bleeding, physicians should consider initiating dabigatran 110 mg twice daily and low-dose aspirin." | 3.96 | Myocardial injury after non-cardiac surgery: diagnosis and management. ( Devereaux, PJ; Szczeklik, W, 2020) |
| "The COMPASS (Cardiovascular Outcomes for People Using Anticoagulation Strategies) trial found clinical benefit of low-dose rivaroxaban plus aspirin, but at the expense of increased bleeding risk in patients with stable vascular disease." | 3.91 | Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients. ( Abtan, J; Bhatt, DL; Darmon, A; Ducrocq, G; Elbez, Y; Montalescot, G; Ohman, EM; Popovic, B; Röther, J; Sorbets, E; Steg, PG; Wilson, PF; Zeymer, U, 2019) |
| "The patient has been treated with statin, ezetimibe, aspirin, and traditional heart failure (HF) medications." | 3.88 | Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report. ( Kuang, H; Li, L; Lu, T; Shou, W; Yi, Q; Zhou, X, 2018) |
| "In clopidogrel treated PCI patients, the 2-year adjusted risk of MACE and NACE was significantly higher in PPI users driven by higher TLR compared to non-PPI users, without a difference in bleeding." | 3.85 | Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. ( Aquino, M; Ariti, C; Baber, U; Bansilal, S; Chandrasekhar, J; Chieffo, A; Cohen, D; Colombo, A; Dangas, G; Faggioni, M; Farhan, S; Gabriel Steg, P; Giustino, G; Henry, T; Kini, A; Mehran, R; Michael Gibson, C; Moliterno, D; Pocock, S; Saporito, R; Sartori, S; Stuckey, T; Vogel, B; Witzenbichler, B, 2017) |
| "Aspirin is recommended in stable coronary artery disease based on myocardial infarction and stroke studies." | 3.81 | Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort. ( Bavry, AA; Cooper-DeHoff, RM; Gong, Y; Handberg, EM; Pepine, CJ, 2015) |
| " Aspirin should be continued perioperatively in the majority of surgical operations, whereas dual antiplatelet therapy should not be withdrawn for surgery in the case of low bleeding risk." | 3.80 | Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies. ( Angiolillo, DJ; Antonelli, M; Biglioli, F; Boni, L; Bovenzi, F; Bozzani, A; Bramucci, E; Buffoli, F; Capodanno, D; Castiglioni, B; Comel, A; Cremonesi, A; Crescini, C; D'Angelo, F; De Servi, S; Dionigi, G; Droghetti, A; Francetti, L; Gadda, F; Guagliumi, G; Lettieri, C; Lettino, M; Lorini, L; Musumeci, G; Parolari, A; Piccaluga, E; Ravelli, P; Rossini, R; Salvi, L; Savonitto, S; Scarone, P; Setacci, C; Staurenghi, G; Trabattoni, D; Valdatta, L; Visconti, LO, 2014) |
| "The role of concomitant aspirin (ASA) therapy in patients with atrial fibrillation (AF) receiving oral anticoagulation (OAC) is unclear." | 3.79 | Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry. ( Ansell, J; Chang, P; Ezekowitz, MD; Fonarow, GC; Gersh, B; Go, AS; Hylek, E; Kim, S; Kowey, P; Lopes, RD; Mahaffey, KW; Peterson, ED; Piccini, JP; Singer, DE; Steinberg, BA; Thomas, L, 2013) |
| " Old age, bilateral diverticulosis, presence of atherosclerosis related diseases (hypertension, diabetes mellitus, ischemic heart disease, obesity), use of aspirin, NSAIDs and calcium channel blocker, increased the risk of bleeding." | 3.78 | [The risk factors for colonic diverticular bleeding]. ( Hwang, JH; Jeong, SH; Jo, HJ; Jung, HC; Kim, HY; Kim, JW; Kim, N; Lee, DH; Lee, SH; Park, H; Park, YS; Seo, PJ; Shin, CM; Song, IS; Suh, S, 2012) |
| "Increased baseline platelet reactivity as well as diabetes mellitus and acute coronary syndrome are associated with low aspirin response in the aged patients." | 3.77 | [Aspirin response and related factors in aged patients]. ( Fan, Y; Feng, XR; Liu, F; Liu, ML; Liu, QZ; Tian, QP, 2011) |
| "To quantify the relative risk of epistaxis for patients taking low-dose aspirin or clopidogrel compared to patients taking neither drug." | 3.75 | Clopidogrel versus low-dose aspirin as risk factors for epistaxis. ( Molony, NC; Rainsbury, JW, 2009) |
| "The aim of this article is to examine whether clopidogrel and ticlopidine treatments produce similar clinical outcomes for patients receiving primary stenting for acute myocardial infarction (AMI)." | 3.74 | Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial. ( Brener, M; Carroll, JD; Cox, DA; Cristea, E; Garcia, E; Grines, CL; Guagliumi, G; Lansky, AJ; Leon, MB; Mehran, R; Moses, J; Pietras, C; Rutherford, BD; Stone, GW; Stuckey, T; Tcheng, JE; Tsuchiya, Y; Turco, M, 2008) |
| "To identify the risk factors for myocardial ischemia in patients undergoing aspirin therapy for coronary artery disease (CAD) presenting with upper gastrointestinal hemorrhage and to ascertain the impacts on mortality and length of hospital stay." | 3.74 | Silent myocardial ischemia in coronary artery disease patients under aspirin therapy presenting with upper gastrointestinal hemorrhage. ( Chen, CC; Chong, CF; Kuo, CD; Wang, TL, 2007) |
| "High post-treatment platelet reactivity (HPPR=adenosine diphosphate [ADP] 10 microM-induced platelet aggregation >70%) identifies low responders to dual antiplatelet therapy with increased risk of recurrent cardiovascular (CV) events after stenting for non-ST elevation acute coronary syndromes (NSTE-ACS)." | 3.74 | High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes. ( Alessi, MC; Bali, L; Bonnet, JL; Cuisset, T; Frere, C; Lambert, M; Mielot, C; Morange, PE; Nait-Saidi, L; Quilici, J, 2007) |
| " Aspirin non-responsiveness is more frequent in severe infections, such as pneumonia." | 3.74 | Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection. ( Karlsson, F; Modica, A; Mooe, T, 2007) |
| "Silent myocardial ischemia (SMI) is a relatively common complication in patients with coronary artery disease (CAD) under aspirin therapy presenting with upper gastrointestinal hemorrhage (UGIH)." | 3.74 | A risk score to predict silent myocardial ischemia in patients with coronary artery disease under aspirin therapy presenting with upper gastrointestinal hemorrhage. ( Chen, CC; Chong, CF; Kuo, CD; Wang, TL, 2007) |
| " All of them concomitantly received 100 mg/day aspirin because of previous ischaemic heart disease and presented similar clinical features: sudden onset of abdominal pain during a severe cough episode due to bronchial infection." | 3.73 | Prophylaxis with enoxaparin can produce a giant abdominal wall haematoma when associated with low doses of aspirin among elderly patients suffering cough attacks. ( Gonzalez-Ordonez, AJ; Macías-Robles, MD; Peliz, MG, 2005) |
| " He was subsequently diagnosed with rheumatoid arthritis and prescribed 20 mg methotrexate weekly, 3 mg/kg ciclosporin daily and 5 mg prednisolone daily." | 3.73 | Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. ( Alivernini, S; De Santis, M; Ferraccioli, G; Loperfido, F; Verrillo, A; Zoli, A, 2006) |
| "Aspirin is used in combination with anticoagulant therapy in patients with atrial fibrillation (AF), but evidence of additional efficacy is not available." | 3.73 | Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials. ( Chaparro, S; Connolly, SJ; Flaker, GC; Goldman, S; Gruber, M; Halinen, MO; Halperin, JL; Horrow, J; Vahanian, A, 2006) |
| "The purpose of the study was to evaluate the clinico-diagnostic importance of the degree of inflammation and endothelial dysfunction in patients with chronic heart failure (CHF) receiving either standard therapy including ACE inhibitors or the same therapy plus aspirin." | 3.73 | [The degree of inflammation and endothelial dysfunction in treatment of chronic heart failure in patients with coronary artery disease]. ( Al'tshuler, MIu; Kozlova, IV; Rebrov, AP; Sazhina, EIu, 2006) |
| "Patients suffering an acute myocardial infarction routinely receive morphine and nonsteroidal anti-inflammatory drugs (NSAIDs) alone or in combination." | 3.72 | Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase. ( Gross, ER; Gross, GJ; Hsu, AK, 2004) |
| " Thus, we assessed whether platelet function under high shear rates (collagen adenosine diphosphate closure times [CADP-CTs]) measured with the platelet function analyzer (PFA-100) may be enhanced in patients with myocardial infarction (MI) and whether it may predict the extent of myocardial damage as measured by creatine kinase (CK-MB) or troponin T (TnT) levels." | 3.72 | Platelet function predicts myocardial damage in patients with acute myocardial infarction. ( Domanovits, H; Frossard, M; Fuchs, I; Hsieh, K; Jilma, B; Laggner, AN; Leitner, JM; Losert, H; Schreiber, W; Vlcek, M, 2004) |
| "Aspirin has been shown to be beneficial after a myocardial infarction and for other acute coronary syndromes." | 3.71 | Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics? ( Elwood, P; Smith, A; Woollard, M, 2001) |
| " The effect of the nitro-derivative of aspirin, NCX4016, was assessed on ischaemic ventricular arrhythmias and myocardial infarct size in anaesthetized pigs in comparison to native aspirin." | 3.71 | NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs. ( Del Soldato, P; Miller, AM; Wainwright, CL; Work, LM, 2002) |
| "Isoproterenol hydrochloride (ISO), a beta adrenergic agonist, is known to cause ischemic necrosis in rats." | 3.70 | Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis. ( Jayakumar, R; Jayasundar, S; Malarvannan, P; Puvanakrishnan, R; Ramesh, CV, 1998) |
| "Elderly men are more likely than elderly women to receive aspirin and ticlopidine and equally like to receive warfarin after a stroke." | 3.70 | Sex differences and similarities in the management and outcome of stroke patients. ( Austin, PC; Holroyd-Leduc, JM; Kapral, MK; Tu, JV, 2000) |
| "To analyse the economic benefits, in comparison with placebo, of the secondary prevention of ischaemic stroke and myocardial infarction (MI) with lysine acetylsalicylate (Kardégic) in patients with a history of ischaemic stroke, MI or stable and unstable angina pectoris." | 3.70 | Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate. ( Lebrun, T; Marissal, JP; Selke, B, 2000) |
| "Mortality after acute myocardial ischemia has been reduced by aspirin (ASA) but mechanisms other than the antiplatelet effect have not been established." | 3.70 | Nonplatelet effects of aspirin during acute coronary occlusion: electrophysiologic and cation alterations in ischemic myocardium. ( Arena, J; Moschos, CB; Regan, TJ; Shehadeh, AA, 2000) |
| "The effects of aspirin and indomethacin on the ventricular arrhythmias produced by ligation (ischaemia) and unligation (reperfusion) of the circumflex branch of the left coronary vessel were evaluated in fifty male rabbits weighing 1." | 3.69 | Effects of aspirin and indomethacin on ventricular arrhythmias--comparative study. ( Bhatti, AS; Khan, HH, 1994) |
| "We conducted a retrospective case-control study to compare the frequency of myocardial infarction (MI) or unstable angina (UA) precipitated by aspirin-induced upper gastrointestinal (GI) bleeding among patients with and without ischemic heart disease(IHD), and to determine whether the risk of MI or UA is related to the hemoglobin level on admission." | 3.69 | Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction. ( Amital, H; Bar Dayan, Y; Levy, Y; Shoenfeld, Y, 1996) |
| "Our results show that myocardial ischemia/reperfusion stimulates production of NO by circulating neutrophils, an effect that was enhanced in the presence of aspirin." | 3.69 | Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits. ( Alonso, J; Caramelo, C; Casado, S; Cernadas, MR; de Frutos, T; de Miguel, LS; Digiuni, E; López-Farré, A; Millás, I; Montón, M; Mosquera, JR; Riesco, A, 1996) |
| "Among 3,602 patients with STEMI who were enrolled in the HORIZONS-AMI (Harmonizing Outcomes with Revascularization and Stents in Acute Myocardial Infarction) trial, all ischemic and bleeding events, including recurrent events, were classified according to the timing of their occurrence as acute (≤24 h after PCI), subacute (1 day to 30 days), and late (30 days to 1 year)." | 2.84 | Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI. ( Brener, SJ; Dangas, GD; Deliargyris, EN; Généreux, P; Giustino, G; Kirtane, AJ; Mehran, R; Pocock, SJ; Prats, J; Redfors, B; Stone, GW, 2017) |
| "60." | 2.79 | Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up. ( Alvarez-Sabín, J; Maisterra, O; Quintana, M; Santamarina, E, 2014) |
| "Patients with Dilated Cardiomyopathy (DCM) were randomised to receive either warfarin or placebo." | 2.72 | Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. ( Cokkinos, DV; Haralabopoulos, GC; Kostis, JB; Toutouzas, PK, 2006) |
| "Aspirin has been associated with adverse heart failure outcomes, probably because of a blunting interaction with angiotensin-converting enzyme (ACE) inhibitors." | 2.72 | Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure. ( Jug, B; Keber, I; Sabovic, M; Sebestjen, M, 2006) |
| "Minor bleeding was more frequent in the enoxaparin group (30." | 2.71 | Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. ( Armstrong, PW; Fitchett, D; Goodman, SG; Langer, A; Tan, M, 2003) |
| "Aspirin treated patients have lower Vascular Endothelial Growth Factor titer levels in the perioperative course." | 2.71 | Aspirin decreases vascular endothelial growth factor release during myocardial ischemia. ( Fogel, M; Gerrah, R; Gilon, D, 2004) |
| "Death and myocardial infarction were recorded during 30 days of follow-up." | 2.71 | N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes. ( Hamm, CW; Heeschen, C; Lantelme, NH; Mitrovic, V; White, HD, 2004) |
| "Aspirin was given to all patients, and ticlopidine 250 mg b." | 2.71 | Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting. ( Balducelli, M; Barlera, S; Bernardi, G; Latini, R; Maggioni, AP; Maresta, A; Moccetti, T; Monici Preti, A; Ribeiro da Silva, EE; Sosa, C; Varani, E, 2005) |
| "Prospective, randomized, double-blind study (POLENOX) proved that administration of low molecular weight heparin (LMWH)--enoxaparin for elective percutaneous coronary interventions (PCI) is as safe and as effective like unfractionated heparin (UFH)." | 2.71 | [Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine]. ( Bartuś, S; Chyrchel, M; Dubiel, JS; Dudek, D; Legutko, J; Rzeszutko, L, 2004) |
| "We examined the prevalence and medical treatment of hypertension among 15,904 ACS patients randomized in the SYMPHONY and 2nd SYMPHONY trials." | 2.71 | Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical ( Armstrong, PW; Aylward, PE; Bhapkar, MV; Frazier, CG; Klein, WW; Kristinsson, A; McGuire, DK; Newby, LK; Sadowski, Z; Shah, SH; Weaver, WD, 2005) |
| "Tirofiban was generally well tolerated and, as compared with heparin, reduced ischemic events during the 48-hour infusion period, during which revascularization procedures were not performed." | 2.69 | A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. ( , 1998) |
| "The six patients with Haemophilia A ranged in severity from moderately to mildly affected." | 2.69 | Cardiac surgery and catheterization in patients with haemophilia. ( MacKinlay, N; Renisson, F; Rickard, K; Taper, J, 2000) |
| "Nonfatal myocardial infarction was present in seven patients in group A, four in group B and none in group C (group B vs." | 2.68 | Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. ( Cerdá, MA; Daroca, AM; Duronto, EA; García, CN; Gurfinkel, EP; Manos, EJ; Mautner, B; Mejaíl, RI, 1995) |
| "Many clinical trials have evaluated the benefit of long-term use of antiplatelet drugs in reducing the risk of clinical thrombotic events." | 2.68 | A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee. ( , 1996) |
| "Treatment with aspirin emerged as an independent predictor of reduced cardiovascular (RR = 0." | 2.68 | Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Israeli BIP Study Group. ( Behar, S; Benderly, M; Goldbourt, U; Harpaz, D; Kishon, Y, 1996) |
| "Eptifibatide treatment did not increase rates of major bleeding or transfusion." | 2.68 | Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. ( , 1997) |
| " Further studies are underway to develop alternative heparin dosing strategies in an effort to reduce the occurrence of bleeding complications associated with c7E3 Fab administration and to assess the benefit of c7E3 Fab-mediated platelet inhibition in lower risk patient subgroups." | 2.67 | Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results. ( Popma, JJ; Satler, LF, 1994) |
| "Aspirin has a complex matrix of benefits and risks, and its use in primary prevention requires individualized decision-making." | 2.58 | Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach. ( Ames, JM; Dugani, S; Manson, JE; Mora, S, 2018) |
| "SIHD is defined as clinical evidence of ischemic heart disease, without an ACS event in the preceding 12 months, and includes patients with stable angina, elective PCI, and remote history of ACS." | 2.53 | Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease. ( Keach, JW; Maddox, TM; Yeh, RW, 2016) |
| "Indeed, Kawasaki disease is no longer a rare cause of acute coronary syndrome presenting in young adults." | 2.53 | Kawasaki Disease. ( Burns, JC; Newburger, JW; Takahashi, M, 2016) |
| "Aspirin was established more than a quarter century ago as an evidence-based therapy to reduce recurrent cardiovascular events in patients with coronary artery disease based on limited data by contemporary standards." | 2.53 | A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. ( Bode, C; Gibson, CM; James, S; Ohman, EM; Povsic, TJ; Roe, MT; Steg, PG; Welsh, RC, 2016) |
| "Major bleeding was the primary end point, whereas all-cause death, myocardial infarction (MI), stent thrombosis, and stroke were secondary ones." | 2.52 | Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention. ( Ballocca, F; Bangalore, S; Barbero, U; Capodanno, D; Cerrato, E; Conrotto, F; D'Ascenzo, F; Dewilde, W; DiNicolantonio, J; Fernández, S; Gaita, F; Giordana, F; Grossomarra, W; Lamberts, M; Meier, P; Meynet, I; Moretti, C; Omedè, P; Persson, J; Quadri, G; Reed, M; Rubboli, A; Taha, S; Zoccai, G, 2015) |
| " This systematic review assesses the efficacy and safety of adjunctive cilostazol to DAT in combination with DAT on reducing clinical adverse events." | 2.49 | Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials. ( Ding, XL; Gao, J; Jiang, B; Miao, LY; Xie, C; Zhang, H; Zhang, JJ; Zhang, LL, 2013) |
| "Aspirin is an antiplatelet drug, inhibiting the cyclooxygenase activity of platelet prostaglandin H synthase-1 and almost complete suppressing platelet capacity to generate the prothrombotic and proatherogenic thromboxane A2." | 2.48 | Clinical use of aspirin in ischemic heart disease: past, present and future. ( De Caterina, R; Renda, G, 2012) |
| "Fibrinolysis is the reference treatment for most myocardial infarctions with ST-segment elevation; alternatives are angioplasty, with or without stent." | 2.43 | New anticoagulants in ischemic heart disease. ( Verheugt, FW, 2005) |
| " The pharmacokinetics of in vivo aspirin- and NO- released by NCX 4016, as well as the bioavailability of the two molecules, were not yet adequately studied." | 2.43 | Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders. ( Gresele, P; Momi, S, 2006) |
| "Aspirin treatment of erythromelalgia in thrombocythemia patients resulted in the disappearance of the erythromelalgic, thrombotic signs and symptoms, correction of the shortened platelet survival times, and a significant reduction of the increased levels of beta-TG, PF4, TM and urinary TxB2 excretion to normal." | 2.42 | Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts. ( Michiels, JJ, 2003) |
| "Aspirin treatment does not preclude control of underlying and comorbid conditions such as diabetes mellitus, hypertension, and dyslipidemia." | 2.41 | Aspirin in the prophylaxis of coronary artery disease. ( Mehta, P, 2002) |
| " They analyze also the effect of dosage (benefit vs." | 2.41 | [Acetylsalicylic acid (ASA)--is everything clear?]. ( Spinar, J; Vítovec, J, 2002) |
| "Patients presenting with unstable angina pectoris or non-Q-wave myocardial infarction (MI), if treated inadequately, are at a high risk of MI and subsequent mortality." | 2.41 | Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial. ( Adgey, AA; Manoharan, G, 2002) |
| "Aspirin was better than placebo, safer than oral anticoagulants, and no different from clopidogrel." | 2.40 | Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage? ( Patrono, C, 1998) |
| "Ischemic heart disease is a serious health problem because it causes considerable mortality and morbidity." | 2.40 | Therapeutic options and cost considerations in the treatment of ischemic heart disease. ( Cleland, JG; Walker, A, 1998) |
| "The final common pathway to the coronary thrombosis underlying ACS involves the aggregation of platelets mediated by the binding of soluble fibrinogen to the platelet receptor glycoprotein (GP) IIb-IIIa." | 2.40 | Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes. ( Harrington, RA, 1999) |
| " This study intends to carry out an evaluation of whether combining rivaroxaben with aspirin will be effective and safe in treating patients experiencing chronic CAD." | 1.72 | Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis. ( Li, X; Wang, H; Wu, H; Wu, X; Xie, G, 2022) |
| "Colchicine (COLC) is a drug with cardiovascular effects." | 1.56 | Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel. ( Cimmino, G; Cirillo, P; Conte, S; Di Serafino, L; Morello, A; Pellegrino, G; Taglialatela, V, 2020) |
| "Objectives A "potential drug-drug interaction" (pDDI) is the possibility one drug has to alter the effects of another when both are administered simultaneously." | 1.56 | Potential drug-drug interactions in ICU patients: a retrospective study. ( Ali, I; Bazzar, A; Hussein, N; Sahhar, E, 2020) |
| "The WMHs and MB were associated with CMBs in patients taking aspirin or clopidogrel for >1 year, and long-term use increased the risks of CMB and bleeding." | 1.51 | Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel. ( Ban, C; Ge, L; Liang, J; Ouyang, X; Wu, H; Wu, Q; Yu, H, 2019) |
| "Five patients (5." | 1.51 | [The Pathways to Increase the Efficacy of Drug Therapy in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting]. ( Barbarash, OL; Hryachkova, ON; Kashtalap, VV; Shibanova, IA; Zykov, MV, 2019) |
| "One-year bleedings were assessed using TIMI (Thrombolysis in Myocardial Infarction), GUSTO (Global Use of Strategies to Open Occluded Arteries), and BARC (Bleeding Academic Research Consortium)." | 1.48 | Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy. ( Cho, YR; Choi, SY; Kim, MH; Min Lee, K; Park, TH; Sung Park, J; Yun, SC, 2018) |
| "The Aspirin-Cardio treatment reduced the mean score of GI symptom severity from the questionnaire (1." | 1.46 | [Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study]. ( Karpukhina, EV; Nekrasov, AA; Petelina, IS; Timoshchenko, ES, 2017) |
| "Treatment with aspirin alone [hazard ratio (HR), 0." | 1.46 | Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study. ( Choi, D; Kang, SM; Kim, HC; Lee, CJ; Lee, SH; Oh, J; Park, S, 2017) |
| "In isoproterenol-treated rats, Zn(ASA)2 treatment normalized significantly impaired left-ventricular contractility index (Emax 2." | 1.42 | Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction. ( Atmanli, A; Barnucz, E; Hegedűs, P; Hirschberg, K; Karck, M; Korkmaz, S; Li, S; Loganathan, S; Radovits, T; Szabó, G; Yasui, H; Yoshikawa, Y, 2015) |
| " With the exception of CVA, all adverse events were significantly higher in positive Tn T group as compared to negative Tn T group." | 1.42 | Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD. ( Campo, G; Ceconi, C; Contoli, M; Guerzoni, F; Malagù, M; Napoli, N; Papi, A; Pavasini, R; Punzetti, S, 2015) |
| " Five adverse events (3." | 1.40 | Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation. ( Cho, YK; Hur, SH; Jung, BC; Kim, H; Kim, KB; Kim, KS; Kim, W; Kim, YN; Lee, BR; Lee, JB; Lee, JH; Nam, CW; Park, HS; Park, JS; Yang, DH; Yoon, HJ, 2014) |
| "In aspirin-treated ACS patients, MRP-8/14 and 11-dehydro-TXB2 were lower versus those not receiving aspirin (P<0." | 1.40 | Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment. ( Davì, G; Di Marco, M; Di Nicola, M; La Barba, S; Lattanzio, S; Liani, R; Mascellanti, M; Paloscia, L; Pascale, S; Santilli, F, 2014) |
| "Aspirin was more effective than L-arginine in prolonging prothrombin time." | 1.37 | Protective effect of L-arginine in experimentally induced myocardial ischemia: comparison with aspirin. ( Abdel Maksoud, SM; El-Maraghy, SA; Gad, MZ; Saleh, AI, 2011) |
| "Chronic myocardial ischemia was induced using a minimally invasive model in 16 landrace pigs." | 1.37 | Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure. ( Abegunewardene, N; Gori, T; Horstick, G; Kreitner, KF; Lehr, HA; Münzel, T; Schmidt, KH; Schreiber, LM; Vosseler, M, 2011) |
| "None experienced strokes or transient ischemic attacks." | 1.35 | Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device. ( Dia, M; Gallagher, C; Silver, MA; Slaughter, MS; Sobieski, MA, 2008) |
| "The lack of reported recurrences may lead to less cautious administration of antithrombotic therapy." | 1.35 | Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy. ( Fonville, S; Ramos, LM; Rinkel, GJ; van der Worp, HB, 2009) |
| "Gastroduodenal ulcers were found in 19 of 101 (18." | 1.35 | Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease. ( Asaka, M; Kato, M; Katsurada, T; Kawai, Y; Nema, H; Nozaki, Y; Okusa, T; Sakurai, M; Sato, K; Takagi, Y; Takiguchi, S; Yoshida, I; Yotsukura, A, 2008) |
| " No clear evidence exists regarding the ideal dosage of aspirin." | 1.35 | Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention: observations from the Ottawa Heart Institute PCI Registry. ( Cook, EF; Davies, R; Froeschl, M; Glover, C; Ha, A; Labinaz, M; Le May, M; Marquis, JF; O'Brien, E; So, D; Williams, W, 2009) |
| "Aspirin was used in 56." | 1.35 | Drug secondary prevention in postmenopausal women with ischemic heart disease. ( Cebanu, M; Pop, D; Sitar-Tăut, A; Zdrenghea, D; Zdrenghea, V, 2009) |
| "A patient with Kawasaki disease is reported who had a medium-sized CAA prematurely occluded with thrombi during regression, resulting in myocardial ischemia." | 1.35 | Accelerated thrombotic occlusion of a medium-sized coronary aneurysm in Kawasaki disease by the inhibitory effect of ibuprofen on aspirin. ( Kwon, K; Sohn, S, 2008) |
| "The aspirin resistance was also linked with the inflammatory process which is a key event for the atherosclerosis development." | 1.34 | Aspirin failure course during exercise and its connection with soluble CD40L. ( Karolko, B; Kobusiak-Prokopowicz, M; Kuliczkowski, W; Mazurek, W; Prajs, I, 2007) |
| "In study 1, 10 patients with ischemic heart disease (IHD) and 10 controls had platelet function assessed by optical platelet aggregation and the PFA-100 method in two 5-week periods." | 1.34 | Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. ( Haghfelt, T; Jørgensen, B; Korsholm, L; Licht, PB; Mickley, H; Poulsen, TS, 2007) |
| "6) by PFA-100], chronic use of aspirin [OR=0." | 1.34 | Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy. ( Abbate, R; Antoniucci, D; Buonamici, P; Gensini, GF; Giglioli, C; Gori, AM; Marcucci, R; Paniccia, R, 2007) |
| "Myocardial ischemia is the leading cause of postoperative mortality and morbidity in patients undergoing major vascular surgery." | 1.34 | Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery. ( Bachoo, P; Brittenden, J; Croal, B; Ford, I; Greaves, M; Hillis, GS; Rajagopalan, S, 2007) |
| "Aspirin resistance was defined as a mean collagen and ATP-induced platelet aggregation >70%." | 1.33 | Aspirin resistance in ischaemic heart disease. ( Halawa, B; Korolko, B; Kuliczkowski, W; Mazurek, W, 2005) |
| "Aspirin resistance was found in 32% of cases." | 1.33 | Prevalence of aspirin resistance measured by PFA-100. ( Castano, S; Coma-Canella, I; Velasco, A, 2005) |
| "Study involved 75 patients (men) with ischemic heart disease, who underwent CABG." | 1.33 | [Influence of preoperative treatment with aspirin or heparin on platelet function and intensity of postoperative bleeding in early period after coronary artery bypass surgery]. ( Cimbolaityte, J; Grybauskas, P; Mongirdiene, A; Sirvinskas, E; Veikutiene, A; Veikutis, V, 2005) |
| " The aim of the monitoring of ASA therapy should be the identification of nonresponders to prevent a long-term intake of the drug without adequate benefit, to justify a dose escalation, or to initiate an alternative antiplatelet drug therapy." | 1.33 | Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100. ( Feuring, M; Losel, R; Schultz, A; Wehling, M, 2005) |
| "The aim of this study was to assess the effect of chronic administration of NCX4016 [2 acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester], a nitric oxide-releasing aspirin derivative on the consequences of coronary artery occlusion in streptozotocin-diabetic rats." | 1.33 | The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat. ( Burke, SG; Furman, BL; Vojnovic, I; Wainwright, CL; Warner, T; Watson, DG, 2006) |
| "Aspirin resistance was dose dependent." | 1.33 | [Acetylsalicylic acid (ASA) resistance in patients with ischemic heart disease (IHD) as bioindicator of the treatment strategy]. ( Bláha, M; Blazek, M; Dulícek, P; Gregor, J; Malý, J; Malý, R; Pecka, M; Pudil, R, 2005) |
| "However, the ratio of stroke to ischemic heart disease is still different between the East and West." | 1.33 | Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy? ( Shinohara, Y, 2006) |
| "However, the treatment of hypercholesterolemia should be improved." | 1.33 | [Recording of risk factors and preventive pharmaceutical therapy among ischemic heart disease patients in family practice during the years 1993-1998]. ( Alperin, M; Goldfracht, M; Hermoni, D, 2006) |
| " However, the concomitant production of superoxide and other reactive oxygen species (ROS) during I/R may diminish the bioavailability of NO and hence compromise the beneficial effects." | 1.33 | Prevention of postischemic myocardial reperfusion injury by the combined treatment of NCX-4016 and Tempol. ( Colantuono, G; Khan, M; Kumbala, D; Kuppusamy, P; Kutala, VK; Mandal, R; Potaraju, V, 2006) |
| "The criteria for dyslipidemia were as follows: total cholesterol > or = 200 mg/dL or LDL-cholesterol > 100 mg/dL, or both, in patients using or not lipid-lowering drugs, and the use of lipid-lowering drugs, even when the total cholesterol or LDL-cholesterol levels were < 200 mg/dL and 100 mg/dL, respectively, or both." | 1.32 | Variability among cardiologists in the management of patients under secondary prevention of ischemic heart disease. ( Alboim, C; Campos, C; Mello, RB; Polanczyk, CA; Rosito, GA; Stein, R, 2004) |
| "Concomitant ischemic heart disease (IHD) is common in older individuals with heart failure (HF)." | 1.31 | Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure? ( Barbour, MM; Hume, AL; Lapane, KL; Lipsitz, LA, 2002) |
| " It is indicated, at a dosage of 75 mg/day, for the reduction of atherosclerotic events including myocardial infarction, ischaemic stroke and vascular death in patients with atherosclerosis manifested by recent stroke, myocardial infarction or established peripheral vascular disease." | 1.31 | [Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)]. ( Scheen, AJ, 2001) |
| "Coronary thrombosis was produced by insertion of a thrombogenic copper coil into the LAD of 40 anesthetized pigs." | 1.30 | Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran. ( Hatori, N; Mattsson, C; Nordlander, R; Rydén, L; Sjöquist, PO; Uriuda, Y; Wang, QD, 1998) |
| "The incidence of ventricular tachycardia (VT) in the abciximab group was significantly lower than in the control group (p < 0." | 1.30 | The effects of antiplatelet agents in the prevention of ventricular tachyarrhythmias during acute myocardial ischemia in rats. ( Ahn, YK; Cho, JG; Cho, JH; Jeong, MH; Kang, JC; Kim, JW; Kim, NH; Kim, SH; Park, JC; Park, JH; Park, WS, 1999) |
| "An increase in the risk of ventricular arrhythmias under conditions of both ischaemia and reperfusion was obvious in the rats that consumed large quantities of saturated fatty acids (coconut oil) and in the group with a very low intake of fat." | 1.29 | Differential effects of various oil diets on the risk of cardiac arrhythmias in rats. ( Isensee, H; Jacob, R, 1994) |
| "Six cases of acute myocardial infarction are reported with early disease reactivation following the abrupt discontinuation of heparin infusion three days after alteplase thrombolysis and concomitant aspirin therapy." | 1.29 | Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction. ( Di Tano, G; Mazzù, A, 1995) |
| "Yohimbine was antiarrhythmic in the presence and absence of platelets, suggesting direct myocardial effects, but BN 52021 had no antiarrhythmic effects." | 1.29 | Myocardial ischaemia induces platelet activation with adverse electrophysiological and arrhythmogenic effects. ( Flores, NA; Goulielmos, NV; Seghatchian, MJ; Sheridan, DJ, 1994) |
| "The essential goal of medical treatment following myocardial infarction with left ventricular dysfunction must be the prevention of secondary cardiac failure." | 1.29 | [What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?]. ( Caviezel, B; Cohen-Solal, A; Gourgon, R; Himbert, D; Laperche, T, 1994) |
| "Aspirin use was found to be associated with less depression and anxiety or worry, as reported by the patient and as perceived by a significant other." | 1.29 | Is aspirin, as used for antithrombosis, an emotion-modulating agent? ( Brymer, J; Ketterer, MW; Kraft, P; Lovallo, WR; Rhoads, K, 1996) |
| "Aspirin 0." | 1.28 | Combined effect of captopril and aspirin in renal hemodynamics in elderly patients with congestive heart failure. ( Averbuch, M; Finkelstein, A; Greenland, M; Kornowski, R; Lehrman, H; Levo, Y; Pines, A; Schwartz, D, 1992) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 108 (24.16) | 18.2507 |
| 2000's | 198 (44.30) | 29.6817 |
| 2010's | 123 (27.52) | 24.3611 |
| 2020's | 18 (4.03) | 2.80 |
| Authors | Studies |
|---|---|
| Melnichnikova, OS | 1 |
| Nazarova, IA | 1 |
| Sirotkina, OV | 1 |
| Panov, AV | 1 |
| Abesadze, IT | 1 |
| Alugishvili, MZ | 1 |
| Lokhovinina, NL | 1 |
| Vavilova, TV | 1 |
| Wang, H | 2 |
| Li, X | 1 |
| Wu, X | 1 |
| Wu, H | 2 |
| Xie, G | 1 |
| Alsharidah, AS | 1 |
| Alsuhaibani, DS | 1 |
| Alsuhaibani, HA | 1 |
| Alsharidah, MS | 1 |
| Hafez Abdel-Moneim, AM | 1 |
| Shrestha, A | 1 |
| Wilson, J | 1 |
| Stys, A | 1 |
| Nakamura, M | 1 |
| Kitazono, T | 1 |
| Kozuma, K | 1 |
| Sekine, T | 1 |
| Nakamura, S | 2 |
| Shiosakai, K | 1 |
| Iizuka, T | 1 |
| Brunetti, ND | 1 |
| De Gennaro, L | 1 |
| Di Biase, M | 1 |
| Caldarola, P | 1 |
| Garg, S | 1 |
| Chichareon, P | 1 |
| Kogame, N | 1 |
| Takahashi, K | 1 |
| Modolo, R | 1 |
| Chang, CC | 1 |
| Tomaniak, M | 1 |
| Fath-Ordoubadi, F | 1 |
| Anderson, R | 1 |
| Oldroyd, KG | 1 |
| Stables, RH | 2 |
| Kukreja, N | 1 |
| Chowdhary, S | 1 |
| Galasko, G | 1 |
| Hoole, S | 1 |
| Zaman, A | 1 |
| Hamm, CW | 2 |
| Steg, PG | 7 |
| Jüni, P | 1 |
| Valgimigli, M | 1 |
| Windecker, S | 1 |
| Onuma, Y | 2 |
| Serruys, PW | 2 |
| Cheng, Y | 1 |
| Liu, X | 1 |
| Zhao, Y | 1 |
| Sun, Y | 1 |
| Zhang, D | 1 |
| Liu, F | 2 |
| Ma, Y | 1 |
| Zhou, Y | 1 |
| Cirillo, P | 1 |
| Taglialatela, V | 1 |
| Pellegrino, G | 1 |
| Morello, A | 1 |
| Conte, S | 1 |
| Di Serafino, L | 1 |
| Cimmino, G | 1 |
| Korish, AA | 1 |
| Alkhalil, M | 1 |
| Shahmohammadi, M | 1 |
| Spence, MS | 1 |
| Owens, CG | 1 |
| Calderone, D | 1 |
| Capodanno, D | 4 |
| Angiolillo, DJ | 5 |
| Ali, I | 1 |
| Bazzar, A | 1 |
| Hussein, N | 1 |
| Sahhar, E | 1 |
| Smilowitz, NR | 3 |
| Berger, JS | 1 |
| Mattioli, M | 1 |
| Benfaremo, D | 1 |
| Fustini, E | 1 |
| Gennarini, S | 1 |
| Zamorano-León, JJ | 1 |
| Gascón, M | 1 |
| Martínez, CH | 1 |
| Freixer, G | 1 |
| Guerra, R | 1 |
| Zekri-Nechar, K | 1 |
| Bernardo, E | 2 |
| Serna-Soto, M | 1 |
| Segura, A | 1 |
| Giner, M | 1 |
| García-Fernández, MA | 1 |
| Macaya, C | 2 |
| López-Farré, AJ | 2 |
| Magnani, G | 1 |
| Ardissino, D | 1 |
| Im, K | 1 |
| Budaj, A | 2 |
| Storey, RF | 3 |
| Bhatt, DL | 6 |
| Cohen, M | 4 |
| Oude Ophius, T | 1 |
| Goudev, A | 1 |
| Parkhomenko, A | 1 |
| Kamensky, G | 1 |
| López-Sendón, J | 2 |
| Johanson, P | 1 |
| Braunwald, E | 4 |
| Sabatine, MS | 1 |
| Bonaca, MP | 1 |
| Tanner, R | 1 |
| Cronin, M | 1 |
| Macken, L | 1 |
| Murphy, R | 1 |
| Maree, AO | 1 |
| Ullah, I | 1 |
| Cosgrave, J | 1 |
| O'Connor, S | 1 |
| Daly, C | 1 |
| Zhou, W | 1 |
| Zhang, B | 1 |
| Fan, K | 1 |
| Yin, X | 1 |
| Liu, J | 1 |
| Gou, S | 1 |
| Brás, R | 1 |
| Caiado, J | 1 |
| Pedro, E | 1 |
| Wadowski, PP | 1 |
| Eichelberger, B | 1 |
| Kopp, CW | 1 |
| Pultar, J | 1 |
| Seidinger, D | 1 |
| Koppensteiner, R | 1 |
| Lang, IM | 1 |
| Panzer, S | 1 |
| Gremmel, T | 1 |
| Kong, DF | 1 |
| Saito, S | 1 |
| Mehran, R | 9 |
| Rowland, SM | 1 |
| Handler, A | 1 |
| Al-Khalidi, HR | 1 |
| Krucoff, MW | 3 |
| Pareek, M | 1 |
| Ten Berg, JM | 2 |
| Kristensen, SD | 2 |
| Grove, EL | 1 |
| Fuertes Ferre, G | 1 |
| Laita Monreal, S | 1 |
| Ortas Nadal, MDR | 1 |
| Sánchez Insa, E | 1 |
| Sánchez Rubio-Lezcano, J | 1 |
| Galache Osuna, JG | 1 |
| Ovrakh, T | 1 |
| Serik, S | 1 |
| Kochubiei, O | 1 |
| Subramanyam, P | 1 |
| Gianos, E | 2 |
| Reynolds, HR | 2 |
| Shah, B | 2 |
| Sedlis, SP | 2 |
| Giustino, G | 3 |
| Dangas, GD | 2 |
| Kirtane, AJ | 3 |
| Redfors, B | 2 |
| Généreux, P | 2 |
| Brener, SJ | 3 |
| Prats, J | 1 |
| Pocock, SJ | 1 |
| Deliargyris, EN | 1 |
| Stone, GW | 5 |
| Bennaghmouch, N | 1 |
| de Veer, AJWM | 1 |
| Bode, K | 1 |
| Mahmoodi, BK | 1 |
| Dewilde, WJM | 1 |
| Lip, GYH | 1 |
| Brueckmann, M | 1 |
| Kleine, E | 1 |
| Strisciuglio, T | 1 |
| Barbato, E | 2 |
| De Biase, C | 1 |
| Di Gioia, G | 1 |
| Cotugno, M | 1 |
| Stanzione, R | 1 |
| Trimarco, B | 1 |
| Sciarretta, S | 1 |
| Volpe, M | 1 |
| Wijns, W | 1 |
| Delrue, L | 1 |
| Rubattu, S | 1 |
| Cleland, JGF | 1 |
| Song, YB | 1 |
| Oh, SK | 1 |
| Oh, JH | 1 |
| Im, ES | 1 |
| Cho, DK | 1 |
| Cho, BR | 1 |
| Lee, JY | 1 |
| Lee, JM | 2 |
| Park, TK | 1 |
| Yang, JH | 1 |
| Choi, JH | 1 |
| Choi, SH | 1 |
| Lee, SH | 3 |
| Gwon, HC | 1 |
| Hahn, JY | 1 |
| Dugani, S | 1 |
| Ames, JM | 1 |
| Manson, JE | 1 |
| Mora, S | 1 |
| Nekrasov, AA | 1 |
| Timoshchenko, ES | 1 |
| Petelina, IS | 1 |
| Karpukhina, EV | 1 |
| Perepech, NB | 1 |
| Mikhaylova, IE | 1 |
| Golukhova, EZ | 2 |
| Grigoryan, MV | 2 |
| Ryabinina, MN | 2 |
| Bulaeva, NI | 2 |
| Fukushi, K | 1 |
| Tominaga, K | 1 |
| Nagashima, K | 1 |
| Kanamori, A | 1 |
| Izawa, N | 1 |
| Kanazawa, M | 1 |
| Sasai, T | 1 |
| Hiraishi, H | 1 |
| Kuang, H | 1 |
| Zhou, X | 1 |
| Li, L | 1 |
| Yi, Q | 1 |
| Shou, W | 1 |
| Lu, T | 1 |
| Choi, SY | 1 |
| Kim, MH | 2 |
| Cho, YR | 1 |
| Sung Park, J | 1 |
| Min Lee, K | 1 |
| Park, TH | 1 |
| Yun, SC | 1 |
| Rico-Mesa, JS | 1 |
| Uribe, C | 1 |
| Prasad, M | 1 |
| Luis, SA | 1 |
| Ge, L | 1 |
| Ouyang, X | 1 |
| Ban, C | 1 |
| Yu, H | 1 |
| Wu, Q | 1 |
| Liang, J | 1 |
| Sumaya, W | 1 |
| Geisler, T | 1 |
| Finn, MT | 1 |
| Karmpaliotis, D | 1 |
| Green, P | 1 |
| McAndrew, T | 1 |
| Liu, M | 1 |
| Cloney, MB | 1 |
| Witzenbichler, B | 3 |
| Weisz, G | 2 |
| Stuckey, TD | 2 |
| Brodie, BR | 2 |
| Rinaldi, MJ | 3 |
| Neumann, FJ | 3 |
| Metzger, DC | 1 |
| Henry, TD | 2 |
| Cox, DA | 3 |
| Duffy, PL | 2 |
| Mazzaferri, EL | 2 |
| Rizvi, SKA | 1 |
| Mohsin, S | 1 |
| Saeed, T | 1 |
| Ahmad, S | 1 |
| Devereaux, PJ | 3 |
| Szczeklik, W | 1 |
| Barbarash, OL | 1 |
| Kashtalap, VV | 1 |
| Zykov, MV | 1 |
| Hryachkova, ON | 1 |
| Shibanova, IA | 1 |
| Darmon, A | 1 |
| Sorbets, E | 1 |
| Ducrocq, G | 2 |
| Elbez, Y | 1 |
| Abtan, J | 1 |
| Popovic, B | 1 |
| Ohman, EM | 5 |
| Röther, J | 1 |
| Wilson, PF | 1 |
| Montalescot, G | 5 |
| Zeymer, U | 1 |
| Lynch, DR | 1 |
| Dantzler, D | 1 |
| Robbins, M | 1 |
| Zhao, D | 1 |
| Gurbel, PA | 5 |
| Tantry, US | 3 |
| Sarafoff, N | 1 |
| Martischnig, A | 1 |
| Wealer, J | 1 |
| Mayer, K | 1 |
| Mehilli, J | 1 |
| Sibbing, D | 1 |
| Kastrati, A | 1 |
| Tan, C | 1 |
| Chen, W | 1 |
| Wu, Y | 1 |
| Lin, J | 1 |
| Lin, R | 1 |
| Tan, X | 1 |
| Chen, S | 1 |
| Steinberg, BA | 1 |
| Kim, S | 1 |
| Piccini, JP | 1 |
| Fonarow, GC | 1 |
| Lopes, RD | 1 |
| Thomas, L | 1 |
| Ezekowitz, MD | 1 |
| Ansell, J | 1 |
| Kowey, P | 1 |
| Singer, DE | 1 |
| Gersh, B | 1 |
| Mahaffey, KW | 4 |
| Hylek, E | 1 |
| Go, AS | 1 |
| Chang, P | 1 |
| Peterson, ED | 1 |
| Cattaneo, M | 1 |
| Ottani, F | 1 |
| Park, MW | 1 |
| Her, SH | 1 |
| Kim, HS | 2 |
| Choi, YS | 1 |
| Park, CS | 1 |
| Koh, YS | 1 |
| Park, HJ | 1 |
| Kim, PJ | 1 |
| Kim, CJ | 1 |
| Jeon, DS | 1 |
| Shin, DI | 1 |
| Seo, SM | 1 |
| Yoo, KD | 1 |
| Kim, DB | 1 |
| Kim, HY | 2 |
| Chung, WS | 1 |
| Seung, KB | 1 |
| Shin, JG | 1 |
| Chang, K | 1 |
| Zhang, HZ | 1 |
| Han, JY | 1 |
| Jeong, YH | 1 |
| Alvarez-Sabín, J | 1 |
| Quintana, M | 1 |
| Santamarina, E | 1 |
| Maisterra, O | 1 |
| Zaval's'ka, TV | 1 |
| Cho, YK | 1 |
| Nam, CW | 1 |
| Park, HS | 1 |
| Yoon, HJ | 1 |
| Kim, H | 1 |
| Hur, SH | 1 |
| Kim, YN | 1 |
| Lee, JH | 1 |
| Yang, DH | 1 |
| Lee, BR | 1 |
| Jung, BC | 1 |
| Kim, W | 1 |
| Park, JS | 1 |
| Lee, JB | 1 |
| Kim, KS | 1 |
| Kim, KB | 1 |
| Rossini, R | 2 |
| Musumeci, G | 2 |
| Visconti, LO | 1 |
| Bramucci, E | 1 |
| Castiglioni, B | 1 |
| De Servi, S | 1 |
| Lettieri, C | 2 |
| Lettino, M | 1 |
| Piccaluga, E | 1 |
| Savonitto, S | 1 |
| Trabattoni, D | 1 |
| Buffoli, F | 1 |
| Parolari, A | 1 |
| Dionigi, G | 1 |
| Boni, L | 1 |
| Biglioli, F | 1 |
| Valdatta, L | 1 |
| Droghetti, A | 1 |
| Bozzani, A | 1 |
| Setacci, C | 1 |
| Ravelli, P | 1 |
| Crescini, C | 1 |
| Staurenghi, G | 1 |
| Scarone, P | 1 |
| Francetti, L | 1 |
| D'Angelo, F | 1 |
| Gadda, F | 1 |
| Comel, A | 1 |
| Salvi, L | 1 |
| Lorini, L | 1 |
| Antonelli, M | 1 |
| Bovenzi, F | 1 |
| Cremonesi, A | 1 |
| Guagliumi, G | 3 |
| Christodoulidis, G | 1 |
| Baber, U | 4 |
| Khan, J | 1 |
| Alonso-Coello, P | 1 |
| Santilli, F | 2 |
| Paloscia, L | 2 |
| Liani, R | 1 |
| Di Nicola, M | 1 |
| Di Marco, M | 1 |
| Lattanzio, S | 2 |
| La Barba, S | 1 |
| Pascale, S | 1 |
| Mascellanti, M | 1 |
| Davì, G | 3 |
| Simms, AD | 1 |
| Weston, CF | 1 |
| West, RM | 1 |
| Hall, AS | 1 |
| Batin, PD | 2 |
| Timmis, A | 1 |
| Hemingway, H | 2 |
| Fox, K | 3 |
| Gale, CP | 2 |
| Limbruno, U | 1 |
| Tarantini, G | 1 |
| Russo, N | 1 |
| Calabria, P | 1 |
| Romano, M | 2 |
| Inashvili, A | 1 |
| Sirbu, V | 1 |
| Valsecchi, O | 1 |
| Senni, M | 1 |
| Gavazzi, A | 1 |
| Mauri, L | 1 |
| Kereiakes, DJ | 3 |
| Yeh, RW | 2 |
| Driscoll-Shempp, P | 1 |
| Cutlip, DE | 1 |
| Normand, SL | 1 |
| Wiviott, SD | 2 |
| Cohen, DJ | 1 |
| Holmes, DR | 3 |
| Hermiller, J | 1 |
| Dauerman, HL | 1 |
| Simon, DI | 1 |
| Kandzari, DE | 1 |
| Garratt, KN | 1 |
| Lee, DP | 1 |
| Pow, TK | 1 |
| Ver Lee, P | 1 |
| Massaro, JM | 1 |
| Bavry, AA | 1 |
| Gong, Y | 1 |
| Handberg, EM | 1 |
| Cooper-DeHoff, RM | 1 |
| Pepine, CJ | 2 |
| Warren, J | 1 |
| Weeks, PA | 1 |
| Sieg, A | 1 |
| Paruthi, C | 1 |
| Rajapreyar, I | 1 |
| Korkmaz, S | 1 |
| Atmanli, A | 1 |
| Li, S | 1 |
| Radovits, T | 1 |
| Hegedűs, P | 1 |
| Barnucz, E | 1 |
| Hirschberg, K | 1 |
| Loganathan, S | 1 |
| Yoshikawa, Y | 1 |
| Yasui, H | 1 |
| Karck, M | 1 |
| Szabó, G | 1 |
| Campo, G | 1 |
| Pavasini, R | 1 |
| Malagù, M | 1 |
| Punzetti, S | 1 |
| Napoli, N | 1 |
| Guerzoni, F | 1 |
| Papi, A | 1 |
| Ceconi, C | 1 |
| Contoli, M | 1 |
| D'Ascenzo, F | 1 |
| Taha, S | 1 |
| Moretti, C | 1 |
| Omedè, P | 1 |
| Grossomarra, W | 1 |
| Persson, J | 1 |
| Lamberts, M | 1 |
| Dewilde, W | 1 |
| Rubboli, A | 1 |
| Fernández, S | 1 |
| Cerrato, E | 1 |
| Meynet, I | 1 |
| Ballocca, F | 1 |
| Barbero, U | 1 |
| Quadri, G | 1 |
| Giordana, F | 1 |
| Conrotto, F | 1 |
| DiNicolantonio, J | 1 |
| Bangalore, S | 1 |
| Reed, M | 1 |
| Meier, P | 1 |
| Zoccai, G | 1 |
| Gaita, F | 1 |
| Khanna, V | 1 |
| Mikael, R | 1 |
| Thayalasamy, K | 1 |
| Sambu, N | 1 |
| Dimitrov, BD | 1 |
| Englyst, N | 1 |
| Calver, AL | 1 |
| Corbett, S | 1 |
| Gray, H | 1 |
| Simpson, IA | 1 |
| Wilkinson, JR | 1 |
| Curzen, N | 1 |
| Maki, M | 1 |
| Tsubochi, H | 1 |
| Endo, T | 1 |
| Endo, S | 1 |
| Miyake, K | 1 |
| Akimoto, T | 1 |
| Hanada, Y | 1 |
| Nagoya, H | 1 |
| Kodaka, Y | 1 |
| Ueki, N | 1 |
| Kusunoki, M | 1 |
| Kawagoe, T | 1 |
| Futagami, S | 1 |
| Takahashi, Y | 1 |
| Takano, H | 1 |
| Sakamoto, C | 1 |
| Ayoub, K | 1 |
| Marji, M | 1 |
| Nairooz, R | 1 |
| Arif, SA | 1 |
| D'Souza, J | 1 |
| Gil, M | 1 |
| Gim, S | 1 |
| Fernández-Fernández, FJ | 1 |
| Ameneiros-Lago, E | 1 |
| Sesma, P | 1 |
| Pía, G | 1 |
| Keach, JW | 1 |
| Maddox, TM | 1 |
| Newburger, JW | 1 |
| Takahashi, M | 1 |
| Burns, JC | 1 |
| Maehara, A | 1 |
| Metzger, C | 1 |
| Francese, DP | 1 |
| Ozan, O | 1 |
| Lip, GY | 1 |
| Fauchier, L | 1 |
| Freedman, SB | 1 |
| Van Gelder, I | 1 |
| Natale, A | 1 |
| Gianni, C | 1 |
| Nattel, S | 1 |
| Potpara, T | 1 |
| Rienstra, M | 1 |
| Tse, HF | 1 |
| Lane, DA | 1 |
| Weiss, MC | 1 |
| Mauricio, R | 1 |
| Mahajan, AM | 1 |
| Dugan, KE | 1 |
| Devanabanda, A | 1 |
| Pulgarin, C | 1 |
| Radford, M | 1 |
| Dondo, TB | 1 |
| Hall, M | 1 |
| Timmis, AD | 1 |
| Yan, AT | 1 |
| Oliver, G | 1 |
| Alabas, OA | 1 |
| Norman, P | 1 |
| Deanfield, JE | 1 |
| Bloor, K | 1 |
| Kulik, A | 1 |
| Chandrasekhar, J | 1 |
| Bansilal, S | 1 |
| Sartori, S | 1 |
| Aquino, M | 1 |
| Farhan, S | 1 |
| Vogel, B | 1 |
| Faggioni, M | 1 |
| Ariti, C | 1 |
| Colombo, A | 1 |
| Chieffo, A | 1 |
| Kini, A | 1 |
| Saporito, R | 1 |
| Michael Gibson, C | 1 |
| Cohen, D | 1 |
| Moliterno, D | 1 |
| Stuckey, T | 2 |
| Henry, T | 1 |
| Pocock, S | 1 |
| Dangas, G | 1 |
| Gabriel Steg, P | 1 |
| Rosa, GM | 1 |
| Bianco, D | 1 |
| Valbusa, A | 1 |
| Massobrio, L | 1 |
| Chiarella, F | 1 |
| Brunelli, C | 1 |
| Cortellini, G | 1 |
| Romano, A | 1 |
| Santucci, A | 1 |
| Barbaud, A | 1 |
| Bavbek, S | 1 |
| Bignardi, D | 1 |
| Blanca, M | 1 |
| Bonadonna, P | 1 |
| Costantino, MT | 1 |
| Laguna, JJ | 1 |
| Lombardo, C | 1 |
| Losappio, LM | 1 |
| Makowska, J | 1 |
| Nakonechna, A | 1 |
| Quercia, O | 1 |
| Pastorello, EA | 1 |
| Patella, V | 1 |
| Terreehorst, I | 1 |
| Testi, S | 1 |
| Cernadas, JR | 1 |
| Dionicio Elera, J | 1 |
| Lippolis, D | 1 |
| Voltolini, S | 1 |
| Grosseto, D | 1 |
| Welsh, RC | 1 |
| Roe, MT | 2 |
| James, S | 1 |
| Povsic, TJ | 1 |
| Bode, C | 1 |
| Gibson, CM | 1 |
| Webster, TD | 1 |
| Vaishnava, P | 1 |
| Eagle, KA | 1 |
| Meyhoff, CS | 1 |
| Isbye, D | 1 |
| Halle, BM | 1 |
| Pedersen, S | 1 |
| Itenov, TS | 1 |
| Taskiran, M | 1 |
| Gögenur, I | 1 |
| Lee, CJ | 1 |
| Oh, J | 1 |
| Kang, SM | 1 |
| Choi, D | 1 |
| Kim, HC | 1 |
| Park, S | 1 |
| Saydam, F | 1 |
| Değirmenci, İ | 1 |
| Birdane, A | 1 |
| Özdemir, M | 1 |
| Ulus, T | 1 |
| Özbayer, C | 1 |
| Çolak, E | 1 |
| Ata, N | 1 |
| Güneş, HV | 1 |
| Suwalski, G | 1 |
| Suwalski, P | 1 |
| Filipiak, KJ | 2 |
| Postuła, M | 1 |
| Majstrak, F | 1 |
| Opolski, G | 2 |
| Ng, FH | 1 |
| Lam, KF | 1 |
| Wong, SY | 1 |
| Chang, CM | 1 |
| Lau, YK | 1 |
| Yuen, WC | 1 |
| Chu, WM | 1 |
| Wong, BC | 1 |
| Muir, AR | 1 |
| McMullin, MF | 1 |
| Patterson, C | 1 |
| McKeown, PP | 1 |
| Djukanovic, N | 1 |
| Todorovic, Z | 1 |
| Grdinic, A | 1 |
| Vojvodic, D | 1 |
| Prostran, M | 1 |
| Ostojic, M | 1 |
| Nema, H | 2 |
| Kato, M | 2 |
| Katsurada, T | 2 |
| Nozaki, Y | 2 |
| Yotsukura, A | 2 |
| Yoshida, I | 2 |
| Sato, K | 2 |
| Kawai, Y | 2 |
| Takagi, Y | 2 |
| Okusa, T | 2 |
| Takiguchi, S | 2 |
| Sakurai, M | 2 |
| Asaka, M | 2 |
| Juhlin, T | 1 |
| Jönsson, BA | 1 |
| Höglund, P | 1 |
| Faĭl', IL | 1 |
| Dolgikh, VT | 1 |
| Morova, NA | 1 |
| Kireeva, NV | 1 |
| Smirnov, DE | 1 |
| Kovaleva, SV | 1 |
| Jolly, SS | 1 |
| Pogue, J | 2 |
| Haladyn, K | 1 |
| Peters, RJ | 1 |
| Fox, KA | 10 |
| Avezum, A | 1 |
| Gersh, BJ | 4 |
| Rupprecht, HJ | 1 |
| Yusuf, S | 7 |
| Mehta, SR | 4 |
| Slaughter, MS | 1 |
| Sobieski, MA | 1 |
| Gallagher, C | 1 |
| Dia, M | 1 |
| Silver, MA | 1 |
| van der Worp, HB | 1 |
| Fonville, S | 1 |
| Ramos, LM | 1 |
| Rinkel, GJ | 1 |
| Satler, LF | 2 |
| Lansky, AJ | 1 |
| Tsuchiya, Y | 1 |
| Brener, M | 1 |
| Cristea, E | 1 |
| Pietras, C | 1 |
| Grines, CL | 2 |
| Garcia, E | 1 |
| Tcheng, JE | 1 |
| Turco, M | 1 |
| Carroll, JD | 1 |
| Rutherford, BD | 1 |
| Leon, MB | 1 |
| Moses, J | 1 |
| Suryadevara, S | 1 |
| Capranzano, P | 1 |
| Zenni, MZ | 1 |
| Guzman, LA | 1 |
| Bass, TA | 1 |
| Nakashima, K | 1 |
| Kirsch, ME | 1 |
| Vermes, E | 1 |
| Rosanval, O | 1 |
| Loisance, D | 1 |
| Kremneva, LV | 1 |
| Shalaev, SV | 1 |
| So, D | 1 |
| Cook, EF | 1 |
| Le May, M | 1 |
| Glover, C | 1 |
| Williams, W | 1 |
| Ha, A | 1 |
| Davies, R | 2 |
| Froeschl, M | 1 |
| Marquis, JF | 1 |
| O'Brien, E | 1 |
| Labinaz, M | 1 |
| Zibaeenezhad, MJ | 1 |
| Mazloum, Y | 1 |
| Fung, CY | 1 |
| Marcus, AJ | 3 |
| Broekman, MJ | 3 |
| Mahaut-Smith, MP | 1 |
| Alexander, JH | 1 |
| Becker, RC | 1 |
| Cools, F | 1 |
| Crea, F | 1 |
| Dellborg, M | 1 |
| Goodman, SG | 4 |
| Harrington, RA | 5 |
| Huber, K | 2 |
| Husted, S | 1 |
| Lewis, BS | 1 |
| Mohan, P | 1 |
| Ruda, M | 1 |
| Ruzyllo, W | 1 |
| Verheugt, F | 1 |
| Wallentin, L | 3 |
| Rainsbury, JW | 1 |
| Molony, NC | 1 |
| Buriachkovskaia, LI | 1 |
| Uchitel', IA | 1 |
| Sumarokov, AV | 1 |
| Popov, EG | 1 |
| Reny, JL | 2 |
| Bonvini, RF | 1 |
| Barazer, I | 1 |
| Berdagué, P | 1 |
| de Moerloose, P | 2 |
| Schved, JF | 1 |
| Gris, JC | 1 |
| Fontana, P | 2 |
| Ranjith, MP | 1 |
| Divya, R | 1 |
| Mehta, VK | 1 |
| Krishnan, MG | 1 |
| KamalRaj, R | 1 |
| Kavishwar, A | 1 |
| Lonn, E | 1 |
| Zdrenghea, D | 1 |
| Pop, D | 1 |
| Sitar-Tăut, A | 1 |
| Cebanu, M | 1 |
| Zdrenghea, V | 1 |
| Hoeks, SE | 2 |
| Scholte op Reimer, WJ | 1 |
| van Gestel, YR | 1 |
| Schouten, O | 2 |
| Lenzen, MJ | 1 |
| Flu, WJ | 2 |
| van Kuijk, JP | 2 |
| Latour, C | 1 |
| Bax, JJ | 2 |
| van Urk, H | 1 |
| Poldermans, D | 2 |
| Mateos-Cáceres, PJ | 1 |
| Azcona, L | 1 |
| Modrego, J | 1 |
| Mahillo, E | 1 |
| Fernandez-Ortiz, A | 1 |
| Solomon, S | 1 |
| Vacek, JL | 1 |
| García Paredes, T | 1 |
| Escudero Varela, JC | 1 |
| Mora Ordóñez, JM | 1 |
| Tsukahara, K | 1 |
| Kimura, K | 1 |
| Morita, S | 1 |
| Ebina, T | 1 |
| Kosuge, M | 1 |
| Hibi, K | 1 |
| Okuda, J | 1 |
| Iwahashi, N | 1 |
| Maejima, N | 1 |
| Nakachi, T | 1 |
| Ohtsuka, F | 1 |
| Hashiba, K | 1 |
| Tahara, Y | 1 |
| Sugano, T | 1 |
| Umemura, S | 1 |
| Basili, S | 1 |
| Cavoni, A | 1 |
| Guizzardi, G | 1 |
| De Feudis, L | 1 |
| Traisci, G | 1 |
| Pettinella, C | 1 |
| Minuz, P | 1 |
| Meneguzzi, A | 1 |
| Ciabattoni, G | 1 |
| Patrono, C | 3 |
| Renda, G | 3 |
| Zurro, M | 2 |
| De Caterina, R | 3 |
| Crown, N | 1 |
| Mysak, T | 1 |
| Berger, PB | 3 |
| Fuster, V | 2 |
| Shao, M | 1 |
| Brennan, DM | 2 |
| Hacke, W | 1 |
| Steinhubl, SR | 4 |
| Topol, EJ | 7 |
| Mangiacapra, F | 1 |
| Lee, SP | 1 |
| Suh, JW | 1 |
| Park, KW | 1 |
| Lee, HY | 1 |
| Kang, HJ | 1 |
| Koo, BK | 1 |
| Chae, IH | 1 |
| Choi, DJ | 1 |
| Rha, SW | 1 |
| Bae, JW | 1 |
| Cho, MC | 1 |
| Kwon, TG | 1 |
| Bae, JH | 1 |
| Karia, VR | 1 |
| Hescock, GC | 1 |
| Gedalia, A | 1 |
| Gedelia, A | 1 |
| Ross-Ascuitto, N | 1 |
| Voute, MT | 1 |
| Chonchol, M | 1 |
| Boersma, EE | 1 |
| Verhagen, HJ | 1 |
| Saleh, AI | 1 |
| Abdel Maksoud, SM | 1 |
| El-Maraghy, SA | 1 |
| Gad, MZ | 1 |
| Shimokhina, NIu | 1 |
| Petrova, MM | 1 |
| Savchenko, AA | 1 |
| Shibata, T | 1 |
| Kamano, T | 1 |
| Hirata, I | 1 |
| Sun, JC | 1 |
| Teoh, KH | 1 |
| Lamy, A | 1 |
| Sheth, T | 1 |
| Ellins, ML | 1 |
| Jung, H | 1 |
| Anand, S | 1 |
| Connolly, S | 1 |
| Whitlock, RP | 1 |
| Eikelboom, JW | 1 |
| Edfors, K | 1 |
| Andersen, SE | 1 |
| Saito, Y | 1 |
| Morimoto, T | 1 |
| Ogawa, H | 1 |
| Nakayama, M | 1 |
| Uemura, S | 1 |
| Doi, N | 1 |
| Jinnouchi, H | 1 |
| Waki, M | 1 |
| Soejima, H | 1 |
| Sugiyama, S | 1 |
| Okada, S | 1 |
| Akai, Y | 1 |
| Watanabe, M | 1 |
| Kawai, T | 1 |
| Takata, Y | 1 |
| Yamashina, A | 1 |
| Laguta, PS | 1 |
| Katkova, OV | 1 |
| Dobrovol'skiĭ, AB | 1 |
| Titaeva, EV | 1 |
| Deev, AD | 1 |
| Panchenko, EP | 1 |
| Refiker, M | 1 |
| Gassanov, N | 1 |
| Caglayan, E | 1 |
| Erdmann, E | 1 |
| Er, F | 1 |
| Nandish, S | 1 |
| Wyatt, J | 1 |
| Bailon, O | 1 |
| Smith, M | 1 |
| Oliveros, R | 1 |
| Chilton, R | 1 |
| Cuisset, T | 3 |
| Quilici, J | 3 |
| Grosdidier, C | 1 |
| Fourcade, L | 1 |
| Gaborit, B | 1 |
| Pankert, M | 1 |
| Molines, L | 1 |
| Morange, PE | 3 |
| Bonnet, JL | 3 |
| Alessi, MC | 3 |
| Kossiva, L | 1 |
| Lydia, K | 1 |
| Karanassios, E | 1 |
| Evangelos, K | 1 |
| Papadopoulos, G | 1 |
| George, P | 1 |
| Karavanaki, K | 1 |
| Kyriaki, K | 1 |
| Ait-Mokhtar, O | 1 |
| Bonello, L | 1 |
| Benamara, S | 1 |
| Paganelli, F | 1 |
| Leonardi, S | 1 |
| Tricoci, P | 1 |
| Abegunewardene, N | 1 |
| Schmidt, KH | 1 |
| Vosseler, M | 1 |
| Kreitner, KF | 1 |
| Schreiber, LM | 1 |
| Lehr, HA | 1 |
| Gori, T | 1 |
| Münzel, T | 1 |
| Horstick, G | 1 |
| Motoda, C | 1 |
| Ueda, H | 1 |
| Hayashi, Y | 1 |
| Toyofuku, M | 1 |
| Okimoto, T | 1 |
| Otsuka, M | 1 |
| Tamekiyo, H | 1 |
| Kawase, T | 1 |
| Kihara, Y | 1 |
| Feng, XR | 1 |
| Liu, ML | 1 |
| Tian, QP | 1 |
| Fan, Y | 1 |
| Liu, QZ | 1 |
| Suzuki, K | 1 |
| Uchiyama, S | 1 |
| Imajyo, K | 1 |
| Tomeno, W | 1 |
| Sakai, E | 1 |
| Yamada, E | 1 |
| Tanida, E | 1 |
| Akiyama, T | 1 |
| Watanabe, S | 1 |
| Endo, H | 1 |
| Fujita, K | 1 |
| Yoneda, M | 1 |
| Takahashi, H | 1 |
| Koide, T | 1 |
| Tokoro, C | 1 |
| Abe, Y | 1 |
| Kawaguchi, M | 1 |
| Gotoh, E | 1 |
| Maeda, S | 1 |
| Nakajima, A | 1 |
| Inamori, M | 1 |
| Tang, FK | 1 |
| Lin, LJ | 1 |
| Hua, N | 1 |
| Lu, H | 1 |
| Qi, Z | 1 |
| Tang, XZ | 1 |
| Vetter, TR | 1 |
| Boudreaux, AM | 1 |
| Papapietro, SE | 1 |
| Smith, PW | 1 |
| Taylor, BB | 1 |
| Porterfield, JR | 1 |
| George, MG | 1 |
| Tong, X | 1 |
| Sonnenfeld, N | 1 |
| Hong, Y | 1 |
| Qiu, H | 1 |
| Liu, JY | 1 |
| Wei, D | 1 |
| Li, N | 2 |
| Yamoah, EN | 1 |
| Hammock, BD | 1 |
| Chiamvimonvat, N | 1 |
| May, CH | 1 |
| Lincoff, AM | 4 |
| Namazi, MH | 1 |
| Mohagheghi, A | 1 |
| Ostovaneh, MR | 1 |
| Sepanlou, SG | 1 |
| Farzadfar, F | 1 |
| Jafari, E | 1 |
| Danaei, G | 1 |
| Guirguis-Blake, J | 1 |
| Erlinge, D | 1 |
| Neely, B | 1 |
| Neely, M | 1 |
| Chan, MY | 1 |
| Cornel, JH | 1 |
| Brown, E | 1 |
| Zhou, C | 1 |
| Jakubowski, JA | 1 |
| White, HD | 5 |
| Prabhakaran, D | 1 |
| Armstrong, PW | 4 |
| Diletti, R | 1 |
| Farooq, V | 1 |
| Sudhir, K | 1 |
| Dorange, C | 1 |
| Miquel-Hebert, K | 1 |
| Veldhof, S | 1 |
| Rapoza, R | 1 |
| Garcia-Garcia, HM | 1 |
| Chevalier, B | 1 |
| Nirantharakumar, K | 1 |
| Marshall, T | 1 |
| Suh, S | 1 |
| Seo, PJ | 1 |
| Park, H | 1 |
| Shin, CM | 1 |
| Jo, HJ | 1 |
| Park, YS | 1 |
| Hwang, JH | 1 |
| Kim, JW | 2 |
| Jeong, SH | 1 |
| Kim, N | 1 |
| Lee, DH | 1 |
| Song, IS | 1 |
| Jung, HC | 1 |
| Consuegra-Sánchez, L | 1 |
| López-Palop, R | 1 |
| Cano, P | 1 |
| Carrillo, P | 1 |
| Picó, F | 1 |
| Villegas, M | 1 |
| Sanchis, J | 1 |
| Kaski, JC | 1 |
| Ding, XL | 1 |
| Xie, C | 1 |
| Jiang, B | 1 |
| Gao, J | 1 |
| Zhang, LL | 1 |
| Zhang, H | 1 |
| Zhang, JJ | 1 |
| Miao, LY | 1 |
| Andrade, C | 1 |
| Chee, FY | 1 |
| How, CH | 1 |
| de Gaetano, G | 2 |
| Cerletti, C | 2 |
| Iacoviello, L | 2 |
| Donati, MB | 2 |
| Lapane, KL | 1 |
| Hume, AL | 1 |
| Barbour, MM | 1 |
| Lipsitz, LA | 1 |
| Gadzhiev, AN | 1 |
| Donnan, GA | 1 |
| Davis, SM | 1 |
| Bolli, R | 1 |
| Shinmura, K | 1 |
| Tang, XL | 1 |
| Kodani, E | 1 |
| Xuan, YT | 1 |
| Guo, Y | 1 |
| Dawn, B | 1 |
| Bennett, KE | 2 |
| Williams, D | 3 |
| Feely, J | 3 |
| Judge, HM | 1 |
| Wilcox, RG | 3 |
| Heptinstall, S | 1 |
| Mehta, P | 1 |
| Talbert, RL | 1 |
| Spinler, SA | 1 |
| Nappi, JM | 1 |
| Bottorff, MB | 1 |
| Bĕlohlávek, J | 1 |
| Aschermann, M | 1 |
| Penka, M | 1 |
| Spinar, J | 1 |
| Vítovec, J | 1 |
| Preobrazhenskiĭ, DV | 1 |
| Sidorenko, BA | 1 |
| Malysheva, NV | 1 |
| Tsurko, VV | 1 |
| Cipollone, F | 1 |
| Ganci, A | 1 |
| Greco, A | 1 |
| Panara, MR | 1 |
| Pasquale, M | 1 |
| Di Gregorio, D | 1 |
| Porreca, E | 1 |
| Mezzetti, A | 1 |
| Cuccurullo, F | 1 |
| Patrignani, P | 2 |
| Fitchett, D | 1 |
| Tan, M | 1 |
| Langer, A | 2 |
| Collet, JP | 2 |
| Fine, E | 1 |
| Golmard, JL | 2 |
| Dalby, M | 1 |
| Choussat, R | 2 |
| Ankri, A | 1 |
| Dumaine, R | 1 |
| Lesty, C | 1 |
| Vignolles, N | 2 |
| Thomas, D | 2 |
| Zhao, F | 3 |
| Commerford, PJ | 1 |
| Blumenthal, M | 1 |
| Wittlinger, T | 1 |
| Borja, J | 1 |
| Pérez, I | 1 |
| De la Cruz, G | 1 |
| Michiels, JJ | 1 |
| Bennett, K | 1 |
| Wald, NJ | 1 |
| Law, MR | 1 |
| Bogomol'tsev, BP | 1 |
| Deviatkin, AV | 1 |
| Takeda, T | 1 |
| Hoshida, S | 1 |
| Nishino, M | 1 |
| Tanouchi, J | 1 |
| Otsu, K | 1 |
| Hori, M | 1 |
| Tolleson, TR | 1 |
| Newby, LK | 4 |
| Bhapkar, MV | 2 |
| Verheugt, FW | 5 |
| Moliterno, DJ | 2 |
| Van de Werf, F | 2 |
| Califf, RM | 7 |
| Eisenberg, MJ | 1 |
| Okrainec, K | 1 |
| Lefkovits, J | 1 |
| Goudreau, E | 1 |
| Deligonul, U | 1 |
| Mak, KH | 1 |
| Duerr, R | 1 |
| Tsang, J | 1 |
| Huynh, T | 1 |
| Sedlis, S | 1 |
| Brown, DL | 1 |
| Brieger, D | 1 |
| Pilote, L | 1 |
| Katz, J | 1 |
| Feldman, MA | 1 |
| Bass, EB | 1 |
| Lubomski, LH | 1 |
| Tielsch, JM | 1 |
| Petty, BG | 1 |
| Fleisher, LA | 1 |
| Schein, OD | 1 |
| Weaver, WD | 2 |
| Emanuelsson, H | 2 |
| Goodvin, A | 1 |
| Nyström, P | 1 |
| Bylock, A | 2 |
| Spektor, S | 1 |
| Agus, S | 1 |
| Merkin, V | 1 |
| Constantini, S | 1 |
| Manoharan, G | 1 |
| Adgey, AA | 1 |
| Faraday, N | 1 |
| Braunstein, JB | 1 |
| Heldman, AW | 1 |
| Bolton, ED | 1 |
| Chiles, KA | 1 |
| Gerstenblith, G | 2 |
| Schulman, SP | 3 |
| Gross, ER | 1 |
| Hsu, AK | 1 |
| Gross, GJ | 1 |
| Gerrah, R | 1 |
| Fogel, M | 1 |
| Gilon, D | 1 |
| Ikonomidis, I | 1 |
| Andreotti, F | 1 |
| Nihoyannopoulos, P | 1 |
| Steimle, AE | 1 |
| Bakhritdinov, FSh | 1 |
| Kamilov, ShM | 1 |
| Trynkin, AV | 1 |
| Babadzhanov, SA | 1 |
| Helø, OH | 1 |
| Madsen, JK | 1 |
| Kastrup, J | 1 |
| Kohmoto, T | 1 |
| Oz, MC | 1 |
| Naka, Y | 1 |
| Wolski, KE | 1 |
| Bogaty, P | 1 |
| Brophy, JM | 1 |
| Noel, M | 1 |
| Boyer, L | 1 |
| Simard, S | 1 |
| Bertrand, F | 1 |
| Dagenais, GR | 1 |
| Frossard, M | 1 |
| Fuchs, I | 1 |
| Leitner, JM | 1 |
| Hsieh, K | 1 |
| Vlcek, M | 1 |
| Losert, H | 1 |
| Domanovits, H | 1 |
| Schreiber, W | 1 |
| Laggner, AN | 1 |
| Jilma, B | 1 |
| Peters, R | 1 |
| Lakkis, N | 1 |
| Stiefelhagen, P | 1 |
| Akbulut, M | 1 |
| Ozbay, Y | 1 |
| Karaca, I | 1 |
| Ilkay, E | 1 |
| Gundogdu, O | 1 |
| Arslan, N | 1 |
| Bolognese, L | 1 |
| Ducci, K | 1 |
| Angioli, P | 1 |
| Falsini, G | 1 |
| Liistro, F | 1 |
| Baldassarre, S | 1 |
| Burali, A | 1 |
| Stein, R | 1 |
| Alboim, C | 1 |
| Campos, C | 1 |
| Mello, RB | 1 |
| Rosito, GA | 1 |
| Polanczyk, CA | 1 |
| Blanchet, B | 1 |
| Tanguy, ML | 1 |
| Beygui, F | 1 |
| Payot, L | 1 |
| Metzger, JP | 1 |
| Rioufol, G | 1 |
| Gilard, M | 1 |
| Finet, G | 1 |
| Ginon, I | 1 |
| Boschat, J | 1 |
| André-Fouët, X | 1 |
| Hirsh, J | 2 |
| Heeschen, C | 1 |
| Mitrovic, V | 1 |
| Lantelme, NH | 1 |
| Taneja, AK | 1 |
| Collinson, J | 1 |
| Flather, MD | 1 |
| Bakhai, A | 1 |
| de Arenaza, DP | 1 |
| Wang, D | 1 |
| Adgey, J | 1 |
| Wilson, AM | 1 |
| Boyle, AJ | 1 |
| Fox, P | 1 |
| Ahn, JC | 1 |
| Song, WH | 1 |
| Kwon, JA | 1 |
| Park, CG | 1 |
| Seo, HS | 1 |
| Oh, DJ | 1 |
| Rho, YM | 1 |
| Maresta, A | 1 |
| Balducelli, M | 1 |
| Latini, R | 1 |
| Bernardi, G | 1 |
| Moccetti, T | 1 |
| Sosa, C | 1 |
| Barlera, S | 1 |
| Varani, E | 1 |
| Ribeiro da Silva, EE | 1 |
| Monici Preti, A | 1 |
| Maggioni, AP | 1 |
| Higashikuni, Y | 1 |
| Sata, M | 1 |
| Nagai, R | 1 |
| Macías-Robles, MD | 1 |
| Peliz, MG | 1 |
| Gonzalez-Ordonez, AJ | 1 |
| Kuliczkowski, W | 3 |
| Halawa, B | 1 |
| Korolko, B | 1 |
| Mazurek, W | 3 |
| Papp, E | 1 |
| Havasi, V | 1 |
| Bene, J | 1 |
| Komlosi, K | 1 |
| Czopf, L | 1 |
| Magyar, E | 1 |
| Feher, C | 1 |
| Feher, G | 2 |
| Horvath, B | 2 |
| Marton, Z | 1 |
| Alexy, T | 1 |
| Habon, T | 1 |
| Szabo, L | 1 |
| Toth, K | 2 |
| Melegh, B | 1 |
| Dudek, D | 1 |
| Chyrchel, M | 1 |
| Legutko, J | 1 |
| Bartuś, S | 1 |
| Rzeszutko, L | 1 |
| Dubiel, JS | 1 |
| Coma-Canella, I | 1 |
| Velasco, A | 1 |
| Castano, S | 1 |
| Hippisley-Cox, J | 1 |
| Coupland, C | 1 |
| Veikutiene, A | 1 |
| Sirvinskas, E | 1 |
| Grybauskas, P | 1 |
| Cimbolaityte, J | 1 |
| Mongirdiene, A | 1 |
| Veikutis, V | 1 |
| Ferguson, JJ | 2 |
| Feuring, M | 1 |
| Schultz, A | 1 |
| Losel, R | 1 |
| Wehling, M | 1 |
| Meine, TJ | 1 |
| Patel, MR | 1 |
| DePuy, V | 1 |
| Curtis, LH | 1 |
| Rao, SV | 1 |
| Schulman, KA | 1 |
| Jollis, JG | 2 |
| Douglas, JS | 1 |
| Block, E | 1 |
| Ghazzal, ZM | 1 |
| Morris, DC | 1 |
| Liberman, H | 1 |
| Parker, K | 1 |
| Jurkovitz, C | 1 |
| Murrah, N | 1 |
| Foster, J | 1 |
| Hyde, P | 1 |
| Mancini, GB | 1 |
| Weintraub, WS | 1 |
| Burke, SG | 1 |
| Wainwright, CL | 2 |
| Vojnovic, I | 1 |
| Warner, T | 1 |
| Watson, DG | 1 |
| Furman, BL | 1 |
| Coakley, M | 1 |
| Self, R | 1 |
| Marchant, W | 1 |
| Mackie, I | 1 |
| Mallett, SV | 1 |
| Mythen, M | 1 |
| Malý, J | 1 |
| Pecka, M | 1 |
| Gregor, J | 1 |
| Dulícek, P | 1 |
| Blazek, M | 1 |
| Malý, R | 1 |
| Pudil, R | 1 |
| Bláha, M | 1 |
| Frazier, CG | 1 |
| Shah, SH | 1 |
| McGuire, DK | 1 |
| Sadowski, Z | 1 |
| Kristinsson, A | 1 |
| Aylward, PE | 1 |
| Klein, WW | 1 |
| Henrikson, CA | 1 |
| Howell, EE | 1 |
| Bush, DE | 1 |
| Chandra-Strobos, N | 1 |
| Shinohara, Y | 1 |
| Vasil'eva, EIu | 1 |
| Kas'ianova, OV | 1 |
| Shpektor, AV | 1 |
| Goldfracht, M | 1 |
| Alperin, M | 2 |
| Hermoni, D | 1 |
| Santos, MT | 2 |
| Vallés, J | 2 |
| Aznar, J | 2 |
| Lago, A | 2 |
| Sanchez, E | 2 |
| Cosin, J | 2 |
| Moscardó, A | 1 |
| Piñón, M | 1 |
| Głuszek, J | 1 |
| Tykarski, A | 1 |
| Jankowska, K | 1 |
| Hawkey, CJ | 1 |
| Hawkey, GM | 1 |
| Everitt, S | 1 |
| Skelly, MM | 1 |
| Stack, WA | 1 |
| Gray, D | 1 |
| Ferraccioli, G | 1 |
| Zoli, A | 1 |
| Alivernini, S | 1 |
| De Santis, M | 1 |
| Verrillo, A | 1 |
| Loperfido, F | 1 |
| Walsh, SJ | 1 |
| McClelland, AJ | 1 |
| Adgey, JA | 1 |
| Cokkinos, DV | 1 |
| Haralabopoulos, GC | 1 |
| Kostis, JB | 1 |
| Toutouzas, PK | 1 |
| Kobusiak-Prokopowicz, M | 2 |
| Prajs, I | 2 |
| Karolko, B | 2 |
| Serebruany, VL | 2 |
| Midei, MG | 1 |
| Meilman, H | 1 |
| Malinin, AI | 2 |
| Lowry, DR | 1 |
| Késmárky, G | 1 |
| Koltai, K | 1 |
| Jug, B | 1 |
| Sebestjen, M | 1 |
| Sabovic, M | 1 |
| Keber, I | 1 |
| Rotondo, S | 1 |
| Dell'Elba, G | 1 |
| Manarini, S | 1 |
| Evangelista, V | 1 |
| Tacconelli, S | 1 |
| Capone, ML | 1 |
| Sacchetta, D | 1 |
| Santarelli, F | 1 |
| Sciulli, MG | 1 |
| Zimarino, M | 1 |
| Grana, M | 1 |
| D'Amelio, E | 1 |
| Price, TS | 1 |
| Gresele, P | 1 |
| Momi, S | 1 |
| Gami, A | 1 |
| Heeg, B | 1 |
| van Gestel, A | 1 |
| Hout, Bv | 1 |
| Olsen, J | 1 |
| Haghfelt, TH | 1 |
| Kutala, VK | 1 |
| Khan, M | 1 |
| Mandal, R | 1 |
| Potaraju, V | 1 |
| Colantuono, G | 1 |
| Kumbala, D | 1 |
| Kuppusamy, P | 1 |
| Poulsen, TS | 1 |
| Mickley, H | 1 |
| Korsholm, L | 1 |
| Licht, PB | 1 |
| Haghfelt, T | 1 |
| Jørgensen, B | 1 |
| Flaker, GC | 1 |
| Gruber, M | 1 |
| Connolly, SJ | 1 |
| Goldman, S | 2 |
| Chaparro, S | 1 |
| Vahanian, A | 1 |
| Halinen, MO | 1 |
| Horrow, J | 1 |
| Halperin, JL | 1 |
| Krötz, F | 1 |
| Hellwig, N | 1 |
| Schiele, TM | 1 |
| Klauss, V | 1 |
| Sohn, HY | 1 |
| Chen, CC | 2 |
| Chong, CF | 2 |
| Kuo, CD | 2 |
| Wang, TL | 2 |
| Frere, C | 2 |
| Saut, N | 1 |
| Romero-Barra, M | 1 |
| Camoin, L | 1 |
| Lambert, M | 2 |
| Juhan-Vague, I | 1 |
| Nait-Saidi, L | 1 |
| Mielot, C | 1 |
| Bali, L | 1 |
| Birnbaum, Y | 1 |
| Lin, Y | 1 |
| Ye, Y | 1 |
| Martinez, JD | 1 |
| Huang, MH | 1 |
| Lui, CY | 1 |
| Perez-Polo, JR | 1 |
| Uretsky, BF | 1 |
| Sazhina, EIu | 1 |
| Kozlova, IV | 1 |
| Rebrov, AP | 1 |
| Al'tshuler, MIu | 1 |
| Małek, ŁA | 1 |
| Spiewak, M | 1 |
| Grabowski, M | 1 |
| Szpotańska, M | 1 |
| Rosiak, M | 1 |
| Główczyńska, R | 1 |
| Imiela, T | 1 |
| Huczek, Z | 1 |
| Moussouttas, M | 1 |
| Chih, S | 1 |
| McKeown, B | 1 |
| Modica, A | 1 |
| Karlsson, F | 1 |
| Mooe, T | 1 |
| Okura, H | 1 |
| Taguchi, H | 1 |
| Kubo, T | 1 |
| Toda, I | 1 |
| Yoshiyama, M | 1 |
| Yoshikawa, J | 1 |
| Yoshida, K | 1 |
| Kakuliia, MSh | 1 |
| Majdoub, MA | 1 |
| Sauguet, A | 1 |
| Tchetche, D | 1 |
| Benamer, H | 1 |
| Himbert, D | 2 |
| Aubry, P | 1 |
| Feldman, LJ | 1 |
| Juliard, JM | 1 |
| Marcucci, R | 2 |
| Gori, AM | 3 |
| Paniccia, R | 2 |
| Giglioli, C | 2 |
| Buonamici, P | 1 |
| Antoniucci, D | 1 |
| Gensini, GF | 4 |
| Abbate, R | 2 |
| Galla, JM | 1 |
| Antonucci, E | 1 |
| Poli, S | 1 |
| Romano, E | 1 |
| Valente, S | 1 |
| Fedi, S | 1 |
| Prisco, D | 1 |
| Rajagopalan, S | 1 |
| Ford, I | 2 |
| Bachoo, P | 1 |
| Hillis, GS | 1 |
| Croal, B | 1 |
| Greaves, M | 2 |
| Brittenden, J | 1 |
| Mehta, RH | 1 |
| Greenbaum, AB | 1 |
| Lokhnygina, Y | 1 |
| Pieper, KS | 1 |
| Granger, CB | 1 |
| Cannon, CP | 3 |
| Sohn, S | 1 |
| Kwon, K | 1 |
| Teirstein, PS | 1 |
| Sarembock, IJ | 1 |
| O'Neill, WW | 1 |
| Waksman, R | 1 |
| Williams, DO | 1 |
| Popma, JJ | 2 |
| Buchbinder, M | 1 |
| Meredith, IT | 1 |
| Moses, JW | 1 |
| Gebel, JM | 1 |
| Perneby, C | 1 |
| Wallén, NH | 1 |
| Hofman-Bang, C | 1 |
| Tornvall, P | 1 |
| Ivert, T | 1 |
| Hjemdahl, P | 1 |
| Pokov, A | 1 |
| Barsness, G | 1 |
| Hanley, DF | 1 |
| Dauzat, M | 1 |
| Tangelder, MJ | 1 |
| Frison, L | 1 |
| Weaver, D | 1 |
| Held, P | 1 |
| Oldgren, J | 1 |
| Popławski, C | 1 |
| Jakubczyk, P | 1 |
| Jakubczyk, M | 1 |
| Liakishev, AA | 1 |
| Antman, EM | 1 |
| Murphy, SA | 1 |
| Voitk, J | 1 |
| Hasin, Y | 1 |
| Widimsky, P | 1 |
| Chandna, H | 1 |
| Macias, W | 1 |
| McCabe, CH | 1 |
| Wanna, FS | 1 |
| Obayashi, DY | 1 |
| Young, JN | 1 |
| DeCampli, WM | 1 |
| Grover, GJ | 1 |
| Schumacher, WA | 1 |
| Ogletree, ML | 1 |
| Bhatti, AS | 1 |
| Khan, HH | 1 |
| Isensee, H | 2 |
| Jacob, R | 2 |
| Di Tano, G | 1 |
| Mazzù, A | 1 |
| Frishman, WH | 1 |
| Burns, B | 1 |
| Atac, B | 1 |
| Alturk, N | 1 |
| Altajar, B | 1 |
| Lerrick, K | 1 |
| Gurfinkel, EP | 4 |
| Manos, EJ | 1 |
| Mejaíl, RI | 1 |
| Cerdá, MA | 1 |
| Duronto, EA | 1 |
| García, CN | 1 |
| Daroca, AM | 1 |
| Mautner, B | 2 |
| Magnani, B | 2 |
| Semprini, F | 1 |
| Fuchs, J | 1 |
| Numano, F | 1 |
| Kishi, Y | 1 |
| Ashikaga, T | 1 |
| Hata, A | 1 |
| Makita, T | 1 |
| Watanabe, R | 1 |
| Bertolet, BD | 1 |
| Neri Serneri, GG | 2 |
| Modesti, PA | 2 |
| Branzi, A | 1 |
| Melandri, G | 1 |
| Poggesi, L | 2 |
| Rostagno, C | 2 |
| Tamburini, C | 1 |
| Carnovali, M | 1 |
| Bodó, I | 1 |
| Németh, C | 1 |
| Littmann, L | 1 |
| Flores, NA | 1 |
| Goulielmos, NV | 1 |
| Seghatchian, MJ | 1 |
| Sheridan, DJ | 1 |
| Meade, TW | 2 |
| Miller, GJ | 1 |
| Cohen-Solal, A | 1 |
| Caviezel, B | 1 |
| Laperche, T | 1 |
| Gourgon, R | 1 |
| Xiong, J | 1 |
| Parry, G | 1 |
| Adams, PC | 1 |
| Chamberlain, D | 1 |
| Wieczorek, I | 1 |
| McBride, R | 1 |
| Chesebro, JH | 1 |
| Shetty, K | 1 |
| Seth, SD | 1 |
| Maulik, M | 1 |
| Manchanda, SC | 1 |
| Maulik, SK | 1 |
| McKenzie, JE | 2 |
| Cost, EA | 2 |
| Scandling, DM | 2 |
| Ahle, NW | 1 |
| Savage, RW | 2 |
| Holdright, D | 1 |
| Patel, D | 1 |
| Cunningham, D | 1 |
| Thomas, R | 2 |
| Hubbard, W | 2 |
| Hendry, G | 2 |
| Sutton, G | 1 |
| Howarth, DJ | 1 |
| Brennan, PJ | 1 |
| Jafri, SM | 1 |
| Goldstein, S | 1 |
| Boddi, M | 1 |
| Martini, F | 1 |
| Ieri, A | 1 |
| Margheri, M | 1 |
| Rosendaal, FR | 1 |
| Algra, A | 1 |
| Rietz, B | 1 |
| Caruzzo, E | 1 |
| Caruzzo, C | 1 |
| Cimminiello, C | 1 |
| Soncini, M | 1 |
| Casazza, F | 1 |
| Coller, BS | 1 |
| Anderson, K | 1 |
| Weisman, HF | 1 |
| Turpie, AG | 2 |
| Weitz, JI | 3 |
| Bar Dayan, Y | 1 |
| Amital, H | 1 |
| Levy, Y | 1 |
| Shoenfeld, Y | 1 |
| Calpe Climent, AV | 1 |
| Tomàs Arbona, FJ | 1 |
| Horrach Pérez, M | 1 |
| Peña Díaz, JJ | 1 |
| Llobera C-anaves, J | 1 |
| Thomàs Mulet, V | 1 |
| Rodríguez Moreno, C | 1 |
| Liu, H | 1 |
| Chen, Z | 1 |
| Gao, R | 1 |
| Ketterer, MW | 1 |
| Brymer, J | 1 |
| Rhoads, K | 1 |
| Kraft, P | 1 |
| Lovallo, WR | 1 |
| Norris, RM | 1 |
| Hart, HH | 1 |
| Williams, BF | 1 |
| Mark, DB | 1 |
| Talley, JD | 1 |
| Bowman, L | 1 |
| Lam, LC | 1 |
| Anderson, KM | 1 |
| Cleman, MW | 1 |
| Lee, KL | 1 |
| Aversano, T | 1 |
| Untereker, WJ | 1 |
| Davidson-Ray, L | 1 |
| Kumar, H | 1 |
| Hollander, JE | 1 |
| Patel, DJ | 2 |
| Holdright, DR | 2 |
| Knight, CJ | 2 |
| Mulcahy, D | 2 |
| Thakrar, B | 1 |
| Wright, C | 2 |
| Sparrow, J | 1 |
| Wicks, M | 1 |
| Sutton, GC | 1 |
| Purcell, H | 2 |
| Lowenthal, MN | 1 |
| van den Brand, MJ | 1 |
| Simoons, ML | 3 |
| de Boer, MJ | 1 |
| van Miltenburg, A | 1 |
| van der Wieken, LR | 1 |
| de Feyter, PJ | 1 |
| Goldschmidt-Clermont, PJ | 1 |
| Navetta, FI | 1 |
| Willerson, JT | 1 |
| Chandra, NC | 1 |
| Guerci, AD | 1 |
| Yakubov, SJ | 1 |
| Bray, PF | 1 |
| Bahr, RD | 1 |
| Wolfe, CL | 1 |
| Yock, PG | 1 |
| Anderson, HV | 1 |
| Nygaard, TW | 1 |
| Mason, SJ | 1 |
| Effron, MB | 1 |
| Fatterpacker, A | 1 |
| Raskin, S | 1 |
| Smith, J | 1 |
| Brashears, L | 1 |
| Gottdiener, P | 1 |
| du Mee, C | 1 |
| Kitt, MM | 1 |
| Harpaz, D | 1 |
| Benderly, M | 1 |
| Goldbourt, U | 2 |
| Kishon, Y | 1 |
| Behar, S | 2 |
| López-Farré, A | 1 |
| Riesco, A | 1 |
| Digiuni, E | 1 |
| Mosquera, JR | 1 |
| Caramelo, C | 1 |
| de Miguel, LS | 1 |
| Millás, I | 1 |
| de Frutos, T | 1 |
| Cernadas, MR | 1 |
| Montón, M | 1 |
| Alonso, J | 1 |
| Casado, S | 1 |
| Kawabata, H | 1 |
| Sugiyama, K | 1 |
| Katori, R | 1 |
| Lenkovsky, F | 1 |
| Neirinck, LG | 1 |
| Glezer, SV | 1 |
| Dapling, RB | 1 |
| Snowden, JA | 1 |
| West, J | 1 |
| Talbot, JF | 1 |
| Nelson, ME | 1 |
| Catella-Lawson, F | 1 |
| FitzGerald, GA | 2 |
| Clarke, D | 1 |
| Fox, KM | 1 |
| López de Sá, E | 1 |
| Calvo, F | 1 |
| Barrabés, JA | 1 |
| García-Dorado, D | 1 |
| Constantine, GR | 1 |
| Thenabadu, PN | 1 |
| Jastrzebska, M | 2 |
| McCartney, P | 1 |
| Macdowall, W | 1 |
| Thorogood, M | 1 |
| Guazzi, M | 1 |
| Melzi, G | 1 |
| Agostoni, P | 1 |
| Osa, A | 1 |
| Dhein, S | 1 |
| Gottwald, M | 1 |
| Gottwald, E | 1 |
| Hohlfeld, T | 1 |
| Salameh, A | 1 |
| Klaus, W | 1 |
| van Es, RF | 1 |
| Grobbee, DE | 1 |
| Deckers, JW | 1 |
| Bak, AA | 1 |
| Jonker, JJ | 1 |
| Carney, RM | 1 |
| Freedland, KE | 1 |
| Eisen, SA | 1 |
| Rich, MW | 1 |
| Skala, JA | 1 |
| Jaffe, AS | 1 |
| Zamorski, MA | 1 |
| Loewen, P | 1 |
| Sunderji, R | 1 |
| Gin, K | 1 |
| Torbus-Lisiecka, B | 1 |
| Pieczul-Mróz, J | 1 |
| Chełstowski, K | 1 |
| Vaidya, JS | 1 |
| Fahey, T | 1 |
| Peters, TJ | 1 |
| Jolobe, OM | 1 |
| Cleland, JG | 2 |
| Charman, WN | 1 |
| Uriuda, Y | 1 |
| Wang, QD | 1 |
| Hatori, N | 1 |
| Nordlander, R | 1 |
| Sjöquist, PO | 1 |
| Mattsson, C | 1 |
| Rydén, L | 1 |
| Anand, SS | 2 |
| Flather, M | 1 |
| Demers, C | 1 |
| Fromell, GJ | 2 |
| Goodman, S | 1 |
| Premmereur, J | 1 |
| Bigonzi, F | 1 |
| Zidar, JP | 1 |
| Gajdos, M | 1 |
| Spustová, V | 1 |
| Sebeková, K | 1 |
| Krivosiková, Z | 1 |
| Dzúrik, R | 1 |
| Klootwijk, P | 1 |
| Meij, S | 1 |
| Melkert, R | 1 |
| Lenderink, T | 1 |
| Ramesh, CV | 1 |
| Malarvannan, P | 1 |
| Jayakumar, R | 1 |
| Jayasundar, S | 1 |
| Puvanakrishnan, R | 1 |
| Walker, A | 1 |
| Gawaz, M | 1 |
| Ruf, A | 1 |
| Pogátsa-Murray, G | 1 |
| Dickfeld, T | 1 |
| Zohlnhöfer, D | 1 |
| Schömig, A | 1 |
| Satoh, T | 1 |
| Otsuka, K | 1 |
| Sakurai, I | 1 |
| Saeed, SA | 1 |
| Gilani, AH | 1 |
| Sultan, BH | 1 |
| Karim, RM | 1 |
| Shah, BH | 1 |
| Kwan, T | 1 |
| Feit, A | 1 |
| Alam, M | 1 |
| Afflu, E | 1 |
| Clark, LT | 1 |
| Rojas-Fernandez, CH | 1 |
| Kephart, GC | 1 |
| Sketris, IS | 1 |
| Kass, K | 1 |
| Bates, SM | 1 |
| Ahn, YK | 1 |
| Cho, JG | 1 |
| Park, WS | 1 |
| Kim, NH | 1 |
| Kim, SH | 1 |
| Cho, JH | 1 |
| Park, JH | 1 |
| Jeong, MH | 1 |
| Park, JC | 1 |
| Kang, JC | 1 |
| Ghali, JK | 1 |
| Thiru, K | 1 |
| Gray, J | 1 |
| Majeed, A | 1 |
| Smith, NL | 1 |
| Reiber, GE | 1 |
| Psaty, BM | 1 |
| Heckbert, SR | 1 |
| Siscovick, DS | 1 |
| Ritchie, JL | 1 |
| Every, NR | 1 |
| Koepsell, TD | 1 |
| Born, G | 1 |
| Bassand, JP | 1 |
| Carrier, M | 1 |
| Rivard, M | 1 |
| Kostuk, W | 1 |
| Latter, D | 1 |
| Daly, P | 1 |
| Teo, K | 1 |
| Gudas, V | 1 |
| Sullivan, J | 1 |
| White, M | 1 |
| Hellstrom, HR | 1 |
| Bouvy, ML | 1 |
| Heerdink, ER | 1 |
| Klungel, OH | 1 |
| de Boer, A | 1 |
| Stuurman-Bieze, AG | 1 |
| Leufkens, HG | 1 |
| Asplund, K | 1 |
| MacKinlay, N | 1 |
| Taper, J | 1 |
| Renisson, F | 1 |
| Rickard, K | 1 |
| Schenck, J | 1 |
| Müller, CH | 1 |
| Lübbers, H | 1 |
| Mahlke, R | 1 |
| Lehnick, D | 1 |
| Lankisch, PG | 1 |
| Stinnett, SS | 1 |
| Weatherley, BD | 1 |
| Santopinto, J | 1 |
| Bozovich, GE | 1 |
| Quispe, A | 1 |
| Strinna, A | 1 |
| Lancellotti, P | 1 |
| Piérard, LA | 1 |
| Holroyd-Leduc, JM | 1 |
| Kapral, MK | 1 |
| Austin, PC | 1 |
| Tu, JV | 1 |
| Hildebrandt, PR | 1 |
| Snorgaard, O | 1 |
| Melchior, TM | 1 |
| Seibaek, MB | 1 |
| Torp-Pedersen, CT | 1 |
| Marissal, JP | 1 |
| Selke, B | 1 |
| Lebrun, T | 1 |
| Chazov, EI | 1 |
| Adachi, H | 1 |
| Sakurai, S | 1 |
| Tanehata, M | 1 |
| Oshima, S | 1 |
| Taniguchi, K | 1 |
| Kiesz, RS | 1 |
| Buszman, P | 1 |
| Martin, JL | 1 |
| Deutsch, E | 1 |
| Rozek, MM | 1 |
| Gaszewska, E | 1 |
| Rewicki, M | 1 |
| Seweryniak, P | 1 |
| Kosmider, M | 1 |
| Tendera, M | 1 |
| Shehadeh, AA | 1 |
| Arena, J | 1 |
| Moschos, CB | 1 |
| Regan, TJ | 1 |
| Epelde, F | 1 |
| Garca-Castrillo Riesgo, L | 1 |
| Loma-Osorio, A | 1 |
| Verdier, J | 1 |
| Recuerda Martnez, E | 1 |
| Heindl, B | 1 |
| Becker, BF | 1 |
| Rossoni, G | 1 |
| Manfredi, B | 1 |
| Colonna, VD | 1 |
| Bernareggi, M | 1 |
| Berti, F | 1 |
| Golański, J | 1 |
| Chizyński, K | 1 |
| Golański, R | 1 |
| Watała, C | 1 |
| Scheen, AJ | 1 |
| Bing, RJ | 1 |
| Peterson, JG | 1 |
| Lauer, MS | 2 |
| Barbash, IM | 1 |
| Gottlieb, S | 1 |
| Leor, J | 1 |
| Laheij, RJ | 1 |
| Jansen, JB | 1 |
| Verbeek, AL | 1 |
| Chrolavicius, S | 1 |
| Tognoni, G | 1 |
| Fox, KK | 1 |
| Majid, A | 1 |
| Delanty, N | 1 |
| Kantor, J | 1 |
| Woollard, M | 1 |
| Smith, A | 1 |
| Elwood, P | 1 |
| O'Connor, FF | 1 |
| Shields, DC | 1 |
| Fitzgerald, A | 1 |
| Fitzgerald, DJ | 1 |
| Abramson, B | 1 |
| Owen, A | 1 |
| Peverill, RE | 1 |
| Moir, S | 1 |
| Tahiliani, N | 1 |
| Trivedi, A | 1 |
| Deshmukh, HG | 1 |
| Yende, S | 1 |
| Miller, AM | 1 |
| Work, LM | 1 |
| Del Soldato, P | 1 |
| Aviles, RJ | 1 |
| Askari, AT | 1 |
| Lindahl, B | 1 |
| Jia, G | 1 |
| Berger, P | 1 |
| Scott, AC | 1 |
| Wensel, R | 1 |
| Davos, CH | 1 |
| Kemp, M | 1 |
| Kaczmarek, A | 1 |
| Hooper, J | 1 |
| Coats, AJ | 1 |
| Piepoli, MF | 1 |
| Balsano, F | 1 |
| Violi, F | 1 |
| Censi, C | 1 |
| Schwartz, D | 1 |
| Kornowski, R | 1 |
| Lehrman, H | 1 |
| Averbuch, M | 1 |
| Pines, A | 1 |
| Greenland, M | 1 |
| Finkelstein, A | 1 |
| Levo, Y | 1 |
| Zadina, K | 1 |
| Copeland, J | 1 |
| Moritz, T | 1 |
| Hennekens, CH | 1 |
| Buring, JE | 1 |
| Peto, R | 1 |
| Klein, W | 1 |
| Eber, B | 1 |
| Fruhwald, F | 1 |
| Akhmedzhanov, MIu | 1 |
| Ezhova, LV | 1 |
| Arkhangel'skiĭ, VV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events[NCT05313620] | Phase 4 | 30 participants (Anticipated) | Interventional | 2022-04-01 | Recruiting | ||
| A Randomized, Double-Blind, Placebo Controlled, Parallel Group, Multinational Trial, to Assess the Prevention of Thrombotic Events With Ticagrelor Compared to Placebo on a Background of Acetyl Salicylic Acid (ASA) Therapy in Patients With History of Myoca[NCT01225562] | Phase 3 | 21,379 participants (Actual) | Interventional | 2010-10-31 | Completed | ||
| Japan-USA Harmonized Assessment by Randomized, Multi-Center Study of OrbusNEich's Combo StEnt (Japan-USA HARMONEE): Assessment of a Novel DES Platform For Percutaneous Coronary Revascularization in Patients With Ischemic Coronary Disease and NSTEMI Acute [NCT02073565] | 572 participants (Actual) | Interventional | 2014-02-28 | Completed | |||
| Comparison Between P2Y12 Antagonist MonotHerapy and Dual Antiplatelet Therapy in Patients UndergOing Implantation of Coronary Drug-Eluting Stents[NCT02079194] | 3,000 participants (Actual) | Interventional | 2014-03-18 | Active, not recruiting | |||
| A Clinical Multicenter, Prospective, Observational Cohort Study to Validate a Prediction Mobile APP for Perioperative Hypothermia[NCT05333120] | 3,000 participants (Anticipated) | Observational [Patient Registry] | 2021-05-25 | Recruiting | |||
| Influence of Different Inspired Oxygen Fractions on Perioperative Myocardial Biomarkers, Myocardial Strain and Outcome in Patients Undergoing General Anaesthesia for Elective Non-cardiac Surgery: A Prospective Randomized Open-label Single Centre Pilot Stu[NCT04808401] | 110 participants (Anticipated) | Interventional | 2021-05-07 | Recruiting | |||
| Closed Incision Negative Pressure Therapy Compared to Conventional Dressing Following Autologous Abdominal Tissue Breast Reconstruction: A Randomized Control Trial[NCT05907941] | 114 participants (Anticipated) | Interventional | 2023-07-31 | Not yet recruiting | |||
| Registry Dedicated to Assess the Risk of Ischemic and Hemorrhagic Complications of Long-term Antithrombotic Therapy in Patients With Chronic Coronary Syndromes[NCT04347200] | 2,000 participants (Anticipated) | Observational [Patient Registry] | 2015-01-15 | Recruiting | |||
| A Randomized Controlled Trial of Rivaroxaban for the Prevention of Major Cardiovascular Events in Patients With Coronary or Peripheral Artery Disease (COMPASS - Cardiovascular OutcoMes for People Using Anticoagulation StrategieS).[NCT01776424] | Phase 3 | 27,395 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| CHoosing Triple or Double therApy in the Era of nOac for patientS Undergoing PCI: the CHAOS a Multicenter Study.[NCT03558295] | 1,000 participants (Anticipated) | Observational [Patient Registry] | 2018-05-01 | Recruiting | |||
| Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)[NCT01165710] | 10,179 participants (Actual) | Observational | 2010-06-30 | Completed | |||
| Management of Antiplatelet Regimen During Surgical Procedures (MARS Registry)[NCT03981835] | 1,492 participants (Anticipated) | Observational [Patient Registry] | 2019-08-01 | Recruiting | |||
| A Large, International, Placebo-controlled, Factorial Trial to Assess the Impact of Clonidine and Acetyl-salicylic Acid (ASA) in Patients Undergoing Noncardiac Surgery Who Are at Risk of a Perioperative Cardiovascular Event[NCT01082874] | Phase 3 | 10,010 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| Effect of Spinal Versus General Anesthesia on Cardiac and Renal Biomarker Levels in Hip and Knee Arthroplasty Surgery[NCT03940651] | Phase 4 | 1 participants (Actual) | Interventional | 2019-09-04 | Terminated (stopped due to Funding ended) | ||
| MONET BRIDGE(Maintenance Of aNtiplatElet Therapy in Patients With Coronary Stenting Undergoing Surgery) - (Mantenimento Della Terapia Antiaggregante Nei Pazienti Portatori di Stent Coronarico Candidati a Chirurgia)[NCT03862651] | Phase 2 | 140 participants (Anticipated) | Interventional | 2019-06-01 | Not yet recruiting | ||
| A Prospective, Multi-center, Randomized, Double-blind Trial to Assess the Effectiveness and Safety of 12 Versus 30 Months of Dual Antiplatelet Therapy in Subjects Undergoing Percutaneous Coronary Intervention With Either Drug-eluting Stent or Bare Metal S[NCT00977938] | Phase 4 | 25,682 participants (Actual) | Interventional | 2009-10-31 | Completed | ||
| Percutaneous Coronary Intervention With the ANgiolite Drug-Eluting Stent: an Optical CoHerence TOmogRaphy Study. The ANCHOR Study[NCT02776267] | 100 participants (Anticipated) | Interventional | 2015-05-31 | Completed | |||
| "Outcome of CHAllenging lesioNs and Patients Treated With Polymer Free Drug-CoatEd Stent (Biofreedom): the CHANCE a Multicenter Study"[NCT03622203] | 1,000 participants (Actual) | Observational [Patient Registry] | 2016-01-01 | Completed | |||
| INternational VErapamil SR Trandolapril STudy[NCT00133692] | Phase 4 | 22,000 participants | Interventional | 1997-09-30 | Completed | ||
| Guideline Recommended Care and Excess Mortality for Non ST-elevation Myocardial Infarction : A National Cohort Study[NCT02436187] | 389,057 participants (Actual) | Observational [Patient Registry] | 2003-01-31 | Completed | |||
| Effects of Artificial Intelligence Assisted Follow-up Strategy Based on a New Remote Contactless Sleep Monitoring System on Secondary Prevention in Patients Received Coronary Artery Bypass Grafting Surgery[NCT04636996] | 200 participants (Anticipated) | Interventional | 2021-01-01 | Not yet recruiting | |||
| A Phase 2, Placebo-Controlled, Randomized, Double Blind, Parallel Arm, Dose Ranging Study to Evaluate Safety and Efficacy of Apixaban in Patients With a Recent Acute Coronary Syndrome.[NCT00313300] | Phase 2 | 1,741 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Fixed-dose Combination Therapy (PolyPill) in Primary and Secondary Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians[NCT01271985] | Phase 3 | 8,410 participants (Actual) | Interventional | 2011-02-28 | Completed | ||
| A Phase III, Multicenter, Multinational, Randomized, Parallel Group, Double-blind Trial of Clopidogrel Versus Placebo in High-risk Patients Aged 45 Years and Older, at Risk of Atherothrombotic Events, and Who Are Receiving Background Therapy Including Low[NCT00050817] | Phase 3 | 15,603 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| Influence of CILostazol-based Triple Anti-platelet Therapy ON Ischemic Complication After Drug-eluting stenT Implantation[NCT00776828] | Phase 4 | 960 participants (Actual) | Interventional | 2006-11-30 | Completed | ||
| Pilot Study of Preoperative Aspirin and Postoperative Clopidogrel's Effects on Graft Patency and Cardiac Events in Coronary Artery Bypass Surgery[NCT00330772] | Phase 3 | 150 participants (Anticipated) | Interventional | 2006-07-31 | Completed | ||
| Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448] | Phase 4 | 2,539 participants (Actual) | Interventional | 2002-12-31 | Completed | ||
| Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study)[NCT03328845] | Phase 4 | 300 participants (Actual) | Interventional | 2017-01-20 | Completed | ||
| A Comparison of Prasugrel and Clopidogrel in Acute Coronary Syndrome Subjects With Unstable Angina/Non-ST-Elevation Myocardial Infarction Who Are Medically Managed[NCT00699998] | Phase 3 | 9,326 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Laboratory Implications of Non Obstructive Atherosclerotic Plaques Identified by Multiple Detector Coronary Angiotomography[NCT03632785] | 90 participants (Actual) | Observational | 2017-03-27 | Completed | |||
| ABSORB II RANDOMIZED CONTROLLED TRIAL A Clinical Evaluation to Compare the Safety, Efficacy and Performance of ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System Against XIENCE Everolimus Eluting Coronary Stent System in the Treatment of Sub[NCT01425281] | 501 participants (Actual) | Interventional | 2011-11-30 | Completed | |||
| French Observatory Evaluating the Use of Intracoronary Prosthesis ABSORB BVS[NCT02238054] | 2,072 participants (Actual) | Observational [Patient Registry] | 2014-09-30 | Completed | |||
| Effectiveness of Polypill for Primary Prevention of Cardiovascular Disease (PolyPars): Study Design and Rationale for a Pragmatic Cluster Randomized Controlled Trial[NCT03459560] | Phase 3 | 4,415 participants (Actual) | Interventional | 2015-12-20 | Active, not recruiting | ||
| Comparative Randomized Single-blind Trial of Amiloride in Coronary Heart Disease[NCT01231165] | Phase 2/Phase 3 | 70 participants (Actual) | Interventional | 2009-02-28 | Completed | ||
| Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug[NCT01321255] | Phase 3 | 2,118 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| China Research for Severe Spontaneous Intracerebral Hemorrhage（CRISIH）[NCT05975398] | 450 participants (Anticipated) | Observational [Patient Registry] | 2022-07-01 | Recruiting | |||
| Effect and Safety of Surgical Intervention for Severe Spontaneous Intracerebral Hemorrhage Patients on Long-term Oral Antiplatelet Treatment[NCT05766865] | 450 participants (Actual) | Observational | 2019-07-10 | Completed | |||
| Clopidogrel After Surgery for Coronary Artery Disease (CASCADE Trial): Does Clopidogrel Prevent Saphenous Vein Graft Disease After Coronary Bypass?[NCT00228423] | Phase 2 | 113 participants (Actual) | Interventional | 2006-05-31 | Completed | ||
| Maintenance of an Antiaggregation by Acetylsalicylic Acid, Less or Equal to 250mg While a Extracorporeal Lithotripsy (ECL) Session on a Kidney Stone is Perfomed: Comparative Unicentric Prospective Study[NCT03437057] | 300 participants (Anticipated) | Interventional | 2018-01-08 | Recruiting | |||
| A Prospective, Double-blinded, Randomised Study to Evaluate the Effects of Different Doses of Statin Treatment on Plaque Volume and Composition in Coronary Disease Determined by Virtual Histology Using Intravascular Ultrasound[NCT01200056] | Phase 4 | 40 participants (Actual) | Interventional | 2007-08-31 | Completed | ||
| Randomized, Double-Blind, Active-Controlled, Multicenter Trial of Abciximab And Bivalirudin in Patients With Non-ST-Segment Elevation Myocardial Infarction Undergoing Percutaneous Coronary Interventions (ISAR-REACT-4)[NCT00373451] | Phase 4 | 1,721 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Phase I/IIa Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2[NCT03333590] | Phase 1/Phase 2 | 2 participants (Actual) | Interventional | 2017-11-06 | Active, not recruiting | ||
| Study of the Efficacy and Safety of Cilostazol in the Prevention of Ischemic Vascular Events in Diabetic Patients With Symptomatic Peripheral Artery Disease.[NCT02983214] | Phase 4 | 826 participants (Actual) | Interventional | 2016-11-30 | Completed | ||
| Effects of APIXaban on BRAIN Protection in Patients With Sinus Rhythm and Heart Failure: APIXBRAIN-HF Trial[NCT04696120] | Phase 2 | 200 participants (Anticipated) | Interventional | 2021-03-02 | Not yet recruiting | ||
| WilL LOWer Dose Aspirin be More Effective Following ACS? (WILLOW-ACS)[NCT02741817] | Phase 4 | 20 participants (Actual) | Interventional | 2016-06-26 | Completed | ||
| A Comparison of CS-747 and Clopidogrel in Acute Coronary Syndrome Subjects Who Are to Undergo Percutaneous Coronary Intervention[NCT00097591] | Phase 3 | 13,619 participants (Actual) | Interventional | 2004-11-30 | Completed | ||
| A Double Blind, Placebo Controlled, Fixed-Flexible Dose Clinical Trial of Guanfacine Extended Release for the Reduction of Aggression and Self-injurious Behavior Associated With Prader-Willi Syndrome[NCT05657860] | Phase 4 | 33 participants (Anticipated) | Interventional | 2020-12-17 | Recruiting | ||
| An Open-Label Clinical Trial of Simultaneous Administration of Oral Aspirin and Ketamine as Adjunct to Oral Antidepressant Therapy in Treatment-Resistant Depression[NCT05615948] | Phase 4 | 20 participants (Anticipated) | Interventional | 2022-12-06 | Recruiting | ||
| Effects of Prolonged Dual Antiplatelet Therapy With Clopidogrel Plus Acetylsalicylic Acid (ASA) After Percutaneous Lower Extremity Revascularization in Patients With Peripheral Arterial Disease[NCT02798913] | Phase 3 | 300 participants (Anticipated) | Interventional | 2016-01-31 | Recruiting | ||
| Aspirin Non-responsiveness and Clopidogrel Endpoint Trial.[NCT00222261] | Phase 4 | 1,001 participants (Actual) | Interventional | 2003-04-30 | Completed | ||
| Comparative Study of Clinical Efficacy and Safety of Different Clopidogrel Salts in Patients With Cardiovascular Disease. A Multi-center Non-interventional Clinical Trial.[NCT02126982] | 1,500 participants (Actual) | Observational | 2012-10-31 | Completed | |||
| A Multicenter Prospective observationaL Study to evAluate the effecT of Clopidogrel on the prEvention of Major vascuLar Events According to the gEnotype of Cytochrome P450 2C19 in Ischemic Stroke paTients; PLATELET Study[NCT04072705] | 2,927 participants (Actual) | Observational | 2019-09-20 | Completed | |||
| Antiplatelet Therapy in HIV - Antiplatelet and Immune Modulating Effects of Aspirin or Clopidogrel in Subjects With HIV[NCT02559414] | Phase 2 | 55 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Influence of Rivaroxaban 2.5 mg Two Times a Day for Intermittent Claudication and Exercise Tolerance in Patients With Symptomatic Peripheral Arterial Disease (PAD) - a Randomised Controlled Trial[NCT04305028] | 100 participants (Anticipated) | Observational | 2021-03-10 | Not yet recruiting | |||
| Efficacy of H2 Receptor Antagonist in Prevention of Thienopyridine-related Peptic Ulcer[NCT02418312] | 228 participants (Actual) | Interventional | 2012-01-31 | Completed | |||
| Genotype Guided Antiplatelet Therapy In Ischemic Stroke[NCT05763862] | 350 participants (Anticipated) | Interventional | 2023-04-24 | Recruiting | |||
| Pantoprazole Versus Famotidine for the Prevention of Recurrent Peptic Ulcers in Thienopyridine Users - a Double-blind Randomized Controlled Trial[NCT02551744] | 101 participants (Actual) | Interventional | 2012-07-31 | Completed | |||
| Intensified Antiplatelet Therapy in Post-PCI Patients With High On-treatment Platelet Reactivity: the OPTIMA-2 Trial[NCT01955200] | Phase 4 | 1,724 participants (Actual) | Interventional | 2013-10-05 | Completed | ||
| The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093] | 280 participants (Actual) | Observational | 2014-06-30 | Completed | |||
| A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330] | Phase 4 | 40 participants (Actual) | Interventional | 2016-06-30 | Completed | ||
| A Randomized, Single Center Trial to Assess the Endothelial Function With Ticagrelor Monotherapy Compared to Aspirin Monotherapy in Patients With History of Acute Coronary Syndrome[NCT03881943] | Phase 4 | 200 participants (Actual) | Interventional | 2017-01-31 | Completed | ||
| A Single-center, Randomized, Open-label, Controlled, Dose-escalating, Parallel-group Study to Assess the Anti-platelet Effect of Berberine in Patients Receiving Aspirin and Clopidogrel After Percutaneous Coronary Intervention[NCT03378934] | Phase 4 | 64 participants (Anticipated) | Interventional | 2018-09-26 | Recruiting | ||
| Gastrointestinal Ulceration in Patients on Dual Antiplatelet Therapy After Percutaneous Coronary Intervention[NCT00413309] | 30 participants (Anticipated) | Interventional | 2006-04-30 | Completed | |||
| The Effect of Inducing the Cytochrome P450 System on the Pharmacodynamic Efficacy of Clopidogrel[NCT01330589] | 0 participants (Actual) | Interventional | 2011-04-30 | Withdrawn (stopped due to Inability to enroll subjects and changes in standard of care for PCI) | |||
| Aspirin Impact on Platelet Reactivity in Acute Coronary Syndrome Patients on Novel P2Y12 Inhibitors Therapy[NCT02049762] | Phase 4 | 29 participants (Actual) | Interventional | 2015-06-30 | Completed | ||
| The Association Between Plasma or Platelet microRNAs and Clopidogrel Low Response and Its Mechanism[NCT02447809] | Phase 4 | 400 participants (Anticipated) | Interventional | 2015-01-31 | Recruiting | ||
| The Efficacy and Safety of Proton Pump Inhibitor ( in Patients With Moderate Bleeding Risk and Coronary Artery Disease Undergoing Percutaneous Coronary: A Randomised, Open ,Compared With Control[NCT05820048] | Phase 4 | 300 participants (Anticipated) | Interventional | 2023-05-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Participants with death from any cause. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent or the last time point the particapant was known to be alive. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who died from any cause within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 5.1 |
| Ticagrelor 60 mg | 4.7 |
| Placebo | 5.2 |
A Thrombolysis in Myocardial Infarction (TIMI) study group major bleeding is defined as any fatal bleeding (leading directly to death within 7 days), any intrcranial bleeding or any clinically overt signs of haemorrhage associated with a drop in Haemoglobin of >= 5g/dL. Events were adjudicated by a clinical events committee. Censoring ocurrs at 7 days following last dose of study drug. The Kaplan-Meier estimate reports the percentage of patients who experienced a TIMI Major bleeding within 3 years from first dose of study drug (NCT01225562)
Timeframe: First dosing up to 48 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.6 |
| Ticagrelor 60 mg | 2.3 |
| Placebo | 1.1 |
Participants with CV death. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 2.9 |
| Ticagrelor 60 mg | 2.9 |
| Placebo | 3.4 |
Participants with CV death, MI or Stroke. If no event, censoring occurs at the earliest of the efficacy cut-off date 14 Sep 2014, withdrawal of consent, non-CV death or at the last time point of complete clinical event assessment. Events were adjudicated by a blinded endpoint committee. The Kaplan-Meier estimate reports the percentage of patients who experienced CV Death, MI or stroke within 3 years from randomization (NCT01225562)
Timeframe: Randomization up to 47 months
| Intervention | Percentage of Patients (Number) |
|---|---|
| Ticagrelor 90 mg | 7.8 |
| Ticagrelor 60 mg | 7.8 |
| Placebo | 9.0 |
The primary clinical endpoint of Target Vessel Failure (TVF), defined as cardiac death, target-vessel myocardial infarction (MI), or ischemia-driven Target Vessel Revascularization(TVR) by percutaneous or surgical methods, at 1 year. (NCT02073565)
Timeframe: 1 year follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| Combo | 20 |
| Everolimus Eluting Stent (EES) | 12 |
Clinically and functionally ischemia-driven target lesion revascularization (TLR), including use of target-vessel Fractional Flow Reserve (FFR), analyzed dichotomously using the Fractional Flow Reserve (FFR) vs. Angiography in Multivessel Evaluation (FAME) study criteria of 0.8 during a 2 minute infusion of adenosine or adenosine triphosphate.34 Abnormal FFR-driven interventions at 1 year will be included in the evaluation of ischemia-driven TLR. (NCT02073565)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Combo | 12 |
| Everolimus Eluting Stent (EES) | 8 |
The secondary efficacy endpoint is mechanistic Optical coherence tomography (OCT) healthy level of intimal tissue coverage, determined by the OCT core laboratory at 1 year for subjects in Cohorts A and B. This reports the percentage of healthy tissue coverage that was great than 40 micrometers. (NCT02073565)
Timeframe: 1 year
| Intervention | Healthy Tissue Strut Coverage (>40 µm) % (Mean) |
|---|---|
| Combo | 91.27 |
| Everolimus Eluting Stent (EES) | 74.82 |
Serum will be assessed for HAMA development at index, 30 days, and 12 months in Cohort B subjects. Human antimurine antibody plasma assessment will be with blood draws performed during index procedure, 30 day follow-up visit, and 1 year catheterizations. (NCT02073565)
Timeframe: Day of device implantation, 30 days, 12 months
| Intervention | Participants (Count of Participants) | ||
|---|---|---|---|
| Baseline HAMA Responders | 30 day HAMA Responders | 1 Year HAMA Responders | |
| Combo | 0 | 0 | 0 |
| Everolimus Eluting Stent (EES) | 0 | 0 | 0 |
Count of participants and time from randomization to death by all cause were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participants, death by any cause after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 313 |
| Rivaroxaban 5mg + Aspirin Placebo | 366 |
| Rivaroxaban Placebo + Aspirin 100mg | 378 |
Count of participants from COMPASS LTOLE initiation visit to death by all cause were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participants, death by any cause after COMPASS LTOLE initiation visit up until the the last LTOLE part contact date was considered. The mean time in follow-up until that date was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 282 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ischemic stroke, ALI, or CV death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 389 |
| Rivaroxaban 5mg + Aspirin Placebo | 453 |
| Rivaroxaban Placebo + Aspirin 100mg | 516 |
Count of participants and time from randomization to the first occurrence of MI, ischemic stroke, ALI, or CHD death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of MI, ALI, or CHD death after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 329 |
| Rivaroxaban 5mg + Aspirin Placebo | 397 |
| Rivaroxaban Placebo + Aspirin 100mg | 450 |
Count of participants and time from randomization to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. Hazard ratios were calculated and reported as statistical analysis. (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 379 |
| Rivaroxaban 5mg + Aspirin Placebo | 448 |
| Rivaroxaban Placebo + Aspirin 100mg | 496 |
Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the composite primary efficacy outcome, MI, stroke, or CV death were evaluated. LTOLE: long-term open-lable extension (NCT01776424)
Timeframe: For each participant, the first occurrence of the composite primary efficacy outcome after from COMPASS LTOLE initiation visit up until last LTOLE part contact date was considered. The mean time in follow-up was 428 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 353 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants and time from randomization to the first occurrence of the primary safety outcome major bleeding were evaluated. Hazard ratios were calculated and reported as statistical analysis." (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding after randomization up until the global rivaroxaban/aspirin outcomes cut-off date (06 FEB 2017) was considered. The mean time in follow-up until that date was 702 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| Rivaroxaban 2.5mg + Aspirin 100mg | 288 |
| Rivaroxaban 5mg + Aspirin Placebo | 255 |
| Rivaroxaban Placebo + Aspirin 100mg | 170 |
"Modified ISTH major bleeding is defined as: i) Fatal bleeding, or ii) Symptomatic bleeding in a critical area or organ, such as intraarticular, intracranial, intramuscular with compartment syndrome, intraocular, intraspinal, liver, pancreas, pericardial, respiratory, retroperitoneal, adrenal gland or kidney; or bleeding into the surgical site requiring reoperation, or iii) Bleeding leading to hospitalization (major bleeding also includes presentation to an acute care facility with discharge on the same day).~Count of participants from COMPASS LTOLE initiation visit to the first occurrence of the primary safety outcome major bleeding was evaluated. LTOLE: long-term open-lable extension" (NCT01776424)
Timeframe: For each participant, the first occurrence of modified ISTH major bleeding from COMPASS LTOLE initiation visit up until 2 days after the last treatment in LTOLE part was considered. The mean time in follow-up was 421 days.
| Intervention | Participants (Count of Participants) |
|---|---|
| LTOLE Part: Rivaroxaban 2.5mg + Aspirin 100mg | 138 |
(NCT01082874)
Timeframe: 30 days
| Intervention | participants (Number) |
|---|---|
| Active Clonidine and Active ASA | 173 |
| Active Clonidine and Placebo ASA | 194 |
| Placebo Clonidine and Active ASA | 178 |
| Placebo Clonidine and Placebo ASA | 161 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 1.70 |
| Propensity-matched BMS | 2.61 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 0.50 |
| BMS 12-month DAPT | 1.11 |
ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.69 |
| DES 12-month DAPT | 1.45 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of definite or probable ST within randomized DES ITT patients between 12 and 30 months post procedure. ST was assessed according to the Academic Research Consortium (ARC) definitions. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 0.40 |
| DES 12-month DAPT | 1.35 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.03 |
| BMS 12-month DAPT | 0.90 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| BMS 30-month DAPT | 2.09 |
| BMS 12-month DAPT | 1.05 |
Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.74 |
| DES 12-month DAPT | 1.88 |
The primary safety endpoint was moderate or severe bleeding within randomized DES ITT patients between 12 and 30 months post procedure. Bleeding was assessed according to the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Arteries (GUSTO) criteria. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| DES 30-month DAPT | 2.53 |
| DES 12-month DAPT | 1.57 |
Secondary powered endpoint (NCT00977938)
Timeframe: 33 months (0-33 months post-index procedure)
| Intervention | percentage of patients (Number) |
|---|---|
| Propensity-matched DES | 11.37 |
| Propensity-matched BMS | 13.24 |
(NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.04 |
| BMS 12-month DAPT | 4.69 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| BMS 30-month DAPT | 4.68 |
| BMS 12-month DAPT | 5.48 |
(NCT00977938)
Timeframe: 21 months (12-33 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 5.62 |
| DES 12-month DAPT | 6.49 |
The coprimary efficacy endpoints were the cumulative incidence of MACCE and the cumulative incidence of ARC definite or probable stent thrombosis within randomized DES ITT patients between 12 and 30 months post procedure. (NCT00977938)
Timeframe: 18 months (12-30 months post-index procedure)
| Intervention | percentage of patients (KM estimate) (Number) |
|---|---|
| DES 30-month DAPT | 4.34 |
| DES 12-month DAPT | 5.92 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events included major bleeding, clinically relevant non-major bleeding and minor bleeding. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 6.1 |
| Apixaban 2.5mg BID | 15.1 |
| Apixaban 10mg QD | 17.6 |
| Apixaban 10mg BID | 24.2 |
| Apixaban 20 mg QD | 23.9 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). All bleeding events includes major bleeding, clinically relevant non-major bleeding and minor bleeding. Treatment Period refers to the period from first dose through 2 days, or through 30 days for Serious Adverse Event (SAE) tabulations, after discontinuation of study drug. Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: first dose (Day 1) to last dose plus 2 days (or for SAEs, plus 30 days), up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 10.5 |
| Apixaban 2.5mg BID | 20.6 |
| Apixaban 10mg QD | 22.5 |
Bleeding was assessed using ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups and the lower duration of exposure. Phase B Adjusted Treatment Period=safety events occurring in the period from first dose through 2 days (or through 30 days for SAE tabulations) after the earliest of last dose date or 1-Oct-2007 (termination date for the 10 mg BID group). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 5.0 |
| Apixaban 10mg QD | 5.6 |
| Apixaban 10mg BID | 7.8 |
| Apixaban 20 mg QD | 7.3 |
Bleeding was assessed using the International Society on Thrombosis and Hemostasis (ISTH) guidelines. Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). The primary outcome is based on data for the placebo and 2 apixaban low-dose groups (2.5 mg BID and 10 mg QD) combined across Phase A and Phase B. The analyses of Phase B data across all doses of apixaban are secondary because of the premature termination of the apixaban high-dose groups (10mg BID, 20mg QD) and the resulting lower duration of exposure for these groups. (NCT00313300)
Timeframe: From first dose of study drug (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 3.0 |
| Apixaban 2.5mg BID | 5.7 |
| Apixaban 10mg QD | 7.9 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the CEC. Event rate was number of participants with events divided by the number of participants treated (%). (NCT00313300)
Timeframe: From first dose (Day 1) to last dose, plus 2 days (plus 30 days for SAEs), up to high dose termination, 1 October 2007
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.0 |
| Apixaban 2.5mg BID | 0.8 |
| Apixaban 10mg QD | 0.0 |
| Apixaban 10mg BID | 2.9 |
| Apixaban 20 mg QD | 4.1 |
Bleeding was assessed using the ISTH guidelines. Events were adjudicated by the Clinical Events Committee. Event rate was number of participants with events divided by the number of participants treated, measured as a percentage (%). (NCT00313300)
Timeframe: from first dose (Day 1) to last dose plus 2 days, up to Year 2 of the Study
| Intervention | percentage of participants (Number) |
|---|---|
| Placebo | 0.8 |
| Apixaban 2.5mg BID | 1.6 |
| Apixaban 10mg QD | 1.9 |
Events were adjudicated by the Clinical Events Committee (CEC). Event rate was number of participants with events divided by the number of participants treated (%). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B (NCT00313300)
Timeframe: Day of randomization to 182 days after day of randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 54 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 20 |
Events were adjudicated by the Clinical Events Committee (CEC). Intended Treatment Period refers to the period starting on the day of randomization and ending 182 days after the day of randomization (for a total period duration of 183 days). Data in this outcome are combined across Phase A and Phase B. (NCT00313300)
Timeframe: Randomization to 182 days after randomization (183 days)
| Intervention | participants (Number) |
|---|---|
| Placebo | 53 |
| Apixaban 2.5mg BID | 24 |
| Apixaban 10mg QD | 19 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on termination date of high dose apixaban, 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization and ends on high dose termination date, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
Phase B Adjusted Intended Treatment Period=day of randomization and ends on 1-Oct-2007. The analyses of Phase B data across all doses of apixaban are secondary due to the premature termination of the apixaban high dose groups and the lower duration of exposure. (NCT00313300)
Timeframe: Day of randomization up to high dose termination, 1-Oct-2007
| Intervention | participants (Number) |
|---|---|
| Placebo | 16 |
| Apixaban 2.5mg BID | 6 |
| Apixaban 10mg QD | 4 |
| Apixaban 10mg BID | 8 |
| Apixaban 20 mg QD | 7 |
The percentage of participants is the total number of participants experiencing an all-cause death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.61 |
| Prasugrel: 75 Years of Age or Older | 27.04 |
| Clopidogrel: <75 Years of Age | 11.12 |
| Clopidogrel: 75 Years of Age or Older | 26.83 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, or nonfatal stroke divided by number of participants in the treatment arm multiplied by 100. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 10.06 |
| Prasugrel: 75 Years of Age or Older | 24.64 |
| Clopidogrel: <75 Years of Age | 10.96 |
| Clopidogrel: 75 Years of Age or Older | 24.13 |
The percentage of participants is the total number of participants experiencing a CV death or nonfatal MI divided by number of participants in the treatment arm. Endpoint events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 9.61 |
| Prasugrel: 75 Years of Age or Older | 22.53 |
| Clopidogrel: <75 Years of Age | 10.21 |
| Clopidogrel: 75 Years of Age or Older | 22.69 |
The percentage of participants is the total number of participants experiencing a CV death, nonfatal MI, nonfatal stroke or re-hospitalization for a recurrent UA divided by number of participants in the treatment arm. Endpoints events were adjudicated by the Clinical Endpoint Committee. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | percentage of participants with an event (Number) |
|---|---|
| Prasugrel: <75 Years of Age | 12.13 |
| Prasugrel: 75 Years of Age or Older | 26.27 |
| Clopidogrel: <75 Years of Age | 12.83 |
| Clopidogrel: 75 Years of Age or Older | 25.67 |
Brain natriuretic peptide (BNP) is secreted by the ventricles of the heart in response to hemodynamic stress and is a biomarker associated with increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 6 Months
| Intervention | picograms per milliliter (pg/mL) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=725, 125, 701, 174) | |
| Clopidogrel: <75 Years of Age | 319.345 | 250.982 |
| Clopidogrel: 75 Years of Age or Older | 951.359 | 722.750 |
| Prasugrel: <75 Years of Age | 313.494 | 253.434 |
| Prasugrel: 75 Years of Age or Older | 1082.396 | 770.132 |
C-Reactive Protein (CRP) is a biomarker associated with inflammation and increased CV risk. Results are presented as geometric least squares means (Geometric LS means). Geometric LS means were adjusted for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and Month 6
| Intervention | milligrams per liter (mg/L) (Geometric Mean) | |
|---|---|---|
| Day 30 | 6 Months (n=755, 143, 745, 178) | |
| Clopidogrel: <75 Years of Age | 2.287 | 2.149 |
| Clopidogrel: 75 Years of Age or Older | 2.226 | 1.543 |
| Prasugrel: <75 Years of Age | 2.330 | 2.272 |
| Prasugrel: 75 Years of Age or Older | 2.441 | 1.593 |
Seattle Angina Questionnaire (SAQ) is a validated, disease-specific questionnaire containing 11 questions (Q) yielding 5 summary scales related to angina: physical limitations, angina stability, angina frequency, treatment satisfaction and disease perception. In this study only angina frequency and the physical limitations scales were assessed. Anginal Frequency was assessed using Q3 and Q4 which consists of a Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how often a patient is having symptoms now. Physical limitations was assessed using Q1 which contains 9 items each assessed via Likert scale ranging from 1 to 6 (higher values equals better quality of life) to assess how much a participant's condition is hampering their ability to do what they want to do. Scale scores are transformed to a 0-100 by subtracting the lowest possible score, dividing by the range of the scale, and multiplying by 100. Higher values equal better quality of life. (NCT00699998)
Timeframe: Baseline and follow-up (24 months)
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| Baseline, physical limitations | Baseline, angina frequency | 24 Months, physical limitations (n=420, 412) | 24 Months, angina frequency (n=420, 412) | |
| Clopidogrel | 67.0 | 73.1 | 74.5 | 89.5 |
| Prasugrel | 67.8 | 73.6 | 75.1 | 89.7 |
Variation in the genes encoding the cytochrome P450 (CYP) enzymes (CYP2C19) can reduce the ability to metabolize clopidogrel and a reduced platelet response and have been associated with increased rates of CV events including CV death. Participants were classified as extensive metabolizers (EM); reduced metabolizers (RM); or unknown (UNK) metabolizers based on their CYP2C19 genotype. Possible extensive metabolizer (EM) phenotypes include EM=extensive metabolizer, UM=ultra-rapid metabolizer, and EM (non-UM) that are not UM. Possible reduced metabolizer (RM) phenotypes include IM=intermediate metabolizer and PM=poor metabolizer. Genotypes associated with each predicted phenotype are presented; predicted phenotype is presented first followed by the genotype. Percentage=(number of participants with the predicted phenotype and genotype divided by the total number of participants per arm) multiplied by 100. (NCT00699998)
Timeframe: Baseline
| Intervention | percentage participants with geneotype (Number) | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| UM, *1/*17 | UM, *17/*17 | EM (non-UM), *1/*1 | IM, *1/*2 | IM, *1/*3 | IM, *1/*4 | IM, *1/*6 | IM, *1/*8 | PM, *2/*2 | PM, *2/*3 | PM, *2/*4 | PM, *2/*6 | PM, *2/*8 | PM, *3/*3 | UNK, *1/*10 | UNK, *1/*13 | UNK, *1/*9 | UNK, *1/*9, *9/*17 | UNK, *13/*17 | UNK, *2/*13 | UNK, *2/*17 | UNK, *2/*9 | UNK, *3/*17 | UNK, *4/*17 | UNK, *4/*9 | UNK, *6/*17 | UNK, *8/*17 | UNK, *9/*17 | UNK, Undefined genotype | |
| Clopidogrel: <75 Years of Age | 25.1 | 5.4 | 35.7 | 19.8 | 0.5 | 0.1 | 0.0 | 0.4 | 4.3 | 0.3 | 0.2 | 0.0 | 0.0 | 0.2 | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.8 | 0.1 | 0.0 | 0.2 | 0.0 | 0.0 | 0.1 | 0.0 | 0.5 |
| Clopidogrel: 75 Years of Age or Older | 21.8 | 4.3 | 41.2 | 19.7 | 0.6 | 0.3 | 0.2 | 0.3 | 3.8 | 0.3 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 6.2 | 0.0 | 0.3 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.6 |
| Prasugrel: <75 Years of Age | 24.0 | 5.1 | 38.8 | 18.6 | 0.8 | 0.4 | 0.0 | 0.1 | 3.9 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.0 | 0.0 | 0.0 | 6.3 | 0.0 | 0.1 | 0.2 | 0.0 | 0.0 | 0.2 | 0.0 | 0.7 |
| Prasugrel: 75 Years of Age or Older | 25.0 | 3.6 | 42.1 | 18.3 | 0.6 | 0.0 | 0.2 | 0.5 | 2.2 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.2 | 0.2 | 0.0 | 0.0 | 0.0 | 6.1 | 0.0 | 0.0 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.6 |
Platelet aggregation was measured by as measured by Accumetrics Verify Now™ P2Y12. Results were reported in P2Y12 Reaction Units (PRU). PRU represents the rate and extent of adenosine (ADP)-stimulated platelet aggregation. Lower values indicate greater P2Y12 platelet inhibition and lower platelet activity and aggregation. ANCOVA Model was used and values were corrected for treatment + baseline value + clopidogrel status at randomization. (NCT00699998)
Timeframe: Day 30 and 12 Months
| Intervention | P2Y12 Reaction Units (PRU) (Least Squares Mean) | |
|---|---|---|
| Day 30 | Month 12 (n=386, 76, 400, 103) | |
| Clopidogrel: <75 Years of Age | 193.489 | 199.003 |
| Clopidogrel: 75 Years of Age or Older | 200.285 | 181.360 |
| Prasugrel: <75 Years of Age | 93.280 | 94.529 |
| Prasugrel: 75 Years of Age or Older | 151.872 | 135.096 |
All deaths, regardless of possible relatedness, with the exception of 1 event, were adjudicated by the Clinical Endpoint Committee (CEC) and are reported in this table. The 1 event which was not adjudicated was a result of the revocation of consent by the participant prior to their death. Deaths possibly related to study drug in the opinion of the investigator are also contained in the Serious Adverse Event (SAE) module. (NCT00699998)
Timeframe: Randomization through end of study (30-month visit)
| Intervention | participants (Number) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Congestive Heart Failure | Cardiogenic Shock | Cardiac Rupture | Myocardial Infarction | Dysrhythmia | Stent Thrombosis | Directly Related to Revascularization-CABG or PCI | Intracranial Hemorrhage | Non-Hemorrhagic Stroke | Sudden death due to cardiovascular event | Pulmonary Embolism | Stroke, unknown type | Other Cardiovascular Event | Cardiovascular event, unknown type | Accidental | Trauma | Hemorrhage, not intracranial | Infection | Malignancy | Suicide | Other Non-Cardiovascular event | Cause unknown (nonadjudicated event) | |
| Clopidogrel: <75 Years of Age | 13 | 10 | 0 | 24 | 6 | 0 | 1 | 4 | 4 | 70 | 2 | 0 | 0 | 45 | 1 | 0 | 0 | 16 | 14 | 0 | 8 | 0 |
| Clopidogrel: 75 Years of Age or Older | 23 | 9 | 0 | 21 | 3 | 0 | 1 | 1 | 3 | 43 | 1 | 0 | 1 | 45 | 1 | 1 | 4 | 17 | 11 | 0 | 6 | 0 |
| Prasugrel: <75 Years of Age | 10 | 8 | 0 | 16 | 5 | 0 | 1 | 2 | 4 | 75 | 0 | 0 | 6 | 40 | 1 | 2 | 1 | 14 | 14 | 1 | 8 | 0 |
| Prasugrel: 75 Years of Age or Older | 21 | 4 | 1 | 24 | 2 | 0 | 1 | 1 | 4 | 39 | 1 | 1 | 1 | 41 | 0 | 3 | 1 | 21 | 7 | 0 | 4 | 1 |
In-scaffold:Within the margins of the scaffold. (NCT01425281)
Timeframe: 3 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS™ | 0.05 |
| XIENCE™ | 0.06 |
In-scaffold:Within the margins of the scaffold. (NCT01425281)
Timeframe: 3 years
| Intervention | mm (Mean) |
|---|---|
| Absorb BVS™ | -0.37 |
| XIENCE™ | -0.25 |
Successful delivery and deployment of the first study scaffold/stent the intended target lesion and successful withdrawal of the delivery system with attainment of final in-scaffold/stent residual stenosis of less than 50% by quantitative coronary angiography (QCA). (NCT01425281)
Timeframe: From the start of index procedure to end of index procedure
| Intervention | Percentage of lesions (Number) |
|---|---|
| Absorb BVS™ | 99.5 |
| XIENCE™ | 100 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 1 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 180 Days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 1 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 4 |
| XIENCE™ | 1 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 8 |
| XIENCE™ | 6 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 0 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 11 |
| XIENCE™ | 7 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 7 |
"All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in subjects with coexisting potentially fatal non-cardiac disease (e.g. cancer, infection) should be classified as cardiac.~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 0 |
"All deaths includes~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI Development of new, pathological Q wave on the ECG.~Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 3 |
"All deaths includes~• Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~• Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~• Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI Development of new, pathological Q wave on the ECG.~Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 35 |
| XIENCE™ | 12 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 22 |
| XIENCE™ | 5 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 33 |
| XIENCE™ | 11 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma. Myocardial Infarction (MI)~Q wave MI Development of new, pathological Q wave on the ECG.~Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 37 |
| XIENCE™ | 13 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI) Q wave MI Development of new, pathological Q wave on the ECG. Non-Q wave MI Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
"All deaths includes~Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), unwitnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Vascular death: Death due to non-coronary vascular causes such as cerebrovascular disease, pulmonary embolism, ruptured aortic aneurysm, dissecting aneurysm, or other vascular cause.~Non-cardiovascular death: Any death not covered by the above definitions such as death caused by infection, malignancy, sepsis, pulmonary causes, accident, suicide or trauma.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 3 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 29 |
| XIENCE™ | 9 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 29 |
| XIENCE™ | 10 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI) Q wave MI: Development of new, pathological Q wave on the ECG. Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves" (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 2 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 20 |
| XIENCE™ | 4 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 28 |
| XIENCE™ | 8 |
"Cardiac death: Any death due to proximate cardiac cause (e.g. MI, low-output failure, fatal arrhythmia), un witnessed death and death of unknown cause, all procedure related deaths including those related to concomitant treatment.~Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 19 |
| XIENCE™ | 4 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 27 |
| XIENCE™ | 5 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of Creatine kinase (CK) levels to ≥ two times the upper limit of normal (ULN) with elevated Creatine kinase-MB (CK-MB) in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI) - Q wave MI: Development of new, pathological Q wave on the ECG.~-Non-Q wave MI: Elevation of Creatine kinase (CK) levels to ≥ two times the upper limit of normal (ULN) with elevated Creatine kinase-MB (CK-MB) in the absence of new pathological Q waves." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
"Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 27 |
| XIENCE™ | 5 |
"Myocardial Infarction (MI)~Q wave MI: Development of new, pathological Q wave on the ECG.~Non-Q wave MI: Elevation of CK levels to ≥ two times the upper limit of normal (ULN) with elevated CK-MB in the absence of new pathological Q waves." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 27 |
| XIENCE™ | 6 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 12 |
| XIENCE™ | 12 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 7 |
| XIENCE™ | 6 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 22 |
| XIENCE™ | 18 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 49 |
| XIENCE™ | 33 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 2 |
| XIENCE™ | 2 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 57 |
| XIENCE™ | 34 |
"Revascularization:~Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold.~Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion.~Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion.~Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 1 |
| XIENCE™ | 0 |
Revascularization: Target Lesion Revascularization (TLR) is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. The target lesion is defined as the treated segment from 5 mm proximal to the scaffold and to 5 mm distal to the test scaffold. Target Vessel Revascularization (TVR) is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion. Non Target Lesion Revascularization (Non-TLR) is any revascularization in the target vessel for a lesion other than the target lesion. Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 59 |
| XIENCE™ | 34 |
DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 76 |
| XIENCE™ | 40 |
DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 80 |
| XIENCE™ | 41 |
DMR is the composite of All Death, All MI, All Revascularization (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 24 |
| XIENCE™ | 15 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 19 |
| XIENCE™ | 9 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 38 |
| XIENCE™ | 21 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 68 |
| XIENCE™ | 39 |
DMR is the composite of All Death, All MI, All Revascularization. (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 4 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 17 |
| XIENCE™ | 5 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 3 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 25 |
| XIENCE™ | 7 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 38 |
| XIENCE™ | 11 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 2 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 40 |
| XIENCE™ | 12 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 41 |
| XIENCE™ | 13 |
Major adverse cardiac events (MACE) is defined as the composite of cardiac death, all myocardial infarction, and ischemic driven target lesion revascularization (ID-TLR). (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 6 |
| XIENCE™ | 6 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 4 |
| XIENCE™ | 3 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 10 |
| XIENCE™ | 11 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 22 |
| XIENCE™ | 19 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 1 |
| XIENCE™ | 0 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 29 |
| XIENCE™ | 20 |
Non Target Vessel Revascularization (Non-TVR)is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 0 |
| XIENCE™ | 0 |
Non Target Vessel Revascularization (Non-TVR) is any revascularization in a vessel other than the target vessel. (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 30 |
| XIENCE™ | 20 |
Achievement of final in-scaffold/stent residual stenosis of less than 50% by QCA with successful delivery and deployment of at least one study scaffold/stent at the intended target lesion and successful withdrawal of the delivery system for all target lesions without the occurrence of cardiac death, target vessel MI or repeat TLR during the hospital stay. (NCT01425281)
Timeframe: From the start of index procedure to end of index procedure
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 322 |
| XIENCE™ | 164 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 16 |
| XIENCE™ | 5 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 3 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 23 |
| XIENCE™ | 5 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 34 |
| XIENCE™ | 8 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 37 |
| XIENCE™ | 9 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 38 |
| XIENCE™ | 9 |
Target Lesion Failure is composite of Cardiac death/ Target Vessel Myocardial Infarction (TV-MI)/ Ischemic-Driven Target Lesion Revascularization (ID-TLR). (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 12 |
| XIENCE™ | 2 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated (CI) or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 2 |
| XIENCE™ | 0 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated (CI) or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 1 |
| XIENCE™ | 0 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 4 |
| XIENCE™ | 3 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 2 |
| XIENCE™ | 1 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 9 |
| XIENCE™ | 3 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 24 |
| XIENCE™ | 8 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 27 |
| XIENCE™ | 8 |
"Target Lesion Revascularization is defined as any repeat percutaneous intervention of the target lesion or bypass surgery of the target vessel performed for restenosis or other complication of the target lesion. All TLR should be classified prospectively as clinically indicated [CI] or not clinically indicated by the investigator prior to repeat angiography. An independent angiographic core laboratory should verify that the severity of percent diameter stenosis meets requirements for clinical indication and will overrule in cases where investigator reports are not in agreement.~The target lesion is defined as the treated segment from 5 mm proximal to the stent and to 5 mm distal to the scaffold/stent." (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 28 |
| XIENCE™ | 8 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR) (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 45 |
| XIENCE™ | 21 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR) (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 47 |
| XIENCE™ | 22 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 18 |
| XIENCE™ | 8 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 5 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 28 |
| XIENCE™ | 11 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 41 |
| XIENCE™ | 20 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 14 |
| XIENCE™ | 3 |
Target Vessel Failure (TVF) is the composite of Cardiac Death, Myocardial infarction (MI) or Ischemic-Driven Target Vessel Revascularization (ID-TVR). (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 13 |
| XIENCE™ | 2 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 8 |
| XIENCE™ | 8 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 180 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 4 |
| XIENCE™ | 4 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 2 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 15 |
| XIENCE™ | 9 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 3 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 33 |
| XIENCE™ | 19 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 30 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 2 |
| XIENCE™ | 2 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 4 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 38 |
| XIENCE™ | 19 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 41 |
| XIENCE™ | 19 |
Target Vessel Revascularization is defined as any repeat percutaneous intervention or surgical bypass of any segment of the target vessel. The target vessel is defined as the entire major coronary vessel proximal and distal to the target lesion which includes upstream and downstream branches and the target lesion itself. (NCT01425281)
Timeframe: In-hospital (≤ 7 days of post index procedure)
| Intervention | Participants (Count of Participants) |
|---|---|
| Absorb BVS™ | 1 |
| XIENCE™ | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: <=1 day
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 1 | 0 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: 0-30 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 2 | 0 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: 0-1853 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 8 | 1 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: 31-365 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 0 | 1 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: > 1-30 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 1 | 0 |
| XIENCE™ | 0 | 0 |
"Scaffold/Stent thrombosis should be reported as a cumulative value at the different time points.~Timings:~Acute:0-24 hours;Subacute:>24 hours-30 days;Late:30 days-1 year;Very late:>1 year.~Definite stent thrombosis occurred by either angiographic/pathologic confirmation.~Angiographic confirmation:The presence of a thrombus that originates in the stent or in the segment 5 mm proximal or distal to the stent&presence of at least 1 of the following criteria within a 48-hour time window~-Acute onset of ischemic symptoms at rest;New ischemic ECG changes;Typical rise&fall in cardiac biomarkers;Nonocclusive/Occlusive thrombus~Pathological confirmation:Evidence of recent thrombus.~Probable stent thrombosis may occur after intracoronary stenting due to:~Unexplained death within first 30 days~Any MI that is related to documented acute ischemia in the territory of the implanted stent without angiographic confirmation of stent thrombosis&in the absence of any other obvious cause." (NCT01425281)
Timeframe: > 365 days
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Definite | Probable | |
| Absorb BVS™ | 6 | 0 |
| XIENCE™ | 0 | 0 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 4 |
| Placebo | 5 |
(NCT00228423)
Timeframe: 1 year
| Intervention | Participants (Count of Participants) |
|---|---|
| 75mg Clopidogrel | 1 |
| Placebo | 0 |
Postoperative angiogram 12 months post-CABG (NCT00228423)
Timeframe: One year following surgery
| Intervention | percentage (Number) |
|---|---|
| 75mg Clopidogrel | 94.3 |
| Placebo | 93.2 |
IVUS imaging 12 months post-CABG, and the average intimal area in the proximal 40 mm of one vein graft per patient will be assessed (NCT00228423)
Timeframe: One year following surgery
| Intervention | mm (Mean) |
|---|---|
| 75mg Clopidogrel | 4.1 |
| Placebo | 4.5 |
Percentage of fibers expressing GALGT2 in each biopsy sample. (NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)
| Intervention | Percentage of Positive Fibers (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 1.95 |
| Cohort 2 | 1.72 |
(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1)
| Intervention | ng/mg total protein (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 12 |
| Cohort 2 | 14.6 |
(NCT03333590)
Timeframe: 2 years
| Intervention | events (Number) |
|---|---|
| Cohort 1 (Minimal Efficacious Dose) | 0 |
| Cohort 2 | 0 |
(NCT03333590)
Timeframe: Day 90 (Cohort 2) and Day 120 (Cohort 1) and Day 180 for both cohorts
| Intervention | meters (Number) | |
|---|---|---|
| Day 90 (Cohort 2) /Day 120 (Cohort 1) | Day 180 | |
| Cohort 1 (Minimal Efficacious Dose) | 320 | 324 |
| Cohort 2 (Minimal Efficacious Dose) | 405 | 416 |
The NSAA provides a score between 0 and 34 where higher numbers represent greater muscle function. (NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24
| Intervention | score on a scale (Number) | ||||
|---|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | Month 24 | |
| Cohort 1 (Minimal Efficacious Dose) | 16 | 14 | 10 | 6 | 2 |
| Cohort 2 | 21 | 23 | 23 | 23 | 23 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1) and both Cohorts at Day 180, Months 12, 18 and 24
| Intervention | kg (Number) | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 90/Day 120-Right Knee Extension | Day 90/Day 120-Right Knee Flexion | Day 90/Day 120- Left Knee Extension | Day 90/Day 120-Left Knee Flexion | Day 180-Right Knee Extension | Day 180-Right Knee Flexion | Day 180-Left Knee Extension | Day 180-Left Knee Flexion | Month 12-Right Knee Extension | Month 12-Right Knee Flexion | Month 12-Left Knee Extension | Month 12-Left Knee Flexion | Month 18-Right Knee Extension | Month 18-Right Knee Flexion | Month 18-Left Knee Extension | Month 18-Left Knee Flexion | Month 24-Right Knee Extension | Month 24-Right Knee Flexion | Month 24-Left Knee Extension | Month 24-Left Knee Flexion | |
| Cohort 1 (Minimal Efficacious Dose) | 7.42 | 6.06 | 8.78 | 6.12 | 7.13 | 6.1 | 8.66 | 6.69 | 7.49 | 5.67 | 7.5 | 5.32 | 4.55 | 6.11 | 4.96 | 6.26 | 5.06 | 4.41 | 6.93 | 4.17 |
| Cohort 2 | 7.04 | 8.12 | 5.9 | 8.4 | 9.73 | 4.24 | 8.19 | 5.25 | 9.85 | 5.85 | 8.02 | 5.12 | 7.67 | 6.89 | 7.34 | 6.08 | 9.81 | 5.04 | 5.21 | 4.87 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24
| Intervention | seconds (Number) | |||
|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | |
| Cohort 1 (Minimal Efficacious Dose) | 98.2 | 110.9 | 144.5 | 167.8 |
(NCT03333590)
Timeframe: Days 90 (Cohort 2), 120 (Cohort 1); both Cohorts at Day 180, Months 12, 18 and Cohort 2 at Month 24
| Intervention | seconds (Number) | ||||
|---|---|---|---|---|---|
| Day 90/Day 120 | Day 180 | Month 12 | Month 18 | Month 24 | |
| Cohort 2 | 56.1 | 44.9 | 44.7 | 65.6 | 48.4 |
The endpoint in this measure is a combination of all-cause death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 692 |
| Clopidogrel | 822 |
The endpoint in this measure is a combination of CV death, nonfatal MI, nonfatal stroke, or rehospitalization for cardiac ischemic events. Results are reported for the All ACS population. (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) |
|---|---|
| Prasugrel | 797 |
| Clopidogrel | 938 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. Results are reported for the All ACS population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 502 | 573 |
| Prasugrel | 389 | 462 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or nonfatal stroke. The data is presented by the study population, which is represented as follows: 1) subjects who presented with unstable angina and non-ST-segment elevation myocardial infarction (UA/NSTEMI), 2) subjects who presented with ST segment elevation myocardial infarction (STEMI), and 3) all subjects with acute coronary syndromes (ACS) (i.e. all subjects with UA/NSTEMI or STEMI). (NCT00097591)
Timeframe: Randomization up to 15 months
| Intervention | Participants (Number) | ||
|---|---|---|---|
| UA/NSTEMI (n=5044, n=5030) | STEMI (n=1769, n=1765) | All ACS (n=6813, n=6795) | |
| Clopidogrel | 565 | 216 | 781 |
| Prasugrel | 469 | 174 | 643 |
The endpoint in this measure is a combination of CV death, nonfatal MI, or UTVR. Results are reported for the All ACS subject population for the 30 and 90 day periods. (NCT00097591)
Timeframe: Randomization to 30 days; randomization to 90 days
| Intervention | Participants (Number) | |
|---|---|---|
| All ACS (Through 30 days) | All ACS (Through 90 days) | |
| Clopidogrel | 504 | 588 |
| Prasugrel | 399 | 472 |
TIMI classification for major and minor bleeding in the subset of subjects who did not undergo a coronary artery bypass operation (CABG) were defined as follows: Major bleeding: any intracranial hemorrhage (ICH) OR any clinically overt bleeding (including bleeding evident on imaging studies) associated with a fall in hemoglobin (Hgb) of ≥5 grams/deciliter (gm/dL)from baseline. Minor Bleeding: any clinically overt bleeding associated with a fall in Hgb of ≥3 gm/dL but <5 gm/dL from baseline. Major bleeding events were further examined as events that were deemed life threatening and/or fatal. (NCT00097591)
Timeframe: First dose of study drug up to 15 months (while at risk)
| Intervention | Participants (Number) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| TIMI Major or Minor Bleeding | TIMI Major Bleeding | TIMI Major Bleeding - Life-threatening (LT) | LT - Fatal | LT - Symptomatic intracranial hemorrage (ICH) | LT - Requiring inotropes | LT - Requiring surgical intervention | LT - Requiring transfusion (>=4 units) | TIMI Minor Bleeding | |
| Clopidogrel | 231 | 111 | 56 | 5 | 17 | 8 | 19 | 30 | 125 |
| Prasugrel | 303 | 146 | 85 | 21 | 19 | 21 | 19 | 45 | 164 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to endothelial function. (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 14.06 |
| Placebo Follow up | 13.84 |
| Aspirin Baseline | 11.18 |
| Aspirin Randomization | 12.11 |
| Clopidogrel Baseline | 13.06 |
| Clopidogrel Randomization | 12.29 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to immune activity (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 15.53 |
| Placebo Follow up | 15.43 |
| Aspirin Baseline | 13.15 |
| Aspirin Follow up | 14.96 |
| Clopidogrel Baseline | 16.03 |
| Clopidogrel Follow up | 14.85 |
Secondary objectives will compare the effect of each antiplatelet therapy drug on biomarkers related to inflammation (NCT02559414)
Timeframe: 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
(NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 69.45 |
| Placebo Follow up | 80.33 |
| Aspirin Baseline | 82.04 |
| Aspirin Randomization | 62.00 |
| Clopidogrel Baseline | 78.86 |
| Clopidogrel Randomization | 39.88 |
The primary objective of these analyses will be to compare the effects of aspirin versus control and clopidogrel versus control for the outcome of platelet activity. Aspirin is expected to decrease arachidonic acid-induced platelet aggregation by 50% versus control. Clopidogrel is expected to decrease ADP-induced platelet aggregation by 50% versus control. (NCT02559414)
Timeframe: Baseline, 14 Days
| Intervention | %aggregation (Mean) |
|---|---|
| Placebo Baseline | 72.35 |
| Placebo Follow up | 79.11 |
| Aspirin Baseline | 72.79 |
| Aspirin Randomization | 26.77 |
| Clopidogrel Baseline | 71.07 |
| Clopidogrel Randomization | 65.00 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02418312)
Timeframe: 6 months
| Intervention | participants (Number) |
|---|---|
| Histamine-2 Receptor Antagonist Group | 106 |
| Placebo Group | 101 |
Follow-up endoscopy was performed at the end of the 6th month (NCT02551744)
Timeframe: six month
| Intervention | participants (Number) |
|---|---|
| Proton Pump Inhibitor Group | 1 |
| Histamine-2 Receptor Antagonist Group | 7 |
94 reviews available for aspirin and Myocardial Ischemia
| Article | Year |
|---|---|
Management of Antiplatelet Agents in Patients with History of Coronary Artery Disease in Various Medical Conditions.
Topics: Acute Coronary Syndrome; Aspirin; Coronary Artery Disease; Humans; Myocardial Ischemia; Platelet Agg | 2019 |
An updated drug profile of ticagrelor with considerations on the treatment of patients with coronary artery disease and diabetes mellitus.
Topics: Aspirin; Clinical Trials as Topic; Coronary Artery Disease; Diabetes Complications; Drug Therapy, Co | 2020 |
Perioperative Cardiovascular Risk Assessment and Management for Noncardiac Surgery: A Review.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Anticoagul | 2020 |
Antithrombotic strategies for preventing long-term major adverse cardiovascular events in patients with non-valvular atrial fibrillation who undergo percutaneous coronary intervention.
Topics: Anticoagulants; Aspirin; Atrial Fibrillation; Clopidogrel; Coronary Artery Disease; Drug Therapy, Co | 2017 |
Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy: A Meta-Analysis of Randomized Trials.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Comorbidity; Drug Interact | 2018 |
Weighing the Anti-Ischemic Benefits and Bleeding Risks from Aspirin Therapy: a Rational Approach.
Topics: Aspirin; Atrial Fibrillation; Hemorrhage; Humans; Myocardial Ischemia; Platelet Aggregation Inhibito | 2018 |
[Antiaggregants in Primary Prevention of Cardiovascular Diseases and Prevention of Atherothrombosis in Patients With Stable Ischemic Heart Disease: Aspects of Efficacy and Safety].
Topics: Aspirin; Cardiovascular Diseases; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Prim | 2018 |
Dual Antiplatelet or Dual Antithrombotic Therapy for Secondary Prevention in High-Risk Patients with Stable Coronary Artery Disease?
Topics: Acute Coronary Syndrome; Aged; Algorithms; Aspirin; Cardiovascular Diseases; Coronary Artery Disease | 2019 |
Considerations in antithrombotic therapy among patients undergoing transcatheter aortic valve implantation.
Topics: Aortic Valve Stenosis; Aspirin; Cardiac Catheterization; Clopidogrel; Fibrinolytic Agents; Heart Val | 2013 |
Should P2Y12 inhibitors be given for 12 months in acute coronary syndrome?
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Humans; Myocardial Ischemia; Percutaneous Coronary In | 2014 |
Myocardial injury after noncardiac surgery.
Topics: Aspirin; Cause of Death; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Monitoring, Intraop | 2014 |
Antiplatelet therapy after drug-eluting stent implantation.
Topics: Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Hemorrhage; Humans; Myocardial Ischemia; | 2015 |
Antiplatelet Therapy Considerations in Ischemic Cardiogenic Shock: Implications of Metabolic Bioactivation.
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Humans; Myocardial Infarction; Myocardi | 2015 |
Meta-analysis of randomized controlled trials and adjusted observational results of use of clopidogrel, aspirin, and oral anticoagulants in patients undergoing percutaneous coronary intervention.
Topics: Administration, Oral; Anticoagulants; Aspirin; Clopidogrel; Drug Therapy, Combination; Hemorrhage; H | 2015 |
Vorapaxar for reduction of thrombotic cardiovascular events in myocardial infarction and peripheral artery disease.
Topics: Aspirin; Clopidogrel; Drug Interactions; Drug Therapy, Combination; Half-Life; Hemorrhage; Humans; L | 2015 |
Dual Antiplatelet Therapy in Patients with Stable Ischemic Heart Disease.
Topics: Aspirin; Drug Combinations; Humans; Meta-Analysis as Topic; Myocardial Ischemia; Platelet Aggregatio | 2016 |
Kawasaki Disease.
Topics: Adaptive Immunity; Adrenergic beta-Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Co | 2016 |
Atrial fibrillation.
Topics: Ablation Techniques; Anticoagulants; Aspirin; Atrial Fibrillation; Dizziness; Dyspnea; Electric Coun | 2016 |
Secondary prevention after coronary artery bypass graft surgery: a primer.
Topics: Aspirin; Coronary Artery Bypass; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial | 2016 |
Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.
Topics: Acute Coronary Syndrome; Adenosine; Animals; Aspirin; Clopidogrel; Drug Therapy, Combination; Humans | 2016 |
A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease.
Topics: Adenosine; Antithrombins; Aspirin; Clopidogrel; Drug Therapy, Combination; Evidence-Based Medicine; | 2016 |
[Practical management of troponin screening after non-cardiac surgery].
Topics: Aspirin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Myocardial Inf | 2017 |
Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Resistance; Drug | 2009 |
[Resistance to desaggregants: causes, clinical implication, methods of diagnosis and correction].
Topics: Aspirin; Clopidogrel; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Resistance; Drug T | 2008 |
P2X(1) receptor inhibition and soluble CD39 administration as novel approaches to widen the cardiovascular therapeutic window.
Topics: Adenosine Triphosphate; Antigens, CD; Apyrase; Aspirin; Biomedical Research; Cardiovascular Diseases | 2009 |
Polypill: the evidence and the promise.
Topics: Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Drug Combinations; Humans; Hydroxymethylg | 2009 |
Safety of fixed-dose aspirin-extended-release dipyridamole in patients with ischemic heart disease.
Topics: Aspirin; Aspirin, Dipyridamole Drug Combination; Dipyridamole; Drug Combinations; Drug-Related Side | 2010 |
Residual platelet reactivity: predicting short- and long-term clinical outcome in patients undergoing percutaneous coronary revascularization.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Humans; Myocardial Ischemia; | 2010 |
[Low-dose aspirin induced intestinal damage -including the influence of low-dose aspirin to existing lesions-].
Topics: Animals; Aspirin; Capsule Endoscopy; Cerebrovascular Disorders; Cyclooxygenase Inhibitors; Gastroint | 2010 |
[ADP receptor blockers: new insights in the therapy and prophylaxis of ischemic heart disease].
Topics: Acute Coronary Syndrome; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clopidogr | 2011 |
Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus.
Topics: Aspirin; Atherosclerosis; Biomarkers; Calcium; Coronary Vessels; Diabetic Angiopathies; Disease Prog | 2011 |
High on treatment platelet reactivity.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Combined Modality Therapy; Cyclooxygenase Inhi | 2012 |
Promises of PAR-1 inhibition in acute coronary syndrome.
Topics: Acute Coronary Syndrome; Aspirin; Female; Humans; Imines; Lactones; Male; Myocardial Ischemia; Plate | 2012 |
Clinical use of aspirin in ischemic heart disease: past, present and future.
Topics: Animals; Aspirin; Blood Platelets; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Hemorrhage; History, | 2012 |
Antiplatelet agents in ischemic heart disease.
Topics: Angina, Unstable; Aspirin; Humans; Myocardial Infarction; Myocardial Ischemia; Myocardial Revascular | 2012 |
Cardiovascular disease prevention using fixed dose pharmacotherapy in Iran: updated meta-analyses and mortality estimation.
Topics: Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; | 2012 |
Adding ACE inhibitors or ARBs to standard therapy for stable ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Angioedema; Angiotensin Receptor Antagonists; Angiotensin-Converting En | 2012 |
Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials.
Topics: Aspirin; Cardiovascular Diseases; Cilostazol; Combined Modality Therapy; Cyclooxygenase Inhibitors; | 2013 |
Drug interactions in the treatment of depression in patients with ischemic heart disease.
Topics: Aged; Antidepressive Agents; Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Comorbidity; Cytoc | 2012 |
Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Enzym | 2002 |
Aspirin in the prophylaxis of coronary artery disease.
Topics: Aspirin; Brain Ischemia; Coronary Disease; Dipyridamole; Drug Therapy, Combination; Humans; Myocardi | 2002 |
Combination antiplatelet therapy: implications for pharmacists.
Topics: Adult; Aspirin; Clopidogrel; Coronary Restenosis; Drug Therapy, Combination; Eptifibatide; Female; H | 2002 |
[Acetylsalicylic acid (ASA)--is everything clear?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Interactions; Heart Failure; Humans; Myocard | 2002 |
[Aspirin in primary prevention of ischemic heart disease].
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Humans; Male; Mid | 2002 |
Antiplatelet therapy: aspirin.
Topics: Aspirin; Controlled Clinical Trials as Topic; Coronary Thrombosis; Dose-Response Relationship, Drug; | 2003 |
Platelet-mediated microvascular inflammation and thrombosis in thrombocythemia vera: a distinct aspirin-responsive arterial thrombophilia, which transforms into a bleeding diathesis at increasing platelet counts.
Topics: Aspirin; Blood Platelets; Brain Ischemia; Erythromelalgia; Hemorrhagic Disorders; Humans; Myocardial | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
A strategy to reduce cardiovascular disease by more than 80%.
Topics: Adult; Aged; Aged, 80 and over; Antihypertensive Agents; Aspirin; Drug Combinations; Female; Folic A | 2003 |
[Clinical implications of impaired microcirculation and hemodynamics in acute respiratory viral infections and their pharmacological correction].
Topics: Acute Disease; Aged; Aspirin; Blood Flow Velocity; Blood Viscosity; Electrocardiography; Female; Hem | 2003 |
Current management of unstable angina: lessons from the TACTICS-TIMI 18 trial.
Topics: Angina, Unstable; Angioplasty, Balloon; Aspirin; Dalteparin; Drug Therapy, Combination; Fibrinolytic | 2002 |
[Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Topics: Aspirin; Clopidogrel; Coronary Disease; Coronary Thrombosis; Drug Therapy, Combination; Humans; Myoc | 2004 |
Late bleeding from right internal mammary artery after HeartMate left ventricular assist device implantation.
Topics: Adult; Anticoagulants; Antineoplastic Combined Chemotherapy Protocols; Aspirin; Cardiomyopathy, Dila | 2004 |
Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Bl | 2004 |
Comparative benefits of clopidogrel and aspirin in high-risk patient populations: lessons from the CAPRIE and CURE studies.
Topics: Angina, Unstable; Aspirin; Clopidogrel; Comorbidity; Diabetes Mellitus; Humans; Hypercholesterolemia | 2004 |
New anticoagulants in ischemic heart disease.
Topics: Anticoagulants; Aspirin; Azetidines; Benzylamines; Cerebral Hemorrhage; Coronary Thrombosis; Drug Th | 2005 |
[Is it recommended simultaneous use of acetylsalicylic acid and angiotensin converting enzyme inhibitors?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Pressure; Drug Antagonism; Drug Synergism; | 2005 |
Clopidogrel in the treatment of ischaemic heart disease.
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Hemorrhage; H | 2006 |
Pharmacologic profile and therapeutic potential of NCX 4016, a nitric oxide-releasing aspirin, for cardiovascular disorders.
Topics: Animals; Aspirin; Atherosclerosis; Endothelium, Vascular; Humans; Molecular Structure; Myocardial Is | 2006 |
Secondary prevention of ischaemic cardiac events.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inhibitor | 2006 |
Aspirin and clopidogrel resistance: consideration and management.
Topics: Adenosine; Adenosine Monophosphate; Angioplasty, Balloon, Coronary; Aspirin; Clinical Trials as Topi | 2006 |
Prothrombotic potential of NSAID in ischemic heart disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cyclooxygenase Inhibitors; Humans; Myocardial Isch | 2006 |
The relationship of platelet reactivity to the occurrence of post-stenting ischemic events: emergence of a new cardiovascular risk factor.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Platelets; Clopidogrel; Combined Modality Therapy; Dr | 2006 |
The role of clopidogrel in the management of ischemic heart disease.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Randomized Contr | 2007 |
Clopidogrel: who, when, and how?
Topics: Acute Disease; Angioplasty, Balloon, Coronary; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug A | 2007 |
Use of the PFA-100 closure time to predict cardiovascular events in aspirin-treated cardiovascular patients: a systematic review and meta-analysis.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Platelets; Cardiology; Clinical Trials as To | 2008 |
[Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation. Results of the BAFTA trial].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Atrial Fibrillation; Humans; | 2008 |
Novel antiplatelet therapies for treatment of patients with ischemic heart disease: inhibitors of the platelet glycoprotein IIb/IIIa integrin receptor.
Topics: Abciximab; Amino Acid Sequence; Animals; Antibodies, Monoclonal; Arteriosclerosis; Aspirin; Disinteg | 1995 |
Daily life cardiac ischaemia. Should it be treated?
Topics: Activities of Daily Living; Adrenergic beta-Antagonists; Aspirin; Calcium Channel Blockers; Drug The | 1995 |
Prescribing for angina.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Aspirin; Calcium Channel Blockers; Humans; Myocardial | 1994 |
Circadian variation of onset of ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Anticoagulants; Aspirin; Calcium Chann | 1993 |
[Secondary prevention of ischemic cardiopathy].
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; | 1995 |
[The new frontier of antithrombotic therapy: ASA + warfarin, the ideal solution?].
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Fibrinolytic Agents; Humans; Myocardial Infarc | 1995 |
New antiplatelet agents: platelet GPIIb/IIIa antagonists.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Animals; Antibodies, Monoclonal; Anticoagulants; Aspirin; | 1995 |
Advances in antithrombotic therapy: novel agents.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Antithrombins; Aspirin; Clinical Trials as Topic; | 1995 |
Cocaine-associated myocardial infarction.
Topics: Adult; Aged; Aspirin; Benzodiazepines; Cocaine; Humans; Middle Aged; Myocardial Infarction; Myocardi | 1996 |
[The use of acetylsalicylic acid in IHD].
Topics: Angina, Unstable; Aspirin; Coronary Vessels; Cyclooxygenase Inhibitors; Dose-Response Relationship, | 1996 |
Confusion in reperfusion. Problems in the clinical development of antithrombotic drugs.
Topics: Abciximab; Antibodies, Monoclonal; Aspirin; Cerebrovascular Disorders; Drug Therapy, Combination; Fi | 1997 |
[Blood platelets and fibrinolysis in ischemic heart disease].
Topics: Aspirin; Blood Platelets; Fibrinolysis; Heparin; Humans; Lipoproteins; Myocardial Ischemia | 1996 |
Unmet therapeutic needs in the management of acute ischemia.
Topics: Angina, Unstable; Anticoagulants; Aspirin; Coronary Artery Disease; Fibrinolytic Agents; Humans; Myo | 1997 |
[Antithrombotic treatment following acute ischemic heart disease: acetylsalicylic acid and (or) oral anticoagulants?; ASPECT-II, a new study].
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Myocardial Ischemia; Platelet Aggregation Inhi | 1997 |
The efficacy and safety of combination warfarin and ASA therapy: a systematic review of the literature and update of guidelines.
Topics: Anticoagulants; Aspirin; Clinical Trials as Topic; Drug Therapy, Combination; Heart Valve Prosthesis | 1998 |
Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?
Topics: Aspirin; Cerebrovascular Disorders; Fibrinolytic Agents; Humans; Myocardial Infarction; Myocardial I | 1998 |
Therapeutic options and cost considerations in the treatment of ischemic heart disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Coronary Artery Bypass; | 1998 |
Prevention of activation of blood coagulation during acute coronary ischemic syndromes: beyond aspirin and heparin.
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Heparin; Humans; Myocardial Ischemia; Platelet Aggrega | 1999 |
Contemporary issues in heart failure.
Topics: Angiotensin-Converting Enzyme Inhibitors; Anticholesteremic Agents; Anticoagulants; Aspirin; Communi | 1999 |
Overview of clinical trials of glycoprotein IIb-IIIa inhibitors in acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Clinical Trials as Topic; Coronary Disease; Coronary Thrombo | 1999 |
[Angioplasty in unstable chest angina. Angioplasty in unstable angina].
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Anti-Inflammatory Age | 1999 |
[Treatment of diabetic patients with ischaemic heart disease].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Diabetes Complicatio | 2000 |
Myocardial ischemia and infarction: growth of ideas.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Colonic Neoplasms; Cyclooxygenase Inhibit | 2001 |
Using aspirin and ACE inhibitors in combination: why the hullabaloo?
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Interactions; Drug Therapy, Combination; Fib | 2001 |
Aspirin and ACE-inhibitors: for wedding or funeral?
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Case-Control Studies; Clinical Trials as | 2001 |
Antiplatelet agents for secondary prevention of ischemic stroke.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Cost-Benefit Analysis; Dipyridamole; Humans; Myocard | 2001 |
Risk factors and primary prevention of ischemic heart disease in women.
Topics: Alcohol Drinking; Antioxidants; Aspirin; Diabetes Complications; Exercise; Female; Humans; Hyperlipi | 2001 |
[Prostaglandins and ischemic cardiopathy].
Topics: Angina, Unstable; Aspirin; Coronary Thrombosis; Humans; Myocardial Ischemia; Platelet Activation; Pr | 1992 |
[Is it necessary to treat silent myocardial ischemia?].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Cause of Death; Coronary Artery Bypass; Co | 1992 |
109 trials available for aspirin and Myocardial Ischemia
| Article | Year |
|---|---|
Impact of established cardiovascular disease on outcomes in the randomized global leaders trial.
Topics: Aged; Aspirin; Drug Administration Schedule; Drug-Eluting Stents; Dual Anti-Platelet Therapy; Female | 2020 |
Predictors, Type, and Impact of Bleeding on the Net Clinical Benefit of Long-Term Ticagrelor in Stable Patients With Prior Myocardial Infarction.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Europe; Female; Follow-U | 2021 |
Rationale and design of the Japan-USA harmonized assessment by randomized, multicenter study of OrbusNEich's combo StEnt (Japan-USA HARMONEE): Assessment of a novel DES platform for percutaneous coronary revascularization in patients with ischemic coronar
Topics: Acute Coronary Syndrome; Albumins; Anticoagulants; Antigens, CD34; Aspirin; Biocompatible Materials; | 2017 |
[IMPACT OF ATORVASTATIN AND ROSUVASTATIN ON RESIDUAL ON-CLOPIDOGREL TREATMENT PLATELET REACTIVITY IN PATIENTS WITH ISCHEMIC HEART DISEASE AND TYPE 2 DIABETES MELLITUS AFTER ACUTE CORONARY SYNDROME].
Topics: Acute Coronary Syndrome; Aspirin; Atorvastatin; Blood Platelets; Clopidogrel; Diabetes Mellitus, Typ | 2017 |
Characterization of the Average Daily Ischemic and Bleeding Risk After Primary PCI for STEMI.
Topics: Aged; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged; Myocardial Ischemia; Percutaneous Cor | 2017 |
Rationale and design of the comparison between a P2Y12 inhibitor monotherapy versus dual antiplatelet therapy in patients undergoing implantation of coronary drug-eluting stents (SMART-CHOICE): A prospective multicenter randomized trial.
Topics: Adult; Aspirin; Coronary Restenosis; Drug Therapy, Combination; Drug-Eluting Stents; Female; Hemorrh | 2018 |
Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study.
Topics: Aged; Aspirin; Blood Platelets; Coronary Occlusion; Drug-Eluting Stents; Female; Fibrinolytic Agents | 2019 |
Triflusal and aspirin in the secondary prevention of atherothrombotic ischemic stroke: a very long-term follow-up.
Topics: Aged; Aspirin; Brain Ischemia; Dyspepsia; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; | 2014 |
[The effect of clopidogrel and aspigrel on myocardial ischemia in patients with unstable angina pectoris].
Topics: Aged; Angina, Unstable; Aspirin; Clopidogrel; Drug Combinations; Drug Therapy, Combination; Humans; | 2013 |
Rationale and design of the PeriOperative ISchemic Evaluation-2 (POISE-2) trial: an international 2 × 2 factorial randomized controlled trial of acetyl-salicylic acid vs. placebo and clonidine vs. placebo in patients undergoing noncardiac surgery.
Topics: Aged; Aspirin; Clonidine; Double-Blind Method; Female; Humans; Intraoperative Complications; Male; M | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents.
Topics: Aged; Aspirin; Clopidogrel; Drug Administration Schedule; Drug Therapy, Combination; Drug-Eluting St | 2014 |
Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study.
Topics: Aged; Anemia; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combinat | 2016 |
The effect of off-pump coronary artery bypass grafting on platelet activation in patients on aspirin therapy until surgery day.
Topics: Adult; Aged; Aspirin; Coronary Artery Bypass, Off-Pump; Drug Administration Schedule; Drug Resistanc | 2008 |
Thienopyridine resistance among patients undergoing intracoronary stent implantation and treated with dual antiplatelet therapy: assessment of some modifying factors.
Topics: Adult; Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Vessels; Drug Resistance; Drug Therapy, | 2008 |
Renal effects of aspirin are clearly dose-dependent and are of clinical importance from a dose of 160 mg.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Chromatography, High Pressure Liquid; Cross | 2008 |
Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Death, Sudden, Cardiac; Double-Blind Method; F | 2009 |
Heparin infusion after successful percutaneous coronary intervention: a prospective, randomized trial.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Angiography; Female; | 2009 |
Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial.
Topics: Acute Coronary Syndrome; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Clopidogrel; Dose-Resp | 2009 |
[Difficulties in evaluating the efficacy of antiplatelet therapy in clinical practice].
Topics: Adult; Aspirin; Chronic Disease; Clopidogrel; Data Interpretation, Statistical; Drug Resistance; Dru | 2009 |
Reducing cardiac ischemic events in patients with ACS: prasugrel versus clopidogrel. Commentary.
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Confidence Intervals; Double-Blind Method; Drug Thera | 2010 |
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. nonselective COX-2 inhibitors.
Topics: Aged; Aspirin; Celecoxib; Cyclooxygenase 2 Inhibitors; Drug Therapy, Combination; Humans; Ibuprofen; | 2010 |
Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease: results from the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHAR
Topics: Aged; Aspirin; Clopidogrel; Disease Management; Double-Blind Method; Drug Therapy, Combination; Fema | 2010 |
Study design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemic vas
Topics: Angioplasty, Balloon, Coronary; Aspirin; Brain Ischemia; Cilostazol; Clinical Protocols; Clopidogrel | 2010 |
The efficacy and safety of clopidogrel in vascular surgery patients with immediate postoperative asymptomatic troponin T release for the prevention of late cardiac events: Rationale and design of the Dutch Echocardiographic Cardiac Risk Evaluation Applyin
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clopidogrel; Echocardiography, Stress; Humans; Myo | 2010 |
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Double-Blind Method; Femal | 2010 |
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Creatinine; Diabetes Mellit | 2011 |
[Aspirin resistance in patients with stable ischemic heart disease].
Topics: Aged; Aspirin; Coronary Angiography; Drug Monitoring; Drug Resistance; Echocardiography, Transesopha | 2010 |
Impact of platelet reactivity to adenosine diphosphate before implantation of drug-eluting stents on subsequent adverse cardiac events in patients with stable angina.
Topics: Adenosine Diphosphate; Aged; Aged, 80 and over; Angina, Stable; Aspirin; Drug-Eluting Stents; Female | 2012 |
Earlier application of loading doses of aspirin and clopidogrel decreases rate of recurrent cardiovascular ischemic events for patients undergoing percutaneous coronary intervention.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Female; Humans; Male; Middle Aged | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy.
Topics: Acute Coronary Syndrome; Age Factors; Aged; Angina, Unstable; Aspirin; Body Weight; Clopidogrel; Fem | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary T | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary T | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary T | 2012 |
ABSORB II randomized controlled trial: a clinical evaluation to compare the safety, efficacy, and performance of the Absorb everolimus-eluting bioresorbable vascular scaffold system against the XIENCE everolimus-eluting coronary stent system in the treatm
Topics: Absorbable Implants; Adult; Aged; Aspirin; Coronary Angiography; Coronary Artery Disease; Coronary T | 2012 |
[Dilzem-retard efficiency in patients with ischemic heart disease and heart failure].
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calcium Channel Blockers; Delayed-Action Pre | 2002 |
Modulation of aspirin-insensitive eicosanoid biosynthesis by 6-methylprednisolone in unstable angina.
Topics: Adult; Angina, Unstable; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Double-Blind Method; E | 2003 |
Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide.
Topics: Acute Disease; Aged; Aspirin; Coronary Disease; Electrocardiography; Enoxaparin; Eptifibatide; Femal | 2003 |
Early and late effects of clopidogrel in patients with acute coronary syndromes.
Topics: Acute Disease; Angina, Unstable; Aspirin; Clopidogrel; Double-Blind Method; Drug Therapy, Combinatio | 2003 |
Frequency of stent thrombosis after acute coronary syndromes (from the SYMPHONY and 2nd SYMPHONY trials).
Topics: Acute Disease; Aspirin; Causality; Coronary Disease; Coronary Thrombosis; Female; Humans; Incidence; | 2003 |
Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery.
Topics: Aged; Anticoagulants; Aspirin; Canada; Cataract Extraction; Eye Hemorrhage; Female; Humans; Male; Mi | 2003 |
Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery.
Topics: Aged; Anticoagulants; Aspirin; Canada; Cataract Extraction; Eye Hemorrhage; Female; Humans; Male; Mi | 2003 |
Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery.
Topics: Aged; Anticoagulants; Aspirin; Canada; Cataract Extraction; Eye Hemorrhage; Female; Humans; Male; Mi | 2003 |
Risks and benefits of anticoagulant and antiplatelet medication use before cataract surgery.
Topics: Aged; Anticoagulants; Aspirin; Canada; Cataract Extraction; Eye Hemorrhage; Female; Humans; Male; Mi | 2003 |
Oral ximelagatran for secondary prophylaxis after myocardial infarction: the ESTEEM randomised controlled trial.
Topics: Administration, Oral; Aged; Aspirin; Azetidines; Benzylamines; Double-Blind Method; Drug Therapy, Co | 2003 |
Prospective evaluation of the relationship between platelet-leukocyte conjugate formation and recurrent myocardial ischemia in patients with acute coronary syndromes.
Topics: Adenosine Diphosphate; Adrenergic beta-Antagonists; Aged; Angina, Unstable; Arachidonic Acid; Aspiri | 2004 |
Aspirin decreases vascular endothelial growth factor release during myocardial ischemia.
Topics: Aspirin; Coronary Artery Bypass; Creatine Kinase; Humans; Myocardial Ischemia; Perioperative Care; P | 2004 |
Reduction of daily life ischaemia by aspirin in patients with angina: underlying link between thromboxane A2 and macrophage colony stimulating factor.
Topics: Adult; Aged; Aspirin; Biomarkers; Cohort Studies; Coronary Artery Disease; Cross-Over Studies; Doubl | 2004 |
Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein: a randomized placebo-controlled study.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Aspirin; Biomarkers; Brachial Artery; C-Rea | 2004 |
Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial.
Topics: Acute Disease; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2004 |
The effect of long-term clopidogrel use on neointimal formation after percutaneous coronary intervention.
Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; C | 2004 |
N-terminal pro-B-type natriuretic peptide levels for dynamic risk stratification of patients with acute coronary syndromes.
Topics: Acute Disease; Anticoagulants; Aspirin; Biomarkers; C-Reactive Protein; Drug Therapy, Combination; F | 2004 |
Starc II, a multicenter randomized placebo-controlled double-blind clinical trial of trapidil for 1-year clinical events and angiographic restenosis reduction after coronary angioplasty and stenting.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Blood Vessel Prosthesis Implantation; Coronary Angiography; | 2005 |
[Safety and efficacy of dalteparin administration for elective percutaneous interventions in patients pre-treated with aspirin and ticlopidine].
Topics: Adolescent; Adult; Aged; Angioplasty, Balloon; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dal | 2004 |
Coronary stent restenosis in patients treated with cilostazol.
Topics: Aged; Angina, Unstable; Aspirin; Cilostazol; Coronary Restenosis; Double-Blind Method; Female; Human | 2005 |
Prevalence and management of hypertension in acute coronary syndrome patients varies by sex: observations from the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events postacute cOroNary sYndromes (SYMPHONY) randomized clinical
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Chemistry, Pharmaceutical; Coronary Disease; Female; | 2005 |
Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study.
Topics: Aged; Anticoagulants; Antithrombins; Aspirin; Cardiac Output, Low; Cardiomyopathy, Dilated; Double-B | 2006 |
Clopidogrel is associated with a lesser increase in NT-proBNP when compared to aspirin in patients with ischemic heart failure.
Topics: Aged; Aged, 80 and over; Aspirin; Cardiac Output, Low; Clopidogrel; Cross-Over Studies; Disease Prog | 2006 |
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Celecoxib; Double-Blind Method; Drug Adminis | 2006 |
Platelet aggregation and P-selectin levels during exercise treadmill test in patients with ischaemic heart disease.
Topics: Aged; Aspirin; Coronary Angiography; Exercise Test; Female; Humans; Male; Middle Aged; Myocardial Is | 2006 |
Lack of association between the 807 C/T polymorphism of glycoprotein Ia gene and post-treatment platelet reactivity after aspirin and clopidogrel in patients with acute coronary syndrome.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; Cell Adhesion Molecules; Clopi | 2007 |
[Effectiveness of treatment and prophylactic methods in persons with ischemic heart disease risk factors].
Topics: Adult; Aspirin; Dipyridamole; Drug Therapy, Combination; Exercise; Feeding Behavior; Female; Humans; | 2007 |
Prolonged dual antiplatelet therapy after percutaneous coronary intervention reduces ischemic events without affecting the need for repeat revascularization: insights from the CREDO trial.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Contraindications; Coronary Restenosis; Drug T | 2007 |
Timing of death and myocardial infarction in patients with non-ST elevation acute coronary syndromes: insights from randomized clinical trials.
Topics: Acute Disease; Aged; Angina, Unstable; Aspirin; Female; Hirudin Therapy; Hirudins; Humans; Male; Mid | 2007 |
Effect of clopidogrel treatment on stress-induced platelet activation and myocardial ischemia in aspirin-treated patients with stable coronary artery disease.
Topics: Adenosine Diphosphate; Aged; Aspirin; Blood Platelets; C-Reactive Protein; CD40 Ligand; Clopidogrel; | 2007 |
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial.
Topics: Adult; Analysis of Variance; Aspirin; Biomarkers; Blood Chemical Analysis; Clopidogrel; Diabetes Mel | 2008 |
Effect of ximelagatran on ischemic events and death in patients with atrial fibrillation after acute myocardial infarction in the efficacy and safety of the oral direct thrombin inhibitor ximelagatran in patients with recent myocardial damage (ESTEEM) tri
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; | 2008 |
Early and late benefits of prasugrel in patients with acute coronary syndromes undergoing percutaneous coronary intervention: a TRITON-TIMI 38 (TRial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet InhibitioN with Prasugrel-Thrombolys
Topics: Acute Coronary Syndrome; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Com | 2008 |
Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Drug Therapy, Combination; Female; | 1995 |
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Coronary Angiography; Dose-Response Relationship, Drug; Doub | 1995 |
Randomised comparison of subcutaneous heparin, intravenous heparin, and aspirin in unstable angina. Studio Epoorine Sottocutanea nell'Angina Instobile (SESAIR) Refrattorie Group.
Topics: Angina, Unstable; Aspirin; Female; Heparin; Humans; Infusions, Intravenous; Injections, Subcutaneous | 1995 |
Heparin and aspirin in unstable angina: insufficient sample size may lead to erroneous conclusions.
Topics: Angina, Unstable; Aspirin; Drug Therapy, Combination; Heparin; Humans; Myocardial Ischemia; Sample S | 1995 |
Combined use of aspirin and warfarin in primary prevention of ischemic heart disease in men at high risk.
Topics: Aged; Aspirin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Hemorrhage; Humans; Inci | 1995 |
Prospective comparison of unstable angina versus non-Q wave myocardial infarction during antithrombotic therapy. Antithrombotic Therapy in Acute Coronary Syndromes Research Group.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Drug Therapy | 1993 |
Comparison of the effect of heparin and aspirin versus aspirin alone on transient myocardial ischemia and in-hospital prognosis in patients with unstable angina.
Topics: Adult; Aged; Angina, Unstable; Aspirin; Chi-Square Distribution; Diltiazem; Drug Therapy, Combinatio | 1994 |
Effects of low intensity antithrombotic regimes on the haemoglobin level.
Topics: Aged; Aspirin; Drug Synergism; Drug Therapy, Combination; Fibrinolytic Agents; Hemoglobins; Hemorrha | 1994 |
The role of extraplatelet thromboxane A2 in unstable angina investigated with a dual thromboxane A2 inhibitor: importance of activated monocytes.
Topics: Aged; Angina Pectoris; Angina, Unstable; Aspirin; Double-Blind Method; Female; Follow-Up Studies; Hu | 1994 |
[Effects of low dose aspirin on platelet function and prostaglandins metabolism in systemic and coronary circulation in patients with ischemia heart disease].
Topics: 6-Ketoprostaglandin F1 alpha; Adult; Aspirin; Blood Platelets; Coronary Circulation; Female; Humans; | 1995 |
Comparison of aspirin with a thromboxane antagonist for patients with prolonged chest pain and ST segment depression.
Topics: Aged; Aspirin; Biphenyl Compounds; Coronary Care Units; Double-Blind Method; Electrocardiography; Fe | 1996 |
Economic assessment of platelet glycoprotein IIb/IIIa inhibition for prevention of ischemic complications of high-risk coronary angioplasty. EPIC Investigators.
Topics: Abciximab; Aged; Angioplasty; Antibodies, Monoclonal; Anticoagulants; Aspirin; Blood Transfusion; Co | 1996 |
Early continuous ST segment monitoring in unstable angina: prognostic value additional to the clinical characteristics and the admission electrocardiogram.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Angina, Unstable; Aspirin; Electrocardiography; Electrocar | 1996 |
Antiplatelet therapy in therapy-resistant unstable angina. A pilot study with REO PRO (c7E3).
Topics: Abciximab; Adult; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; As | 1995 |
Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina. A randomized multicenter trial.
Topics: Adult; Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Bleeding Time; Dose-Respo | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.
Topics: Adult; Arteriosclerosis; Aspirin; Brain Ischemia; Clopidogrel; Cohort Studies; Double-Blind Method; | 1996 |
Effect of aspirin on mortality in women with symptomatic or silent myocardial ischemia. Israeli BIP Study Group.
Topics: Aged; Aspirin; Chi-Square Distribution; Cohort Studies; Coronary Disease; Digitalis Glycosides; Fema | 1996 |
Pathophysiology of transient myocardial ischemia in acute coronary syndromes. Characterization by continuous ST-segment monitoring.
Topics: Acute Disease; Angina, Unstable; Anticoagulants; Aspirin; Circadian Rhythm; Drug Therapy, Combinatio | 1997 |
Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II.
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Atherectomy, Coronary; Coronary Disease; Eptifibatide | 1997 |
A randomised controlled trial of feedback to general practitioners of their prophylactic aspirin prescribing.
Topics: Adult; Aged; Aspirin; Coronary Disease; Drug Administration Schedule; Drug Utilization Review; Estro | 1997 |
Comparison of changes in respiratory function and exercise oxygen uptake with losartan versus enalapril in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy.
Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Cardiomyopathy, Dilated; | 1997 |
Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cerebrovascular Disorders; Double-Blind Method; | 1998 |
[Antithrombotic treatment following acute ischemic heart disease: acetylsalicylic acid and (or) oral anticoagulants?; ASPECT-II, a new study].
Topics: Anticoagulants; Aspirin; Fibrinolytic Agents; Humans; Myocardial Ischemia; Platelet Aggregation Inhi | 1997 |
Adherence to a prophylactic medication regimen in patients with symptomatic versus asymptomatic ischemic heart disease.
Topics: Aged; Aspirin; Chi-Square Distribution; Depression; Drug Administration Schedule; Female; Health Kno | 1998 |
Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina.
Topics: Aged; Angina, Unstable; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Fibrinolyti | 1998 |
[Evaluation of platelet function and tissue plasminogen activator activity in ischemic heart disease depending on concurrence with hyperlipoproteinemia and aspirin therapy].
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Fibrinolysis; Humans; Hyperlipoproteinemias | 1997 |
Interpretation of Thrombosis Prevention Trial.
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Humans; Male; Myocardial Ischemia; Smoking; Smoking Ce | 1998 |
Interpretation of Thrombosis Prevention Trial.
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Therapy, Combin | 1998 |
Interpretation of Thrombosis Prevention Trial.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug | 1998 |
Interpretation of Thrombosis Prevention Trial.
Topics: Administration, Oral; Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug; Drug Therapy, | 1998 |
Interpretation of Thrombosis Prevention Trial.
Topics: Anticoagulants; Aspirin; Coronary Thrombosis; Humans; Life Style; Male; Myocardial Ischemia; Risk Fa | 1998 |
Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results.
Topics: Administration, Oral; Angina, Unstable; Angioplasty, Balloon, Coronary; Anticoagulants; Antithrombin | 1998 |
Low-molecular-weight heparins in non-ST-segment elevation ischemia: the ESSENCE trial. Efficacy and Safety of Subcutaneous Enoxaparin versus intravenous unfractionated heparin, in non-Q-wave Coronary Events.
Topics: Adolescent; Adult; Aged; Anticoagulants; Aspirin; Double-Blind Method; Drug Administration Routes; D | 1998 |
Low-molecular-weight heparins in coronary stenting (the ENTICES trial). ENoxaparin and TIClopidine after Elective Stenting.
Topics: Aged; Aspirin; Coronary Angiography; Coronary Thrombosis; Drug Therapy, Combination; Enoxaparin; Fem | 1998 |
Reduction of recurrent ischemia with abciximab during continuous ECG-ischemia monitoring in patients with unstable angina refractory to standard treatment (CAPTURE).
Topics: Abciximab; Aged; Angina, Unstable; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
Early and late clinical outcome following coronary angioplasty performed with platelet glycoprotein IIb/IIIa receptor inhibition: the EPIC Trial results.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Anticoagulants; Aspirin; Coronary | 1994 |
The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Pilot Study: evaluation of acute and long-term therapies for patients with acute coronary syndromes without ST elevation.
Topics: Acute Disease; Aged; Angina, Unstable; Anticoagulants; Aspirin; Canada; Death, Sudden, Cardiac; Dose | 1999 |
Cardiac surgery and catheterization in patients with haemophilia.
Topics: Adolescent; Adult; Aged; Aortic Valve; Aspirin; Cardiac Catheterization; Coronary Angiography; Coron | 2000 |
Predictors of recurrent ischemic events and death in unstable coronary artery disease after treatment with combination antithrombotic therapy.
Topics: Aged; Angina, Unstable; Aspirin; Drug Administration Routes; Drug Therapy, Combination; Electrocardi | 2000 |
Low-molecular-weight heparin alone versus a combination of unfractionated heparin and low-molecular-weight heparin.
Topics: Acute Disease; Angina Pectoris; Anticoagulants; Aspirin; Drug Therapy, Combination; Enoxaparin; Fema | 2000 |
Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study).
Topics: Anticoagulants; Aspirin; Drug Administration Routes; Drug Delivery Systems; Enoxaparin; Female; Foll | 2001 |
[The use of acetylsalicylic acid in patients with ischemic cardiomyopathy cared for in Spanish emergency services (results of the EVICURE Study). Evaluacion del Manejo de la cardiopatia isquemica en los Servicios de Urgencias Hospitalarios of the Sociedad
Topics: Aspirin; Chi-Square Distribution; Emergencies; Emergency Service, Hospital; Fibrinolytic Agents; Fir | 2000 |
Randomized trial of aspirin, sibrafiban, or both for secondary prevention after acute coronary syndromes.
Topics: Aged; Aspirin; Cause of Death; Coronary Disease; Dose-Response Relationship, Drug; Drug Therapy, Com | 2001 |
[Use of platelet function analyzer PFA-100 and whole blood aggregometry to monitor blood platelet sensitivity to acetylsalicylic acid (aspirin). Is it possible to reliably monitor antiplatelet treatment using routine laboratory diagnostic methods?].
Topics: Adult; Aspirin; Drug Resistance; Female; Humans; Male; Middle Aged; Monitoring, Physiologic; Myocard | 2000 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation.
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Elect | 2001 |
Genetic variation in glycoprotein IIb/IIIa (GPIIb/IIIa) as a determinant of the responses to an oral GPIIb/IIIa antagonist in patients with unstable coronary syndromes.
Topics: Aged; Alanine; Angina, Unstable; Antigens, Human Platelet; Aspirin; Double-Blind Method; Female; Gen | 2001 |
Aspirin in ischemic heart disease.
Topics: Aspirin; Cerebrovascular Disorders; Female; Humans; Male; Myocardial Ischemia | 1992 |
245 other studies available for aspirin and Myocardial Ischemia
| Article | Year |
|---|---|
[Integral tests of the hemostasis system in assessing the efficiency of acetylsalicylic acid in patients with ischemic heart disease].
Topics: Aspirin; Female; Hemostasis; Humans; Male; Myocardial Ischemia; Platelet Aggregation Inhibitors; Thr | 2021 |
Evaluation of efficacy and safety of rivaroxaban combined with aspirin in patients with chronic coronary artery disease: A protocol for systematic review and meta-analysis.
Topics: Aspirin; Coronary Artery Disease; Humans; Meta-Analysis as Topic; Myocardial Ischemia; Research Desi | 2022 |
Aspirin resistance among patients with new and recurrent ischemic heart disease episodes in Qassim region, Saudi Arabia.
Topics: Aspirin; Blood Platelets; Drug Resistance; Humans; Middle Aged; Myocardial Ischemia; Platelet Aggreg | 2022 |
Prasugrel for Japanese Patients With Ischemic Heart Disease in Long-Term Clinical Practice (PRASFIT-Practice II) - 1-Year Follow-up Results of a Postmarketing Observational Study.
Topics: Aged; Aged, 80 and over; Anemia; Aspirin; Female; Follow-Up Studies; Hemorrhage; Humans; Incidence; | 2019 |
[PEGASUS or COMPASS? A guide for a wise clinical choice.]
Topics: Aspirin; Cerebrovascular Disorders; Clinical Decision-Making; Clinical Protocols; Drug Administratio | 2019 |
Risk Factors for Postoperative Events in Patients on Antiplatelet Therapy Undergoing Off-Pump Coronary Artery Bypass Grafting Surgery.
Topics: Aged; Aged, 80 and over; Aspirin; Beijing; Clopidogrel; Coronary Artery Bypass, Off-Pump; Drug Admin | 2020 |
Effects of colchicine on platelet aggregation in patients on dual antiplatelet therapy with aspirin and clopidogrel.
Topics: Aspirin; Clopidogrel; Colchicine; Drug Resistance; Dual Anti-Platelet Therapy; Humans; Myocardial Is | 2020 |
Clopidogrel Prophylaxis Abates Myocardial Ischemic Injury and Inhibits the Hyperlipidemia-Inflammation Loop in Hypercholestrolemic Mice.
Topics: Animals; Aspirin; Clopidogrel; Disease Models, Animal; Humans; Hypercholesterolemia; Hyperlipidemias | 2020 |
Aspirin Discontinuation in Patients Requiring Oral Anticoagulation Undergoing Percutaneous Coronary Intervention, The Role of Procedural Complexity.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Drug Administration Schedule | 2020 |
Potential drug-drug interactions in ICU patients: a retrospective study.
Topics: Aspirin; Diabetes Mellitus; Drug Interactions; Enoxaparin; Hospitalization; Humans; Hypertension; In | 2020 |
Atypical Spontaneous Hematomas in a Patient with Severe Coronavirus Disease 2019 (COVID-19).
Topics: Aged, 80 and over; Aspirin; Betacoronavirus; Coronavirus Infections; COVID-19; Erythrocyte Transfusi | 2020 |
Platelet Apoptotic Response May Be Associated With the Capacity of Aspirin to Inhibit Platelets.
Topics: Aged; Apoptosis; Apoptosis Regulatory Proteins; Aspirin; bcl-2 Homologous Antagonist-Killer Protein; | 2020 |
Real-World Experience With Antiplatelet Agents After Percutaneous Coronary Intervention in Patients With an Indication for an Oral Anticoagulant.
Topics: Administration, Oral; Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Dual An | 2021 |
An Original Aspirin-Containing Carbonic Anhydrase 9 Inhibitor Overcomes Hypoxia-Induced Drug Resistance to Enhance the Efficacy of Myocardial Protection.
Topics: Aspirin; Carbonic Anhydrase Inhibitors; Carbonic Anhydrase IX; Cell Line, Tumor; Drug Resistance; Hu | 2022 |
Rapid desensitization to acetylsalicylic acid in patients with ischemic heart disease: 10-year experience of a Portuguese Allergy Department.
Topics: Aspirin; Desensitization, Immunologic; Drug Hypersensitivity; Humans; Myocardial Ischemia; Platelet | 2023 |
Disaggregation Following Agonist-Induced Platelet Activation in Patients on Dual Antiplatelet Therapy.
Topics: Adenosine; Aged; Aspirin; Blood Platelets; Clopidogrel; Drug Monitoring; Drug Resistance; Drug Thera | 2017 |
Triflusal in Patients With Aspirin Hypersensitivity Treated With Coronary Stent Implantation.
Topics: Aged; Aspirin; Drug Hypersensitivity; Female; Fibrinolytic Agents; Graft Occlusion, Vascular; Humans | 2018 |
Treatment and outcomes of type 2 myocardial infarction and myocardial injury compared with type 1 myocardial infarction.
Topics: Aged; Aged, 80 and over; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; | 2018 |
T2238C Atrial Natriuretic Peptide Gene Variant and the Response to Antiplatelet Therapy in Stable Ischemic Heart Disease Patients.
Topics: Aged; Aspirin; Atrial Natriuretic Factor; Clopidogrel; Drug Resistance; Drug Therapy, Combination; F | 2018 |
Physicians Addicted to Prescribing Aspirin-a Disorder Of Cardiologists (PAPA-DOC) Syndrome: The Headache of Nonevidence-Based Medicine for Ischemic Heart Disease?
Topics: Aspirin; Atrial Fibrillation; Cardiologists; Headache; Heart Failure; Humans; Myocardial Ischemia; P | 2018 |
[Safety and efficacy of long-term treatment with different ASA forms in patients with stable IHD and a high risk for development of gastropathy by data from a cross-sectionals study].
Topics: Aged; Aspirin; Cross-Sectional Studies; Female; Gastrointestinal Diseases; Humans; Long-Term Care; M | 2017 |
[High On-Treatment Platelet Reactivity Determinants on Dual Antiplatelet Therapy in Patients With Ischemic Heart Disease Before Elective Percutaneous Coronary Intervention].
Topics: Aged; Aspirin; Blood Platelets; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Humans; Middle Ag | 2018 |
Gastroduodenal ulcer bleeding in elderly patients on low dose aspirin therapy.
Topics: Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascu | 2018 |
Early severe coronary heart disease and ischemic heart failure in homozygous familial hypercholesterolemia: A case report.
Topics: Adolescent; Anticholesteremic Agents; Aspirin; Coronary Disease; Ezetimibe; Female; Heart Failure; H | 2018 |
Performance of PRECISE-DAPT Score for Predicting Bleeding Complication During Dual Antiplatelet Therapy.
Topics: Aged; Aspirin; Clopidogrel; Decision Support Techniques; Drug Therapy, Combination; Female; Hemorrha | 2018 |
When can I stop dual antiplatelet therapy in patients with drug-eluting stents?
Topics: Acute Coronary Syndrome; Aspirin; Drug Therapy, Combination; Drug-Eluting Stents; Humans; Myocardial | 2019 |
High On-Treatment Platelet Reactivity Determinants on Dual Antiplatelet Therapy in Patients With Ischemic Heart Disease Before Elective Percutaneous Coronary Intervention.
Topics: Aged; Aspirin; Blood Platelets; Cytochrome P-450 CYP2C19; Humans; Middle Aged; Myocardial Ischemia; | 2018 |
Cerebral microbleeds in patients with ischemic cerebrovascular disease taking aspirin or clopidogrel.
Topics: Aged; Aspirin; Cerebral Hemorrhage; China; Clopidogrel; Diffusion Magnetic Resonance Imaging; Female | 2019 |
Frequency of aspirin non responsiveness in patients of ischemic heart disease.
Topics: Aspirin; Cross-Sectional Studies; Drug Resistance; Humans; Middle Aged; Myocardial Ischemia; Platele | 2019 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
Myocardial injury after non-cardiac surgery: diagnosis and management.
Topics: Aspirin; Cardiovascular Diseases; Hemorrhage; Humans; Myocardial Ischemia; Postoperative Complicatio | 2020 |
[The Pathways to Increase the Efficacy of Drug Therapy in Patients with Ischemic Heart Disease after Coronary Artery Bypass Grafting].
Topics: Aged; Angina Pectoris; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetes Mellitus, | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Association of Multiple Enrichment Criteria With Ischemic and Bleeding Risks Among COMPASS-Eligible Patients.
Topics: Aged; Aspirin; Factor Xa Inhibitors; Female; Fibrinolytic Agents; Hemorrhage; Humans; Ischemia; Male | 2019 |
Triple antithrombotic therapy with prasugrel in the stented patient: concern for more bleeding.
Topics: Anticoagulants; Aspirin; Drug-Eluting Stents; Female; Humans; Male; Myocardial Ischemia; Piperazines | 2013 |
Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Clopidogrel; Cohort Studies; Drug Therapy, Combina | 2013 |
Chronic aspirin via dose-dependent and selective inhibition of cardiac proteasome possibly contributed a potential risk to the ischemic heart.
Topics: Animals; Aspirin; Cell Survival; Cells, Cultured; Disease Models, Animal; Dose-Response Relationship | 2013 |
Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Benzimidazoles; beta-Alanine; | 2013 |
[The ARCTIC study].
Topics: Acute Coronary Syndrome; Aspirin; Clopidogrel; Drug-Eluting Stents; Heart Diseases; Humans; Myocardi | 2013 |
Impact of the CYP2C19*17 polymorphism on the clinical outcome of clopidogrel therapy in Asian patients undergoing percutaneous coronary intervention.
Topics: Aryl Hydrocarbon Hydroxylases; Aspirin; Clopidogrel; Cytochrome P-450 CYP2C19; Drug Administration S | 2013 |
Defining predictive values using three different platelet function tests for CYP2C19 phenotype status on maintenance dual antiplatelet therapy after PCI.
Topics: Alleles; Aspirin; Blood Platelets; Clopidogrel; Cytochrome P-450 CYP2C19; Drug-Eluting Stents; Genot | 2014 |
Efficacy and safety of antiplatelet-combination therapy after drug-eluting stent implantation.
Topics: Aged; Antiplatyhelmintic Agents; Aspirin; Clopidogrel; Drug Combinations; Drug Resistance; Drug-Elut | 2014 |
Perioperative management of antiplatelet therapy in patients with coronary stents undergoing cardiac and non-cardiac surgery: a consensus document from Italian cardiological, surgical and anaesthesiological societies.
Topics: Anesthesiology; Aspirin; Cardiac Surgical Procedures; Cardiology; Clopidogrel; Eptifibatide; Hemorrh | 2014 |
Circulating myeloid-related protein-8/14 is related to thromboxane-dependent platelet activation in patients with acute coronary syndrome, with and without ongoing low-dose aspirin treatment.
Topics: Acute Coronary Syndrome; Aged; Aspirin; Calgranulin A; Calgranulin B; Chronic Disease; Dinoprost; Fe | 2014 |
Mortality and missed opportunities along the pathway of care for ST-elevation myocardial infarction: a national cohort study.
Topics: Acute Coronary Syndrome; Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Convertin | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Perioperative management of oral antiplatelet therapy and clinical outcomes in coronary stent patients undergoing surgery. Results of a multicentre registry.
Topics: Administration, Oral; Aged; Angina, Stable; Aspirin; Body Mass Index; Clopidogrel; Drug-Eluting Sten | 2015 |
Impact of aspirin according to type of stable coronary artery disease: insights from a large international cohort.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Humans; Male; Middle Aged; Myocardial Infarction; My | 2015 |
Superiority of zinc complex of acetylsalicylic acid to acetylsalicylic acid in preventing postischemic myocardial dysfunction.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coordination Complexes; Electrocardiograp | 2015 |
Relationship between Troponin Elevation, Cardiovascular History and Adverse Events in Patients with acute exacerbation of COPD.
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Cause of Death; Creatinine; Disease Progression; Fema | 2015 |
Does the response to aspirin and clopidogrel vary over 6 months in patients with ischemic heart disease?
Topics: Aged; Area Under Curve; Aspirin; Biomarkers; Blood Platelets; Clopidogrel; Drug Therapy, Combination | 2015 |
[Management of patients with ischemic heart disease in lung cancer resection].
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Female; Heparin; H | 2015 |
Proton pump inhibitors are associated with lower gastrointestinal tract bleeding in low-dose aspirin users with ischaemic heart disease.
Topics: Aged; Aspirin; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Histamine H2 Antagoni | 2015 |
Antithrombotic and Antiplatelet Therapy in Patients Requiring Oral Anticoagulation After Percutaneous Coronary Intervention.
Topics: Anticoagulants; Aspirin; Humans; Myocardial Ischemia; Percutaneous Coronary Intervention; Platelet A | 2015 |
Proton pump inhibitors, histamine-2 receptor antagonists, gastroprotection and lower gastrointestinal tract bleeding in low-dose aspirin users.
Topics: Aspirin; Female; Gastrointestinal Hemorrhage; Histamine H2 Antagonists; Humans; Male; Myocardial Isc | 2016 |
Provoking conditions, management and outcomes of type 2 myocardial infarction and myocardial necrosis.
Topics: Aged; Aged, 80 and over; Aspirin; Electrocardiography; Female; Hospital Mortality; Humans; Hydroxyme | 2016 |
Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.
Topics: Aged; Aged, 80 and over; Aspirin; Cohort Studies; Echocardiography; England; Female; Guideline Adher | 2016 |
Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry.
Topics: Aged; Aspirin; Clopidogrel; Coronary Thrombosis; Drug Administration Schedule; Drug Antagonism; Drug | 2017 |
Clinical approach on challenge and desensitization procedures with aspirin in patients with ischemic heart disease and nonsteroidal anti-inflammatory drug hypersensitivity.
Topics: Aged; Algorithms; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Clinical Decision-Making; Comorb | 2017 |
Perioperative management of dual anti-platelet therapy.
Topics: Acute Coronary Syndrome; Aspirin; Drug Administration Schedule; Drug Therapy, Combination; Drug-Elut | 2016 |
Efficacy of aspirin and statins in primary prevention of cardiovascular mortality in uncomplicated hypertensive participants: a Korean national cohort study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cause of Death; Co | 2017 |
The CYP2C19*2 and CYP2C19*17 Polymorphisms play a Vital Role in Clopidogrel Responsiveness after Percutaneous Coronary Intervention: A Pharmacogenomics Study.
Topics: Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cytochrome P-450 CYP2C19; Female; Gene Frequenc | 2017 |
Upper gastrointestinal bleeding in patients with aspirin and clopidogrel co-therapy.
Topics: Aged; Aged, 80 and over; Aspirin; Clopidogrel; Coronary Disease; Drug Therapy, Combination; Female; | 2008 |
Assessment of aspirin resistance varies on a temporal basis in patients with ischaemic heart disease.
Topics: Aspirin; Drug Resistance; Enzyme-Linked Immunosorbent Assay; Female; Humans; Male; Middle Aged; Myoc | 2009 |
Investigation of gastric and duodenal mucosal defects caused by low-dose aspirin in patients with ischemic heart disease.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Buffers; Drug Administration Schedule; Duode | 2009 |
[Changes in coagulation hemostasis in patients after coronary bypass surgery].
Topics: Anticoagulants; Aspirin; Blood Coagulation Disorders; Coronary Artery Bypass; Fibrin Fibrinogen Degr | 2008 |
Low incidence of neurologic events during long-term support with the HeartMate XVE left ventricular assist device.
Topics: Adult; Aged; Aspirin; Brain Diseases, Metabolic; Cardiomyopathy, Dilated; Cause of Death; Cognition | 2008 |
Recurrent perimesencephalic subarachnoid hemorrhage during antithrombotic therapy.
Topics: Acute Coronary Syndrome; Anticoagulants; Aspirin; Cerebral Angiography; Fatal Outcome; Female; Hepar | 2009 |
Clopidogrel under scrutiny.
Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Drug Therap | 2008 |
Comparison between ticlopidine and clopidogrel in patients undergoing primary stenting in acute myocardial infarction: results from the CADILLAC trial.
Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Clopidogrel; Coron | 2008 |
Endoscopic survey of low-dose-aspirin-induced gastroduodenal mucosal injuries in patients with ischemic heart disease.
Topics: Aged; Aspirin; Case-Control Studies; Drug Administration Schedule; Duodenal Ulcer; Duodenoscopy; Fem | 2008 |
Off-pump replacement of the INCOR implantable axial-flow pump.
Topics: Anticoagulants; Aspirin; Clopidogrel; Equipment Design; Heart-Assist Devices; Humans; Infusion Pumps | 2009 |
Association of aspirin dosage to clinical outcomes after percutaneous coronary intervention: observations from the Ottawa Heart Institute PCI Registry.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Canada; Combined Modality Therapy; Dose-Response Relationsh | 2009 |
Clopidogrel versus low-dose aspirin as risk factors for epistaxis.
Topics: Aspirin; Clopidogrel; Dose-Response Relationship, Drug; Epistaxis; Humans; Hypertension; Myocardial | 2009 |
[The concept of aspirin "resistance": mechanisms and clinical relevance].
Topics: Aspirin; Cardiovascular Diseases; Cyclooxygenase 1; Cyclooxygenase Inhibitors; Drug Resistance; Huma | 2009 |
Significance of platelet volume indices and platelet count in ischaemic heart disease.
Topics: Acute Coronary Syndrome; Adult; Aged; Angina Pectoris; Aspirin; Blood Platelets; Cell Size; Female; | 2009 |
Drug secondary prevention in postmenopausal women with ischemic heart disease.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Female; Humans | 2009 |
Medication underuse during long-term follow-up in patients with peripheral arterial disease.
Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Cardiovascular Agents; Drug Therapy, Combination; Eviden | 2009 |
Different expression of proteins in platelets from aspirin-resistant and aspirin-sensitive patients.
Topics: Aged; Aspirin; Biomarkers; Blood Platelets; Blood Proteins; Blotting, Western; Cell Survival; Cytosk | 2010 |
[Non-occlusive stent thrombosis associated to cardiocirculatory arrest].
Topics: Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Coronary Restenosi | 2010 |
Impact of high-responsiveness to dual antiplatelet therapy on bleeding complications in patients receiving drug-eluting stents.
Topics: Aged; Angioplasty, Balloon, Laser-Assisted; Aspirin; Clopidogrel; Coronary Artery Disease; Drug Ther | 2010 |
Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment.
Topics: Aged; Aged, 80 and over; Aspirin; Epoprostenol; Female; Heart Failure; Humans; Male; Myocardial Isch | 2010 |
Successful emergent coronary thrombolysis in a neonate with Kawasaki's disease.
Topics: Aspirin; Coronary Angiography; Coronary Thrombosis; Echocardiography; Electrocardiography; Emergency | 2010 |
Protective effect of L-arginine in experimentally induced myocardial ischemia: comparison with aspirin.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aorta; Arginine; Aspirin; Cardiotonic Agents; Chol | 2011 |
[Aggregation activity of platelets in various periods of ischemic stroke].
Topics: Aged; Aspirin; Blood Coagulation Disorders; Blood Coagulation Tests; Brain Ischemia; Female; Humans; | 2010 |
Assessment of drug treatment quality in two Danish health-care centres.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2011 |
Gastric mucosal damage evaluated by transnasal endoscopy and QOL assessments in ischemic heart disease patients receiving low-dose aspirin.
Topics: Aged; Aspirin; Endoscopy, Digestive System; Female; Gastric Mucosa; Health Surveys; Humans; Male; Mi | 2011 |
Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the preoperative aspirin and postoperative antiplatelets in coronary artery bypass grafting surgery.
Topics: Aspirin; Clopidogrel; Coronary Angiography; Coronary Artery Bypass; Drug Therapy, Combination; Graft | 2011 |
Comparison of platelet reactivity and clopidogrel response in patients ≤ 75 Years Versus > 75 years undergoing percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Age Factors; Aged; Aged, 80 and over; Angioplasty, B | 2011 |
A girl with extremely refractory Kawasaki disease: an instructive case with unusual course and outcome.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Coronary Aneurysm; Echocardiography; Fatal Outcome | 2012 |
Gene therapy with iNOS enhances regional contractility and reduces delayed contrast enhancement in a model of postischemic congestive heart failure.
Topics: Animals; Anticoagulants; Aspirin; Clopidogrel; Contrast Media; Coronary Angiography; Coronary Stenos | 2011 |
[Aspirin response and related factors in aged patients].
Topics: Acute Coronary Syndrome; Aged; Aged, 80 and over; Arachidonic Acid; Aspirin; Coronary Artery Disease | 2011 |
Risk factors for colonic diverticular hemorrhage: Japanese multicenter study.
Topics: Aged; Aged, 80 and over; Aspirin; Body Mass Index; Case-Control Studies; Diverticulum, Colon; Female | 2012 |
The perioperative management of patients with coronary artery stents: surveying the clinical stakeholders and arriving at a consensus regarding optimal care.
Topics: Adult; Advisory Committees; Alabama; Anesthesiology; Aspirin; Blood Loss, Surgical; Cardiac Catheter | 2012 |
Recommended use of aspirin and other antiplatelet medications among adults--National Ambulatory Medical Care Survey and National Hospital Ambulatory Medical Care Survey, United States, 2005-2008.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Guideline Adhe | 2012 |
Cardiac-generated prostanoids mediate cardiac myocyte apoptosis after myocardial ischaemia.
Topics: Animals; Animals, Newborn; Apoptosis; Aspirin; Cells, Cultured; Cyclooxygenase 1; Cyclooxygenase Inh | 2012 |
Prevention of cardiovascular diseases in developing countries.
Topics: Antihypertensive Agents; Aspirin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2012 |
Polypill: the path from concept to “near” reality in preventing cardiovascular disease.
Topics: Antihypertensive Agents; Aspirin; Fibrinolytic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase I | 2012 |
[The risk factors for colonic diverticular bleeding].
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Calci | 2012 |
Assessment of high on-treatment platelet reactivity in patients with ischemic heart disease: concordance between the Multiplate and VerifyNow assays.
Topics: Adenosine Diphosphate; Aged; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel; Drug Resistanc | 2013 |
Doctor, my dentist wants your opinion.
Topics: Angioplasty; Antibiotic Prophylaxis; Aspirin; Dental Care for Chronically Ill; Dentists; Drug Intera | 2013 |
Ischemic heart disease: the platelet paradox.
Topics: Aspirin; Blood Coagulation Factors; Blood Platelets; Humans; Myocardial Ischemia; Platelet Aggregati | 2002 |
Does aspirin attenuate the effect of angiotensin-converting enzyme inhibitors on health outcomes of very old patients with heart failure?
Topics: Activities of Daily Living; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Drug Interactio | 2002 |
Aspirin therapy should be first line: probably, but watch this space.
Topics: Aspirin; Clinical Trials as Topic; Clopidogrel; Dipyridamole; Drug Synergism; Humans; Myocardial Isc | 2002 |
Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Ant | 2002 |
Inhibition of ADP-induced P-selectin expression and platelet-leukocyte conjugate formation by clopidogrel and the P2Y12 receptor antagonist AR-C69931MX but not aspirin.
Topics: Adenosine Diphosphate; Adenosine Monophosphate; Aspirin; Blood Platelets; Cell Adhesion; Clopidogrel | 2002 |
[Acetylsalicylic acid and ACE inhibitors in heart disease--a phenomenon in dogs and cats?].
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Aspirin; Brain Ischemia; Drug Interactions; Human | 2002 |
[Acetylsalicylic acid--is everything clear? Probably not].
Topics: Aspirin; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Stroke | 2002 |
Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials.
Topics: Aged; Aged, 80 and over; Angina, Unstable; Anticoagulants; Aspirin; Creatinine; Drug Monitoring; Eno | 2003 |
[Clearly superior in acute coronary syndrome. Helps aggressive platelet inhibition even after stroke?].
Topics: Acute Disease; Aspirin; Clinical Trials as Topic; Clopidogrel; Drug Therapy, Combination; Humans; My | 2003 |
Clopidogrel and percutaneous coronary interventions.
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Drug Administration Schedule; | 2003 |
Under-prescribing of cardiovascular therapies for diabetes in primary care.
Topics: Adrenergic beta-Antagonists; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibit | 2003 |
Evidence for an age and gender bias in the secondary prevention of ischaemic heart disease in primary care.
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; B | 2003 |
Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Aspirin; C-Reactive Protei | 2003 |
Medical therapy in patients undergoing percutaneous coronary intervention: results from the ROSETTA registry.
Topics: Adrenergic beta-Antagonists; Aftercare; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting | 2003 |
Low-dose aspirin prophylaxis and risk of intracranial hemorrhage in patients older than 60 years of age with mild or moderate head injury: a prospective study.
Topics: Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Brain Injuries; Dose-Resp | 2003 |
Acute aspirin treatment abolishes, whereas acute ibuprofen treatment enhances morphine-induced cardioprotection: role of 12-lipoxygenase.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arachidonate 12-Lipoxygenase; Aspirin; Blood Press | 2004 |
Antiplatelet therapy for ischemic heart disease.
Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Cost-Benefit Analysis; Drug Therapy, Combinati | 2004 |
[Experience with the use of autoarterial conduits in coronary surgery].
Topics: Anastomosis, Surgical; Angina, Unstable; Anti-Inflammatory Agents, Non-Steroidal; Aorta, Thoracic; A | 2004 |
Platelet function predicts myocardial damage in patients with acute myocardial infarction.
Topics: Abciximab; Adenosine Diphosphate; Aged; Antibodies, Monoclonal; Anticoagulants; Aspirin; Cardiovascu | 2004 |
[Cardiovascular pharmacology].
Topics: Aspirin; Cardiovascular Diseases; Clopidogrel; Fatty Acids, Omega-3; Fibrinolytic Agents; Graft Occl | 2004 |
Elevations in troponin I after percutaneous coronary interventions are associated with abnormal tissue-level perfusion in high-risk patients with non-ST-segment-elevation acute coronary syndromes.
Topics: Abciximab; Acute Disease; Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antibodies, Monoclo | 2004 |
Variability among cardiologists in the management of patients under secondary prevention of ischemic heart disease.
Topics: Ambulatory Care Facilities; Aspirin; Cardiology; Cholesterol, LDL; Cross-Sectional Studies; Epidemio | 2004 |
Impact of prior use or recent withdrawal of oral antiplatelet agents on acute coronary syndromes.
Topics: Acute Disease; Administration, Oral; Aged; Aspirin; Cardiovascular Agents; Cohort Studies; Drug Ther | 2004 |
Evolution of spontaneous atherosclerotic plaque rupture with medical therapy: long-term follow-up with intravascular ultrasound.
Topics: Aged; Aspirin; Biomarkers; Clopidogrel; Coronary Artery Disease; Disease Progression; Female; Follow | 2004 |
Antiplatelet therapy in non-ST-segment elevation acute coronary syndromes.
Topics: Adrenergic beta-Antagonists; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Artery B | 2004 |
Mortality following non-ST elevation acute coronary syndrome: 4 years follow-up of the PRAIS UK Registry (Prospective Registry of Acute Ischaemic Syndromes in the UK).
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Aspirin; Cohort Studies; Coronary Artery Bypass; Female | 2004 |
Management of ischaemic heart disease in women of child-bearing age.
Topics: Adult; Aspirin; Diabetes Mellitus, Type 1; Female; Fibrinolytic Agents; Humans; Hypoglycemic Agents; | 2004 |
Effects of cilostazol on platelet activation in coronary stenting patients who already treated with aspirin and clopidogrel.
Topics: Aspirin; Cilostazol; Clopidogrel; Dose-Response Relationship, Drug; Drug Therapy, Combination; Femal | 2004 |
Reversible left ventricular hypertrophy after tako-tsubo-like cardiomyopathy.
Topics: Aged; Aspirin; Benzimidazoles; Biphenyl Compounds; Cardiomyopathy, Dilated; Chest Pain; Drug Therapy | 2005 |
Prophylaxis with enoxaparin can produce a giant abdominal wall haematoma when associated with low doses of aspirin among elderly patients suffering cough attacks.
Topics: Abdominal Wall; Aged; Aged, 80 and over; Aspirin; Cough; Dose-Response Relationship, Drug; Drug Ther | 2005 |
Aspirin resistance in ischaemic heart disease.
Topics: Aged; Aspirin; Drug Resistance; Female; Humans; Male; Myocardial Ischemia; Platelet Aggregation; Pla | 2005 |
Glycoprotein IIIA gene (PlA) polymorphism and aspirin resistance: is there any correlation?
Topics: Adult; Aged; Alleles; Aspirin; Drug Resistance; Dyslipidemias; Female; Gene Frequency; Genotype; Hum | 2005 |
Prevalence of aspirin resistance measured by PFA-100.
Topics: Aged; Aspirin; Brain Ischemia; Cross-Sectional Studies; Drug Resistance; Female; Humans; Male; Middl | 2005 |
Effect of combinations of drugs on all cause mortality in patients with ischaemic heart disease: nested case-control analysis.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspi | 2005 |
[Influence of preoperative treatment with aspirin or heparin on platelet function and intensity of postoperative bleeding in early period after coronary artery bypass surgery].
Topics: Adult; Aged; Anticoagulants; Aspirin; Blood Coagulation Tests; Blood Platelets; Coronary Artery Bypa | 2005 |
Exploring the role of enoxaparin in the management of high-risk patients with non-ST-elevation acute coronary syndromes: the SYNERGY trial.
Topics: Aged; Anticoagulants; Aspirin; Cardiac Catheterization; Enoxaparin; Female; Hemorrhage; Heparin; Hum | 2005 |
Monitoring acetylsalicylic acid effects with the platelet function analyzer PFA-100.
Topics: Aspirin; Atherosclerosis; Blood Platelets; Brain Ischemia; Cardiovascular Diseases; Clinical Trials | 2005 |
Summaries for patients. Care and outcomes of patients hospitalized with heart attack in December.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Evide | 2005 |
Evidence-based therapies and mortality in patients hospitalized in December with acute myocardial infarction.
Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Evide | 2005 |
The effect of NCX4016 [2-acetoxy-benzoate 2-(2-nitroxymethyl)-phenyl ester] on the consequences of ischemia and reperfusion in the streptozotocin diabetic rat.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Blood Pressure; Calcimycin; Diabetes Mell | 2006 |
Use of the platelet function analyser (PFA-100) to quantify the effect of low dose aspirin in patients with ischaemic heart disease.
Topics: Adult; Aged; Aspirin; Blood Platelets; Drug Resistance; Female; Humans; Male; Middle Aged; Myocardia | 2005 |
[Acetylsalicylic acid (ASA) resistance in patients with ischemic heart disease (IHD) as bioindicator of the treatment strategy].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Drug Resistance; Female; Human | 2005 |
Female sex: a protective role in suspected myocardial ischemia.
Topics: Aspirin; Coronary Artery Disease; Diagnostic Techniques, Cardiovascular; Female; Fibrinolytic Agents | 2006 |
Regional differences in incidence and management of stroke - is there any difference between Western and Japanese guidelines on antiplatelet therapy?
Topics: Aspirin; Brain Infarction; Cilostazol; Humans; Incidence; Japan; Myocardial Ischemia; Platelet Aggre | 2006 |
[Level of C-reactive protein and efficacy of therapy with aspirin in patients with ischemic heart disease.].
Topics: Aspirin; C-Reactive Protein; Coronary Artery Disease; Humans; Myocardial Ischemia | 2006 |
[Recording of risk factors and preventive pharmaceutical therapy among ischemic heart disease patients in family practice during the years 1993-1998].
Topics: Adrenergic beta-Antagonists; Aspirin; Blood Pressure; Cholesterol; Cohort Studies; Family Practice; | 2006 |
Aspirin therapy for inhibition of platelet reactivity in the presence of erythrocytes in patients with vascular disease.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Collagen; Dose-Response Re | 2006 |
Increased risk of myocardial infarction as first manifestation of ischaemic heart disease and nonselective nonsteroidal anti-inflammatory drugs.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Case-Control Studi | 2006 |
Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Aspirin; Clopidogrel; Echocardiography; Humans; Interle | 2006 |
Aspirin failure course during exercise and its connection with soluble CD40L.
Topics: Aged; Aspirin; CD40 Ligand; Collagen; Drug Resistance; Exercise; Female; Humans; Male; Middle Aged; | 2007 |
Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial.
Topics: Angina Pectoris; Aspirin; Chronic Disease; Coronary Stenosis; Drug Therapy, Combination; Humans; Mal | 2006 |
Viscosity, hemostasis and inflammation in atherosclerotic heart diseases.
Topics: Aged; Aspirin; Blood Viscosity; Brain Ischemia; Clopidogrel; Coronary Artery Disease; Diabetes Compl | 2006 |
The lipoxygenase-cyclooxygenase inhibitor licofelone prevents thromboxane A2-mediated cardiovascular derangement triggered by the inflammatory peptide fMLP in the rabbit.
Topics: Acetates; Animals; Aspirin; Blood Pressure; Cyclooxygenase Inhibitors; Disease Models, Animal; Elect | 2006 |
[Cost-effectiveness of clopidogrel vs. aspirin treatment in high-risk acute coronary syndrome patients in Denmark].
Topics: Acute Disease; Aged; Aspirin; Cardiovascular Diseases; Clopidogrel; Coronary Artery Bypass; Coronary | 2006 |
Prevention of postischemic myocardial reperfusion injury by the combined treatment of NCX-4016 and Tempol.
Topics: Animals; Aspirin; Creatine Kinase; Cyclic N-Oxides; L-Lactate Dehydrogenase; Myocardial Ischemia; My | 2006 |
Using the Platelet Function Analyzer-100 for monitoring aspirin therapy.
Topics: Aged; Analysis of Variance; Aspirin; Case-Control Studies; Dose-Response Relationship, Drug; Female; | 2007 |
Risks and benefits of combining aspirin with anticoagulant therapy in patients with atrial fibrillation: an exploratory analysis of stroke prevention using an oral thrombin inhibitor in atrial fibrillation (SPORTIF) trials.
Topics: Aged; Anticoagulants; Aspirin; Atrial Fibrillation; Azetidines; Benzylamines; Drug Therapy, Combinat | 2006 |
Silent myocardial ischemia in coronary artery disease patients under aspirin therapy presenting with upper gastrointestinal hemorrhage.
Topics: Aged; Aspirin; Coronary Disease; Electrocardiography; Female; Gastrointestinal Hemorrhage; Hospital | 2007 |
High post-treatment platelet reactivity is associated with a high incidence of myonecrosis after stenting for non-ST elevation acute coronary syndromes.
Topics: Acute Disease; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Fe | 2007 |
Aspirin before reperfusion blunts the infarct size limiting effect of atorvastatin.
Topics: 6-Ketoprostaglandin F1 alpha; Animals; Aspirin; Atorvastatin; Cyclooxygenase 1; Cyclooxygenase 2; Cy | 2007 |
[The degree of inflammation and endothelial dysfunction in treatment of chronic heart failure in patients with coronary artery disease].
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Biomarkers; C-Reactive Protein; Cytokines; | 2006 |
Persistent platelet activation is related to very early cardiovascular events in patients with acute coronary syndromes.
Topics: Acute Disease; Adult; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; | 2007 |
Emerging therapies: ESPRIT.
Topics: Aspirin; Brain Ischemia; Cerebral Hemorrhage; Clinical Trials as Topic; Dipyridamole; Drug Therapy, | 2007 |
Takotsubo cardiomyopathy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiomyopathi | 2007 |
Platelet aggregation and aspirin non-responsiveness increase when an acute coronary syndrome is complicated by an infection.
Topics: Acute Disease; Aged; Aged, 80 and over; Aspirin; Biomarkers; C-Reactive Protein; Drug Resistance; Fe | 2007 |
Impact of arterial remodelling and plaque rupture on target and non-target lesion revascularisation after stent implantation in patients with acute coronary syndrome: an intravascular ultrasound study.
Topics: Aspirin; Biomarkers; Coronary Angiography; Coronary Restenosis; Coronary Vessels; Female; Fibrinolyt | 2007 |
A risk score to predict silent myocardial ischemia in patients with coronary artery disease under aspirin therapy presenting with upper gastrointestinal hemorrhage.
Topics: Aged; Aspirin; Coronary Artery Disease; Female; Fibrinolytic Agents; Gastrointestinal Hemorrhage; Hu | 2007 |
[Treatment of intrastent restenosis by drug eluting stents: experience from one cardiology centre].
Topics: Adult; Aged; Aged, 80 and over; Angina Pectoris; Aspirin; Clopidogrel; Coronary Angiography; Coronar | 2007 |
Residual platelet reactivity is associated with clinical and laboratory characteristics in patients with ischemic heart disease undergoing PCI on dual antiplatelet therapy.
Topics: Acute Coronary Syndrome; Adenosine Diphosphate; Aged; Angioplasty, Balloon, Coronary; Arachidonic Ac | 2007 |
Comparison of different methods to evaluate the effect of aspirin on platelet function in high-risk patients with ischemic heart disease receiving dual antiplatelet treatment.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Arachidonic Acid; Aspirin; Blood Platelets; Clopidogrel | 2007 |
Platelet activation, myocardial ischemic events and postoperative non-response to aspirin in patients undergoing major vascular surgery.
Topics: Adenosine Diphosphate; Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspi | 2007 |
Accelerated thrombotic occlusion of a medium-sized coronary aneurysm in Kawasaki disease by the inhibitory effect of ibuprofen on aspirin.
Topics: Aspirin; Child; Coronary Occlusion; Coronary Thrombosis; Coronary Vessels; Drug Interactions; Heart; | 2008 |
The truth and consequences of the COURAGE trial.
Topics: Adrenergic beta-Antagonists; Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Coronary Ang | 2007 |
The CAPRIE-like subgroups of CHARISMA: a CAPRIEciously biased analysis of an unCHARISMAtic truth.
Topics: Aspirin; Clopidogrel; Coronary Artery Disease; Drug Therapy, Combination; Humans; Myocardial Ischemi | 2007 |
Analysis of the upper gastrointestinal tract bleeding prevalence in patients treated due ischaemic heart disease.
Topics: Acenocoumarol; Adolescent; Adult; Aged; Aged, 80 and over; Aspirin; Body Mass Index; Clopidogrel; Fe | 2007 |
Simultaneous manipulation of the nitric oxide and prostanoid pathways reduces myocardial reperfusion injury.
Topics: Animals; Arginine; Aspirin; Cardioplegic Solutions; Coronary Circulation; Cyclic GMP; Glucose; Heart | 1995 |
Thromboxane receptor antagonist BMS-180291, but not aspirin, reduces the severity of pacing-induced ischemia in dogs.
Topics: Angina Pectoris; Animals; Aspirin; Bridged Bicyclo Compounds, Heterocyclic; Cardiac Pacing, Artifici | 1994 |
Effects of aspirin and indomethacin on ventricular arrhythmias--comparative study.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Blood Pressure; Cardiac Complexes, Premature; Cause of Death | 1994 |
Differential effects of various oil diets on the risk of cardiac arrhythmias in rats.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Cardiac Complexes, Premature; Coconut Oil; Cocos; Corn Oil; | 1994 |
Early reactivation of ischaemia after abrupt discontinuation of heparin in acute myocardial infarction.
Topics: Aspirin; Drug Administration Schedule; Fibrinolytic Agents; Heparin; Humans; Male; Middle Aged; Myoc | 1995 |
[Low-dose aspirin in the long-term treatment of the patient with ischemic heart disease].
Topics: Angina Pectoris; Angioplasty, Balloon, Coronary; Aspirin; Coronary Artery Bypass; Humans; Myocardial | 1994 |
What effect does controlling platelets have on atherosclerosis?
Topics: Adenylyl Cyclases; Animals; Arteriosclerosis; Aspirin; Blood Platelets; Calcium; Capillary Permeabil | 1995 |
Myocardial ischaemia induces platelet activation with adverse electrophysiological and arrhythmogenic effects.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Biphenyl Compounds; Blood Platelets; Colforsin; Diterpenes; | 1994 |
[What is the appropriate treatment for myocardial infarction with left ventricular dysfunction?].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Vessels; Hu | 1994 |
Role of aspirin in modulating myocardial ischemic reperfusion injury.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Aspirin; Blood Pressure; Creatinine; Disease | 1994 |
Effects of diaspirin crosslinked haemoglobin during coronary angioplasty in the swine.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Coronary Circulation; Electrocardiography; Female; | 1994 |
[20,000 kg aspirin and 45 pages British Medical Journal].
Topics: Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Clinical Trials as Topic; Coronary Disease; Hu | 1994 |
Cardioprotective actions of garlic (Allium sativum).
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Cyclooxygenase Inhibitors; Diet; Electrocardiography; Epopro | 1993 |
Low dose aspirin in patients with ischemic heart disease may precipitate secondary myocardial infarction.
Topics: Aged; Angina, Unstable; Aspirin; Gastrointestinal Hemorrhage; Hemoglobins; Humans; Middle Aged; Myoc | 1996 |
[Prescription of platelet antiaggregants in secondary prevention of ischemic heart disease].
Topics: Age Factors; Aged; Aged, 80 and over; Aspirin; Dipyridamole; Drug Prescriptions; Family Practice; Fe | 1996 |
Is aspirin, as used for antithrombosis, an emotion-modulating agent?
Topics: Affect; Aspirin; Coronary Angiography; Coronary Thrombosis; Cyclooxygenase Inhibitors; Dose-Response | 1996 |
Is aspirin, as used for antithrombosis, an emotion-modulating agent?
Topics: Affect; Aspirin; Coronary Angiography; Coronary Thrombosis; Cyclooxygenase Inhibitors; Dose-Response | 1996 |
Is aspirin, as used for antithrombosis, an emotion-modulating agent?
Topics: Affect; Aspirin; Coronary Angiography; Coronary Thrombosis; Cyclooxygenase Inhibitors; Dose-Response | 1996 |
Is aspirin, as used for antithrombosis, an emotion-modulating agent?
Topics: Affect; Aspirin; Coronary Angiography; Coronary Thrombosis; Cyclooxygenase Inhibitors; Dose-Response | 1996 |
Dose of prophylactic aspirin in IHD and body weight.
Topics: Aspirin; Body Weight; Dose-Response Relationship, Drug; Humans; Myocardial Ischemia; Platelet Aggreg | 1995 |
Low dose aspirin and secondary myocardial infarction.
Topics: Aspirin; Humans; Myocardial Infarction; Myocardial Ischemia; Platelet Aggregation Inhibitors | 1996 |
Aspirin-stimulated nitric oxide production by neutrophils after acute myocardial ischemia in rabbits.
Topics: Animals; Aspirin; Male; Myocardial Ischemia; Neutrophils; Nitric Oxide; Platelet Activation; Platele | 1996 |
Effect of acetylsalicylic acid on metabolism and contractility in the ischemic reperfused heart.
Topics: 6-Ketoprostaglandin F1 alpha; Adenosine Triphosphate; Animals; Aspirin; C-Reactive Protein; Coronary | 1996 |
The microvasculature in myeloproliferative disease. A study using retinal fluorescein angiography.
Topics: Adult; Aged; Aged, 80 and over; Allergens; Antineoplastic Agents; Arterial Occlusive Diseases; Aspir | 1996 |
[Should individuals without evidence of coronary disease and with risk factors receive continuous treatment with aspirin? Arguments against].
Topics: Aspirin; Hemorrhage; Humans; Myocardial Ischemia; Risk Factors | 1996 |
[Should individuals without evidence of coronary disease and with risk factors receive continuous treatment with aspirin? Arguments in favor].
Topics: Age Factors; Aspirin; Cost-Benefit Analysis; Diabetes Complications; Female; Humans; Hypercholestero | 1996 |
Use of aspirin in ischaemic heart disease.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Humans; Myocardial Ischemia | 1996 |
Erythrocyte promotion of platelet reactivity decreases the effectiveness of aspirin as an antithrombotic therapeutic modality: the effect of low-dose aspirin is less than optimal in patients with vascular disease due to prothrombotic effects of erythrocyt
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Blood Platelets; Brain Ischemia; Cerebrovascular Disorders; | 1998 |
Acetylsalicylic acid enhances arrhythmogeneity in a model of local ischemia of isolated rabbit hearts.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, Cardiac; Aspirin; Coronary Circulatio | 1997 |
Warfarin and aspirin for prevention of IHD.
Topics: Aged; Anticoagulants; Aspirin; Double-Blind Method; Drug Combinations; Humans; Male; Middle Aged; My | 1998 |
Interpretation of Thrombosis Prevention Trial.
Topics: Administration, Oral; Anticoagulants; Aspirin; Coronary Thrombosis; Dose-Response Relationship, Drug | 1998 |
Coronary thrombosis/thrombolysis in pigs: effects of heparin, ASA, and the thrombin inhibitor inogatran.
Topics: Animals; Antithrombins; Aspirin; Blood Flow Velocity; Coronary Thrombosis; Glycine; Hemodynamics; He | 1998 |
Effective long-term inhibition of thromboxane production but not of serotonin release in patients with coronary heart disease by 30 mg/d acetylsalicylic acid dosage.
Topics: Aspirin; Blood Coagulation; Coronary Disease; Dose-Response Relationship, Drug; Humans; Myocardial I | 1998 |
Effect of a novel tetrapeptide derivative in a model of isoproterenol induced myocardial necrosis.
Topics: Adrenergic beta-Agonists; Animals; Aspirin; Body Weight; Creatine Kinase; Disease Models, Animal; Fe | 1998 |
Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; | 1998 |
[Prevention in the 21st century. Athero-thrombosis and ischemic events].
Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Clopidogrel; Female; Forecasting; Human | 1998 |
[Method of quantitative measurement of human platelet aggregation in clinical practice].
Topics: Adenosine Diphosphate; Adult; Aged; Aspirin; Dipyridamole; Epinephrine; Female; Humans; Male; Method | 1998 |
Myocardial ischaemia and infarction in isoprenaline-treated rabbits: role of cyclooxygenases.
Topics: Adrenergic beta-Agonists; Animals; Aspirin; Cyclooxygenase Inhibitors; Electrocardiography; Isoprote | 1998 |
ST-T alternans and myocardial ischemia.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Chi-Square Distribution; Coron | 1999 |
Underuse of acetylsalicylic acid in individuals with myocardial infarction, ischemic heart disease or stroke: data from the 1995 population-based Nova Scotia Health Survey.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cerebrovascular Disorders | 1999 |
The effects of antiplatelet agents in the prevention of ventricular tachyarrhythmias during acute myocardial ischemia in rats.
Topics: Abciximab; Animals; Antibodies, Monoclonal; Aspirin; Immunoglobulin Fab Fragments; Male; Myocardial | 1999 |
Management of ischaemic heart disease in primary care: towards better practice. STaRNet. South Thames Region Network.
Topics: Adult; Aged; Anticholesteremic Agents; Aspirin; Body Mass Index; Cross-Sectional Studies; England; H | 1999 |
Trends in the post-hospitalization medical treatment of unstable angina pectoris: 1990 to 1995.
Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Aspirin; Calcium Channel Blockers; Cohort Studi | 1999 |
Effects of aspirin and warfarin on fatal and non-fatal heart attacks.
Topics: Anticoagulants; Aspirin; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Warfarin | 1999 |
The Canadian Study of Cardiac Transplantation. Atherosclerosis. Investigators of the CASCADE Study.
Topics: Adult; Antihypertensive Agents; Arteriosclerosis; Aspirin; Cardiovascular Agents; Cyclosporine; Cyto | 1999 |
Mechanism of protection against vascular smoking-induced changes by hormone replacement therapy.
Topics: Arteries; Aspirin; Estrogen Replacement Therapy; Exercise Therapy; Female; Humans; Myocardial Ischem | 2000 |
Women with angina pectoris receive less antiplatelet treatment than men.
Topics: Aged; Angina Pectoris; Aspirin; Family Practice; Female; Humans; Male; Middle Aged; Myocardial Ische | 1999 |
[Clopidogrel--an expensive thrombocyte inhibitor with a small marginal benefit].
Topics: Aspirin; Clopidogrel; Coronary Disease; Cost-Benefit Analysis; Humans; Myocardial Ischemia; Platelet | 2000 |
Does gastroscopy induce myocardial ischemia in patients with coronary heart disease?
Topics: Adult; Aged; Aspirin; Coronary Disease; Electrocardiography, Ambulatory; Esophageal Diseases; Exerci | 2000 |
[Acute myocardial infarction: management, prognosis and survival].
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents, Non | 2000 |
Sex differences and similarities in the management and outcome of stroke patients.
Topics: Aged; Aged, 80 and over; Anticoagulants; Aspirin; Atrial Fibrillation; Cohort Studies; Comorbidity; | 2000 |
Economic assessment of the secondary prevention of ischaemic events with lysine acetylsalicylate.
Topics: Aspirin; Cost-Benefit Analysis; Humans; Lysine; Myocardial Ischemia; Platelet Aggregation Inhibitors | 2000 |
[Problems in the treatment of patients with ischemic heart disease].
Topics: Adrenergic beta-Antagonists; Algorithms; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Ca | 2000 |
Effect of long-term exercise training on blood viscosity during endurance exercise at an anaerobic threshold intensity.
Topics: Adult; Aged; Anaerobic Threshold; Anticoagulants; Aspirin; Blood Viscosity; Cardiomyopathy, Dilated; | 2000 |
Nonplatelet effects of aspirin during acute coronary occlusion: electrophysiologic and cation alterations in ischemic myocardium.
Topics: Action Potentials; Animals; Aspirin; Coronary Disease; Dogs; Epinephrine; Male; Myocardial Ischemia; | 2000 |
Aspirin, but not the more selective cyclooxygenase (COX)-2 inhibitors meloxicam and SC 58125, aggravates postischaemic cardiac dysfunction, independent of COX function.
Topics: Animals; Aspirin; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase In | 2001 |
ACE inhibitor reduces cardiovascular events by 22%.
Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cardiovascular Diseases; Humans; Multicenter Stud | 2000 |
The nitroderivative of aspirin, NCX 4016, reduces infarct size caused by myocardial ischemia-reperfusion in the anesthetized rat.
Topics: Animals; Arrhythmias, Cardiac; Aspirin; Creatine Kinase; Cyclic GMP; Fibrinolytic Agents; Hemodynami | 2001 |
[Pharmacy clinics. Medication of the month. Clopidogrel (Plavix)].
Topics: Anti-Inflammatory Agents, Non-Steroidal; Arteriosclerosis; Aspirin; Clopidogrel; Coronary Disease; D | 2001 |
Helicobacter pylori infection as a risk factor for gastrointestinal symptoms in patients using aspirin to prevent ischaemic heart disease.
Topics: Aspirin; Calcium Channel Blockers; Deglutition Disorders; Dyspepsia; Fibrinolytic Agents; Flatulence | 2001 |
Clopidogrel in invasive management of non-ST-elevation ACS.
Topics: Angina, Unstable; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Disease; Humans; My | 2001 |
Clopidogrel versus aspirin after cardiac surgery.
Topics: Aspirin; Clopidogrel; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Postoperative Ca | 2001 |
Aspirin and the prevention of ischemic heart disease. A Socratic dialogue between a cardiologist, a clinical pharmacologist and an expert of blood platelets.
Topics: Aspirin; C-Reactive Protein; Humans; Myocardial Ischemia; Platelet Aggregation Inhibitors; Polymorph | 2001 |
Pre-hospital aspirin for suspected myocardial infarction and acute coronary syndromes: a headache for paramedics?
Topics: Acute Disease; Aspirin; Clinical Protocols; Emergency Medical Services; Emergency Medical Technician | 2001 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Cardiovascular Diseases; Clopidogrel; Drug Therapy, Combination; Hemorrhage; | 2002 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Clopidogrel; Combined Modality Therapy; Drug Therapy, Combination; Humans; M | 2002 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Clopidogrel; Creatine Kinase; Creatine Kinase, MB Form; Drug Therapy, Combin | 2002 |
Treatment of acute coronary syndromes.
Topics: Acute Disease; Aspirin; Clopidogrel; Coronary Artery Bypass; Drug Therapy, Combination; Hemorrhage; | 2002 |
NCX4016 (NO-aspirin) reduces infarct size and suppresses arrhythmias following myocardial ischaemia/reperfusion in pigs.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arrhythmias, Cardiac; Aspirin; Coronary Disease; E | 2002 |
Troponin T levels in patients with acute coronary syndromes, with or without renal dysfunction.
Topics: Abciximab; Aged; Angina Pectoris; Antibodies, Monoclonal; Aspirin; Biomarkers; Creatinine; Female; H | 2002 |
Chemical mediators of the muscle ergoreflex in chronic heart failure: a putative role for prostaglandins in reflex ventilatory control.
Topics: Aged; Aspirin; Bradykinin; Chemoreceptor Cells; Chronic Disease; Cyclooxygenase Inhibitors; Exercise | 2002 |
Combined effect of captopril and aspirin in renal hemodynamics in elderly patients with congestive heart failure.
Topics: Aged; Aspirin; Blood Flow Velocity; Captopril; Creatinine; Drug Therapy, Combination; Electrolytes; | 1992 |
Effects of diasprin cross-linked hemoglobin (DCLHb) on cardiac function and ECG in the swine.
Topics: Angioplasty, Balloon, Coronary; Animals; Aspirin; Blood Substitutes; Cross-Linking Reagents; Electro | 1992 |
Aspirin in ischemic heart disease.
Topics: Aspirin; Coronary Artery Bypass; Humans; Myocardial Ischemia; Vascular Patency | 1992 |
[The combination of taking acetylsalicylic acid and a complex of physical factors in the rehabilitative treatment of patients with ischemic heart disease].
Topics: Angina Pectoris; Aspirin; Combined Modality Therapy; Humans; Myocardial Ischemia; Physical Exertion; | 1992 |